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Introducción 
Las Encefalopatías Espongiformes Transmisibles (EETs) son enfermedades 
neurodegenerativas progresivas y mortales que afectan a los seres humanos y a 
otras especies de mamíferos e incluyen la enfermedad de Creutzfeldt-Jacob 
(ECJ), la enfermedad de Gerstmann-Sträussler-Scheinker (GSS) y el insomnio 
familiar fatal (FFI) en los seres humanos, la tembladera en ovinos y caprinos, la 
encefalopatía espongiforme bovina (EEB) en el vaca, y la caquexia crónica (CC) 
en ciervos y alces.  
Un acontecimiento fundamental en la patogénesis de las EETs es el cambio 
conformacional de la proteína priónica celular (PrPC) en una proteína priónica 
patógena (PrPSc) con plegamiento aberrante que es capaz de propagarse 
mediante la conversión de más PrPC en PrPSc. Es bien sabido que ciertos 
cambios aminoacídicos en la secuencia de la PrPC pueden afectar a la eficiencia 
de conversión de la PrPC y a la transmisión de priones. De esta forma, 
individuos de una especie pueden presentar diferentes niveles de 
susceptibilidad a un agente priónico dependiendo de su genotipo de la PrP. 
Este hecho tiene importantes implicaciones en el diseño de estrategias 
encaminadas a controlar y erradicar las EETs a través del cruzamiento selectivo 
de los individuos portadores de genotipos de la PrP asociados con resistencia a 
la infección con priones. Así, los programas de cría selectiva aplicados en el 
ganado ovino para promover el genotipo A136R154R171, con resistencia conocida 
a la tembladera clásica, han reducido notablemente la prevalencia de esta 
enfermedad en muchos países europeos.  
Aparte de las diferencias en la secuencia aminoacídica entre la PrPC y la PrPSc, 
las cepas de priones también modulan la conversión de la PrPC. Por ejemplo, las 
ovejas que expresan el genotipo A136R154R171 tienen una mayor susceptibilidad a 
la tembladera atípica que las ovejas que expresan otros genotipos como el VRQ. 
Por el contrario, las ovejas ARR son menos susceptibles a la tembladera clásica 
que las ovejas VRQ. Este hecho pone en duda los logros de los programas de 
cría selectiva cuyo objetivo es prevenir la infección de las ovejas con tembladera 
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clásica. Todos estos datos sugieren que la infección con priones estaría 
modulada por una combinación compleja de las propiedades conformacionales 
de los agregados de PrPSc y las estructuras locales de la PrPC. Por tanto, es 
necesario estudiar los cambios en la secuencia de la PrP en combinación con las 
cepas de priones a fin de avanzar en el conocimiento de los mecanismos 
moleculares que regulan la susceptibilidad/resistencia a la infección con 
priones; información con implicaciones fundamentales en el control y 
erradicación de las EETs en distintas especies. 
2. Objetivos y diseño experimental  
El objetivo principal de esta tesis es mejorar nuestra comprensión de los 
mecanismos moleculares que gobiernan la susceptibilidad/resistencia a la 
infección con priones. Para ello, se llevó a cabo una serie de objetivos 
específicos:  
1. Estudiar el papel individual de las variantes polimórficas que se encuentran 
naturalmente en el gen de la proteína priónica (prnp) de cabra y de oveja en la 
susceptibilidad/resistencia a la tembladera y la EEB en ratones transgénicos 
(Tg). Para este fin, hemos generado un panel de líneas de ratón Tg que expresan 
o bien la PrPC de la cabra de tipo salvaje (wt) o variantes de la PrPC debidas a 
cambios puntuales de aminoácidos (I/M142, R/H154, R/Q211, Q/K222, Q/R171 y 
N/K176). Estas líneas de ratón Tg fueron desafiadas con varias cepas de priones 
y sus susceptibilidades se evaluaron y se compararon con el fin de determinar 
el papel individual de cada variante de PrPC en la resistencia/susceptibilidad a 
la infección con priones.  
2. Confirmar en el huésped natural (cabras) la fiabilidad de los resultados de los 
modelos de ratón Tg. Para ello, se llevaron a cabo inoculaciones experimentales 
en cabras que expresaban diferentes polimorfismos de la prnp con un caso de 
campo de tembladera o con un aislado de EEB en cabra y sus resultados se 
compararon con los obtenidos en los ratones Tg. 
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3. Materiales y Métodos  
Se generó una colección de líneas de ratón Tg que expresaban diferentes 
variantes polimórficas de la PrPC de cabra y de oveja (M142, H154, R171, K176, K222 
y Q211) mediante mutagénesis dirigida del plásmido pMo-GoPrP.Xho utilizado 
para la obtención de la línea Wt-Tg501 que expresa la PrPC de cabra wt. Los 
fundadores fueron caracterizados i) mediante PCR para determinar su 
capacidad de transmisión del transgén mutado a la progenie; ii) mediante 
Western blot (WB) para analizar sus niveles de expresión de la PrPC en cerebro 
y iii) su estado de comportamiento y de salud. Las líneas de ratón Tg 
seleccionadas se inocularon por vía intracerebral (IC) en el lóbulo parietal 
derecho con una variedad de aislados (homogeneizados de cerebro infectados 
por priones) que diferían en la cepa (tembladera clásica o atípica, o EEB clásica 
o atípica), el origen geográfico, el genotipo de la PrPSc, el perfil de la PrPres por 
WB, y en su comportamiento al ser transmitidas en ratones Tg bovinos BoPrP-
Tg110. Mediante el estudio comparativo de las características de transmisión de 
cada línea Tg (tiempo de supervivencia, tasas de ataque, perfil de la PrPres por 
WB, y alteraciones histopatológicas) determinamos la susceptibilidad 
diferencial a la infección con priones asociada a cada variante de la PrPC.  
En paralelo, trabajamos en colaboración con el ENV (Francia) y el FLI 
(Alemania) para llevar a cabo estudios de transmisión de priones en cabras. Por 
un lado, se desafiaron cabras que expresaban diferentes genotipos de la prnp 
(WT, M142, H154, Q211 o K222) con un caso natural de tembladera clásica por vía 
oral o IC. Para los desafíos orales, los cabritos recibieron una primera dosis del 
inóculo (cerebro infectado con tembladera clásica) por amamantamiento natural 
dentro de las primeras 48 horas después del nacimiento y una segunda dosis a 
la edad de 30 días. Para los desafíos IC, el inóculo (el mismo cerebro infectado 
con tembladera clásica) se inyectó en la corteza temporal de cabras de seis 
meses de edad. Ambos grupos de animales fueron monitorizados para el 
desarrollo de enfermedades neurológicas y sacrificados en la fase clínica de la 
enfermedad. La presencia de PrPSc en sus cerebros se evaluó mediante WB e 
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inmunohistoquímica. Por otro lado, se inocularon cabras con genotipos de la 
prnp WT, R/Q211 o Q/K 222 por vía oral con homogeneizado de cerebro de 
cabras infectados con EEB por amamantamiento natural. Las cabras fueron 
sacrificadas en diferentes momentos del período de incubación y después de la 
aparición de los signos clínicos, y sus cerebros y varios tejidos periféricos se 
analizaron para la detección de la PrPSc por WB, la determinación de 
alteraciones histopatológicas y la detección de infectividad priónica mediante 
bioensayo en ratones BoPrP-Tg110. 
4. Resultados y discusión  
Todas las líneas de ratón Tg seleccionadas expresaron niveles de PrPC en sus 
cerebros similares a los de cabra de cabra. En cada caso, la PrPC expresada era 
idéntica a excepción de los cambios aminoacídicos puntuales correspondientes 
a las variantes polimórficas deseadas (I/M142, R/H154, Q/R171, N/K176, R/Q211 y 
Q/K222). Todas las líneas mostraron un comportamiento fisiológico normal y no 
se observó ninguna alteración histopatológica en su cerebro lo que nos permitió 
descartar el desarrollo de una enfermedad neurológica espontánea como 
resultado de la expresión de la PrPC mutada.  
Los ratones Wt-Tg501, con niveles de expresión de la PrPC en el cerebro 
similares a los de cabra (1X), fueron susceptibles a todos los aislados de 
tembladera y EEB inoculados independientemente de las propiedades de los 
aislados  mencionadas en el apartado anterior. Los ratones Wt-Tg501fueron 
capaces de replicar todos estos agentes de priones manteniendo sus 
propiedades biológicas y bioquímicas. Además, esta línea de ratón nos permitió 
identificar al menos cuatro cepas de tembladera clásica en el panel de aislados 
inoculados. Estos resultados demuestran que la línea Wt-Tg501 es un modelo 
muy valioso para el estudio de la susceptibilidad de las cabras y ovejas a 
diferentes cepas de la tembladera y la EEB, así como para identificar y 
caracterizar las cepas de priones que afectan a estos rumiantes.  
Por el contrario, los ratones K222-Tg516, con niveles de expresión 1X de la PrPC 
mutada K222- PrPC, fueron resistentes a la transmisión primaria de todos los 
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aislados de tembladera clásica inoculados así como a EEB clásico y EEB-L 
atípico de vaca, pero no contra la tembladera atípica o el EEB de oveja o cabra. 
Por lo tanto, el cambio aminoacídico glutamina-lisina en el codón 222 (Q/K222) 
proporciona resistencia contra la infección con los agentes de tembladera 
clásica, EEB clásica y EEB-L atípica de vaca pero no contra la tembladera atípica 
o EEB adaptada a oveja o a cabra. Por otro lado, los ratones heterocigotos 
Q/K222 fueron resistentes a la inoculación con varios aislados de tembladera 
clásica. Estos ratones heterocigotos sólo fueron susceptibles a algunos aislados 
de tembladera clásica mostrando menores tasas de ataque (TA) y tiempos de 
supervivencia (TS) que los ratones Wt-Tg501 lo que indica que la variante 
polimórfica de la PrPC K222 proporciona un efecto dominante negativo sobre la 
secuencia de PrPC wt que resulta en una reducción de la eficacia de propagación 
de la tembladera clásica.  
Los ratones K176-Tg570 (2X) fueron resistentes a todos los aislados de 
tembladera clásica y EEB inoculados pero completamente susceptibles a la 
infección con el aislado de tembladera atípica. Estos resultados demuestran que 
la sustitución aminoacídica asparragina-lisina en el codón 176 (N/K176) de la 
secuencia de PrPC de cabra confiere un alto nivel de protección frente a la 
infección con los agentes de tembladera clásica y EEB pero parece aumentar la 
susceptibilidad a la tembladera atípica.  
Los ratones Q211-Tg580 (1X) y R171-Tg552 (1X) fueron resistentes a la inoculación 
con una variedad de aislados de tembladera clásica pero susceptibles a la 
infección con el agente de tembladera atípica lo que demuestra que los cambios 
aminoacídicos  arginina-glutamina en el codón 211 (R/Q211) y glutamina-
arginina en el codón 171 (Q/R171) afectan a la replicación de la PrPc con los 
agentes de tembladera clásica pero no con el agente de la tembladera atípica. 
A pesar de los bajos niveles de expresión (0.25X) de la PrPC de la línea H154-
Tg563, estos ratones fueron susceptibles a algunas cepas de tembladera y de 
EEB, lo que indica el bajo o nulo efecto de esta variante polimórfica en la 
infección con priones. Sin embargo, sería necesario generar nuevas líneas de 
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ratón Tg que expresen la PrPC mutada H154-PrPC a niveles fisiológicos de cabra 
para concluir sobre su papel en la infección con priones.  
Por último, los ratones M142-Tg541 (1X) fueron susceptibles a todos los aislados 
de tembladera clásica y EEB inoculados aunque mostraron alargamientos en los 
TS estadísticamente significativos con respecto a los ratones Wt-Tg501 cuando 
se desafiaron con los aislados de tembladera clásica. Estos retrasos en los TS 
variaron entre los aislados de tembladera lo que sugiere que el efecto de la 
variante M142-PrPC en la replicación de los agentes de la tembladera clásica es 
dependiente de la cepa. Remarcablemente, ninguno de los ratones M142-Tg541 
sucumbió a la inoculación con el aislado de tembladera atípica lo que indica que 
el cambio de aminoácido isoleucina-metionina en el codón 142 (I/M142) no tiene 
ningún efecto importante en la replicación de la tembladera y el EEB, pero sí 
juega un papel determinante en la replicación de la tembladera atípica.  
Las inoculaciones en cabras con el caso natural de tembladera clásica mostraron 
que los animales que portaban la mutación I/M142 fueron totalmente 
susceptibles a la infección con este agente tanto por la vía oral como IC aunque 
con periodos de incubación más largos que las cabras WT. Estos resultados 
confirman la conclusión de que la variante M142-PrPC prolonga el tiempo de 
supervivencia de los animales pero no confiere resistencia. Las cabras 
portadoras de los genotipos H154, Q211 y alelos K222 fueron resistentes a la 
tembladera clásica tras la exposición oral. Sin embargo, en comparación con los 
animales WT, las cabras H154 y Q211 sólo aumentaron moderadamente sus 
períodos de incubación tras el desafío IC. Notablemente, sólo unas pocas cabras 
portadoras de la variante K222 desarrollaron la enfermedad con períodos de 
incubación que eranc uatro a cinco veces más largos que en los animales WT. 
Estos resultados concuerdan con la resistencia atribuida a las variantes de la 
PrPC Q211 y K222 en los estudios de transmisión en los ratones Tg y refuerzan la 
buena resistencia de la variante K222 a la infección con el agente de tembladera 
clásica.  
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Las inoculaciones orales de las cabras WT, R/Q211 y Q/K222 con el aislado de 
EEB de cabra mostró que las cabras R/Q211 desarrollaron signos clínicos 
similares a la cabra WT pero con tiempos de incubación más largos.  La PrPSc se 
observó sólo en los cerebros de estos animales, mientras que sí se detectó 
infectividad en los tejidos periféricos mediante bioensayo en ratón. Por el 
contrario, ninguna de las cabras Q/K222 mostró ninguna evidencia clínica de 
enfermedad priónica hasta el final del estudio (86 meses después de la 
inoculación). Aunque no se observó acumulación de PrPSc en sus cerebros o 
tejidos periféricos, sí se determinó una infectividad muy baja en algunos tejidos 
después de muy largos tiempos post-inoculación (44-45 meses). Estos 
resultados contrastan con la alta susceptibilidad de los ratones K222-Tg516 a la 
infección IC con EEB de cabra y apoyan la opinión de que otros factores aparte 
de la secuencia de la PrPC (por ejemplo, la vía de inoculación) influyen en la 
eficiencia de transmisión de priones. El efecto protector proporcionado por la 
variante K222-PrPC contra el EEB y la tembladera clásica observado en las cabras 
junto con el efecto protector contra la tembladera clásica obtenido en los ratones 
Tg prueba la capacidad de esta variante para controlar la transmisión horizontal 
de ambas enfermedades en rebaños de cabras a través de programas de cría 
selectiva.
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1. Introduction 
Prion diseases or Transmissible Spongiform Encephalopaties (TSEs) are 
progressive and fatal neurodegenerative diseases that affect humans and other 
mammal species. These diseases include Creutzfeldt-Jacob disease (CJD), 
Gerstmann-Sträussler-Scheinker disease (GSS), and fatal familial insomnia (FFI) 
in humans, as well as scrapie in sheep and goats, bovine spongiform 
encephalopathy (BSE) in cattle, and chronic wasting disease (CWD) in deer and 
elk. 
A fundamental event in the pathogenesis of prion diseases is the misfolding of 
host cellular prion protein (PrPC) into a pathogenic prion protein (PrPSc) that is 
able to propagate by recruiting PrPC. It is well known that certain amino acid 
changes in the PrPC sequence can affect the efficiency of PrPC conversion and 
prion transmission. Indeed, depending on their PrP genotype, individuals from 
a single population of a species can exhibit different levels of susceptibility to a 
prion agent, which has important implications for the design of strategies 
aimed at controlling and eradicating prion diseases via the promotion of PrP 
genotypes associated with resistance to prion infection. Thus, selective breeding 
programs have been successfully implemented in sheep herds that have 
promoted the A136R154R171 genotype given its resistance to classical scrapie. As a 
result, classical scrapie prevalences have declined in many European countries, 
thereby prompting greater use of these strategies to control other prion diseases 
such as CWD in cervids or scrapie in goats. 
Aside from the PrP amino acid differences between host PrPC and donor PrPSc, 
prion strains also modulate prion conversion. For example, A136R154R171 sheep 
have greater susceptibility to atypical scrapie than PrP genotypes such as VRQ 
that are susceptible to classical scrapie. This fact casts a doubt on the 
achievements of selective breeding programs whose aim is to prevent the 
infection of sheep with classical scrapie. It seems that prion occurrence would 
be modulated by a complex combination of the conformational properties of 
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PrPSc aggregates and local structures of PrPC. It is thus necessary to study PrP 
sequence changes in combination to prion strains so as to advance our 
knowledge of the molecular mechanisms governing the 
susceptibility/resistance to prion infection, which will - if successful - have 
fundamental implications in control and eradication of prion diseases. 
2. Objectives and experimental design 
The main objective of this thesis is to improve our understanding of the 
molecular mechanisms driving the susceptibility/resistance to prion infection. 
To address this task, a number of specific aims were pursued: 
1. To study the individual role of the polymorphic variants found naturally in 
goat and sheep prion protein gene (prnp) in the susceptibility/resistance to 
scrapie and BSE infection in transgenic mice. For this purpose, we generated a 
panel of transgenic (Tg) mouse lines expressing either the goat wild type PrPC 
or PrPC variants containing single amino acid exchanges (I/M142, R/H154, 
R/Q211, Q/K222, Q/R171 and N/K176); and challenged them with several prion 
strains. Their susceptibilities were assessed and compared in order to determine 
the individual role of each PrPC variant in the resistance/susceptibility to prion 
infection. 
2. To confirm in the natural host (goats) the reliability of the results of the 
mouse models. Experimental inoculations with goats harboring different PrP 
genotypes with either one scrapie field case or one goat-BSE isolate were 
performed and their results compared with those obtained from Tg mice.  
3. Materials and Methods 
Tg mouse lines expressing different PrPC polymorphic variants of goat and 
sheep (M142, H154, R171, K176, Q211 and K222) were generated by directed mutation 
of the pMo-GoPrP.Xho plasmid used for obtaining the goat Wt-Tg501 mouse 
line which expresses the goat wt PrPC. Founders were characterized by i) a PCR 
used to study their capacity to transmit the mutated transgene to the progeny; 
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ii) Western blot (WB) analysis to measure their  PrPC level of expression in the 
brain; and iii) their behavior and health status, which were monitored for the 
development of abnormalities. Selected Tg mouse lines were then 
intracerebrally (IC) inoculated in the right parietal lobe with a variety of prion 
isolates (consisting of prion infected brain homogenate) that differed in the 
strain (classical or atypical scrapie, or classical or atypical BSE), geographical 
origin, PrPSc genotype, WB PrPres profile, or behavior upon passage in BoPrP-
Tg110 mice. A comparative study of the transmission features (survival times, 
attack rates, PrPres Western-Blot glycoprofile, and histoptahological alterations) 
was carried out to assess the differences between the  Tg mouse lines. 
In parallel, we worked in collaboration with ENV (France) and FLI (Germany) 
to carry out prion transmission studies in goats. On one hand, goats harboring 
different prnp genotypes (WT or prnp variants M142, H154, Q211 or K222) were 
challenged with a natural scrapie isolate by the IC or oral routes. For oral 
challenges, goat kids received the inoculum (scrapie-infected brain) by natural 
suckling within 48 hours of birth and a second dose at the age of 30 days. For IC 
challenges, inoculum (the same homogenized scrapie-infected brain) was 
injected into the temporal cortex of six-month-old goats. Both groups of animals 
were monitored for the development of neurological diseases and euthanized at 
the clinical stage of the disease. The presence of PrPSc was assessed in brains by 
WB and immunohistochemistry (IHC) analysis. 
In parallel, goats harboring WT, R/Q211 or Q/K 222 prnp genotypes were orally 
inoculated with 5ml of pooled goat brain homogenate infected with goat-BSE 
isolate by natural suckling to assess their relative susceptibility to BSE infection. 
Goats were culled at different time points during the incubation period and 
after the onset of clinical signs, and their brains - as well as several peripheral 
tissues - were analyzed for i) the accumulation of pathological prion protein 
(PrPSc) using WB and histopathological analysis; and ii) prion infectivity using 
mouse bioassay in BoPrP-Tg110 mice and non-parametric Mann-Whitney-U 
test.   
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4. Results and discussion 
All selected Tg mouse lines expressed similar levels in their brains of the same 
PrPC sequence except for a single amino acid exchange corresponding to the 
tested PrPC polymorphic variant (I/M142, R/H154, Q/R171, N/K176, R/Q211 and 
Q/K222). None showed any abnormality in their physiological behavior or any 
histopathological alterations in their brains which rules out the development of 
a spontaneous neurological disease as a result of the expression of the mutated 
PrPC. 
Wt-Tg501 mice, expressing 1-fold the PrPC in the goat brain (1X), were 
susceptible to all tested scrapie and BSE isolates regardless of the 
aforementioned properties of the isolates. Wt-Tg501 mice were able to replicate 
all these prion agents and maintain their biological and biochemical properties. 
As well, this mouse line permitted us to identify at least four classical scrapie 
strains among the panel of prion isolates. Conjointly, these transmission studies 
indicate that the Wt-Tg501 mouse line is a highly valuable model for studying 
the susceptibility of goats and sheep to different scrapie and BSE strains, and 
also for identifying and characterizing prion strains affecting sheep and goat. 
In contrast, K222-Tg516 mice, expressing 1X the K222-PrPC, were resistant to the 
primary transmission of all the classical scrapie isolates, classical Cattle-BSE and 
atypical BSE-L isolates inoculated but not against atypical scrapie agent. 
Therefore, the single glutamine-to-lysine amino acid substitution at codon 222 
(Q/K222) provides resistance against classical scrapie, classical cattle BSE and 
cattle BSE L but not against atypical scrapie or BSE adapted to sheep or goat. 
Furthermore, heterozygous Q/K222 mice were resistant to the inoculation with 
several scrapie isolates and when succumbed to the prion disease, they did it 
with lower attack rates (AR) and/or longer survival times (ST) than Wt-Tg501 
mice; thus indicating that the K222-PrPC polymorphic variant provides a 
dominant negative effect over the wild-type PrPC sequence which results in a 
poorer efficacy of classical scrapie prion propagation. 
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None of the K176-Tg570 (2X) mice succumbed to any of the classical scrapie or 
BSE isolates inoculated but were fully susceptible to the infection with atypical 
scrapie, which demonstrates that the asparagine-to-lysine amino acid 
substitution at codon 176 (N/K176) in the goat PrPC sequence triggers a high 
level of resistance to infection with classical scrapie and BSE; although it seems 
to increase the level of susceptibility to atypical scrapie. 
Q211-Tg580 (1X) and R171-Tg552 (1X) mice were resistant to the inoculation with 
a variety of classical scrapie isolates but succumbed to the infection with the 
atypical scrapie isolate. Hence, single arginine-to-glutamine amino acid 
substitutions at codon 211 (R/Q211) and glutamine-to-arginine at codon 171 
(Q/R171) in the goat PrPC sequence confer resistance to infection with classical 
scrapie but not with atypical scrapie.  
Despite the low levels of PrPC expression in their brains (0.25X), H154-Tg563 
mice were susceptible to some scrapie and BSE isolates, thereby indicating the 
low or null effect of this polymorphic variant on prion infection.  The 
generation of new Tg mouse lines expressing the H154-PrPC at goat 
physiological levels is required for concluding on their role in prion infection.  
Finally, M142-Tg541 (1X) mice were susceptible to all the classical scrapie and 
BSE isolates inoculated and had statistically significant longer ST compared to 
Wt-Tg501 mice when scrapie challenged. These delays in ST in animals varied 
among the scrapie challenges suggesting a strain-dependent effect for M142-PrPC 
in the replication of classical scrapie agents. More interestingly, none of the 
M142-Tg541 mice succumbed to the inoculation with the atypical scrapie isolate 
which indicates that the single isoleucine-to-methionine amino acid exchange at 
codon 142 (I/M142) has no major effect on the replication of scrapie and BSE 
agents but does play a determinant role in the replication of the atypical scrapie 
agent. 
Goat bioasssay with the natural scrapie case showed that the I/M142 goats were 
fully susceptible to the scrapie inoculation by both the IC and oral routes 
despite having longer incubation periods than WT goats. These results confirm 
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the finding that the M142-PrPC variant’s function is to prolong survival times. 
Goats carrying the H154, Q211 and K222 PRP alleles were all resistant to scrapie 
infection following oral exposure. However, in comparison to WT animals, the 
H154 and the Q211 allele’s carriers only increased moderately during the 
incubation period following the IC challenge. Notably, only very few IC- 
challenged K222 goats developed the disease with incubation periods that were 
4-5 times longer than in WT animals. These results agree with the resistance 
attributed to Q211 and K222-PrPC variants in transmission studies in Tg mice and 
further support the of the good resistance of the K222-PrPC variant to scrapie 
infection. 
Oral inoculations of WT, R/Q211 or Q/K 222 goats with a Goat-BSE isolate 
showed that R/Q211 goats had similar but delayed clinical signs compared to 
WT goats. PrPSc was detected only in brains, whereas infectivity was also 
present in peripheral tissues in both WT and R/Q211 goats. By contrast, none of 
the Q/K222 goats showed any evidence of clinical prion disease by the end of 
the study (86 months post-inoculation). Although no PrPSc accumulation was 
observed in their brains or peripheral tissues, very low infectivity was detected 
in some tissues after very long post-inoculation times (44–45 months). These 
results contrast the high susceptibility of K222-Tg516 mice to the IC infection 
with Goat-BSE and support the view that factors other than the PrPC sequence 
(e.g. the inoculation route) influence prion transmission efficiency. The 
protective effect provided by the K222-PrPC variant against goat-BSE in goats 
complements its protective effect against scrapie seen in our studies in goats 
and Tg mice and is further evidence of the ability of the K222-PrPC variant to 
control the horizontal transmission of both classical scrapie and goat-BSE 
diseases in goat herds via selective breeding programs.  
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1. Prion diseases: general aspects 
Prion diseases or Transmissible Spongiform Encephalopaties (TSEs) are fatal 
neurodegenerative diseases that affect numerous mammal species and include 
Creutzfeldt-Jacob disease (CJD), kuru, Gerstmann-Sträussler-Scheinker disease 
(GSS), and fatal familial insomnia (FFI) in humans, as well as scrapie in sheep 
and goats, bovine spongiform encephalopathy (BSE) in cattle, and chronic 
wasting disease (CWD) in deer and elk (Table 1).   
TSEs are characterized by long incubation times (from months to decades) and 
the development of neuropathological alterations consisting of astrogliosis, 
spongiosis, and neuronal death. Symptoms are primarily neurological and 
include behavior abnormalities, motor dysfunction, cognitive impairment, and 
cerebral ataxia. Prion diseases do not produce any immune response and no 
effective therapy is yet available to treat them.  
TSEs are caused by the conversion of the physiological cellular prion protein 
(PrPC) into a pathogenic misfolded isoform (designated PrPSc) that is able to 
propagate by recruiting more PrPC. This conformational change confers PrPSc 
with a greater tendency to aggregate, greater insolubility in non-ionic 
detergents, high resistance to heat and chemical sterilization, and partial 
resistance to protease digestion. (Pruden et al., 2004) 
This revolutionary concept of infectious proteins was firstly described in the 
Protein-Only Hypothesis proposed by Prusiner and Griffin (Prusiner, 1991). 
Before this description, prion diseases were thought to be caused by “slow 
viruses” (Gajdusek and Gibbs, 1968; Kimberlin, 1982). However, given the 
evidence that the agent causing scrapie was resistant to heat and formaldehyde, 
as well as to ionizing radiations and UV light (Alper et al., 1967), it was 
suggested that this agent was neither a virus nor any other infectious agent 
harboring nucleic acids.  
On this basis, Griffith proposed that the scrapie agent could be a protein that 
self-replicates through autocatalytic conformational changes (Griffith, 1967). To 
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test this idea, Stanley Prusiner subjected some hamster-adapted scrapie agents 
to physicochemical inactivation (normally used to destroy proteins) and 
observed that they lost their infectivity (Prusiner et al., 1981). This way, scrapie 
became to be considered an infectious protein and a new term “PRION” was 
coined to define this atypical agent. 
Although CJD and kuru were first described in 1920 and 1957, respectively, 
TSEs did not become a pressing concern in public health until the development 
of the BSE epidemics in the 1980s in the United Kingdom. The magnitude of 
this disease, which rapidly spread among cattle in numerous European 
countries as well as the USA, Canada and Japan, was even higher when 
transmitted to humans, thereby giving rise to a new variant of Creutzfeldt-
Jacob disease (vCJD).  
Since then, the group of TSEs identified has continued to grow. Indeed, two 
atypical variants of BSE have recently been reported in cattle (L-BSE (Casalone 
et al., 2004) and H-BSE (Biacabe et al., 2004)). Thus, nowadays more than 17 
TSEs have been reported to affect an increasing number of wild and domestic 
animal species, as well as humans (Table 1).  
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Table 1. Etiology of prion diseases 
Disease Host Etiology 
Year of 
description 
Bovine Spongiform 
Encephalopathy (BSE) 
Cattle Infection with prions of unknown origin 1986 
Bovine Amyloidotic 
Spongiform 
Encephalopathy (BSE-L) 
Cattle Infection with prions of unknown origin 2004 
Atypical Bovine 
Spongiform 
Encephalopathy Type-H 
(BSE-H) 
Cattle Infection with prions of unknown origin 2004 
Scrapie 
Sheep, goats, 
mouflons 
Infection with prions of unknown origin 1972 
Atypical scrapie Sheep and goats 
Spontaneous PrPC to PrPSc conversion or 
somatic mutation in prnpa 
 
Chronic Wasting Disease 
(CWD) 
Cervids Infection with Prions of unknown origin 1967 
Transmissible Mink 
Encephalopathy (TME) 
Minks 
BSE or scrapie-contaminated meat and 
bone meal 
1947 
Feline Spongiform 
Encephalopathy (FSE) 
Cats, cheetahs, 
ocelots, pumas 
and tigers 
BSE-contaminated meat and bone meal 1990 
Exotic ungulate 
Spongiform 
Encephalopathy (EUE) 
Kudu, eland, 
gemsbok, nyala 
oryx, bison 
BSE-contaminated meat and bone meal 1986 
TSEs in non-human 
primates (NHP) 
Lemurs and 
Rhesus macaques 
BSE-contaminated meat and bone meal 1996 
Kuru Human Ritualistic cannibalism 1900s 
Variant CJD (vCJD) Human BSE-contaminated meat and bone meal 1996 
Sporadic CJD (sCJD) Human 
Spontaneous PrPC to PrPSc conversion or 
somatic mutation in prnp 
1920 
Familial CJD (fCJD) Human Mutations in prnp 1924 
Iatrogenic CJD (iCJD) Human 
Infection with prions of human origin 
through medical practices (surgeries, 
transplants) 
1974 
Gerstmann-Sträussler-
Scheinker syndrome, 
(GSS) 
Human Mutations in prnp 1936 
Fatal familial insomnia 
(FFI) 
Human Mutations in prnp 1986 
Sporadic Fatal Insomnia 
(sFI) 
Human 
Spontaneous PrPC to PrPSc conversion or 
somatic mutation in prnp 
1999 
Variably 
protease-sensitive 
prionopathy (VPSPr) 
Human 
Spontaneous PrPC to PrPSc conversion or 
somatic mutation in prnp 
2008 
a prnp:prion protein gene 
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2. Prion conversion: from PrPC to PrPSc 
According to the Prion Protein-Only Hypothesis, prion diseases are uniquely 
caused by the post-translational conversion of the cellular prion protein (PrPC) 
into a pathogenic misfolded isoform (PrPSc) that has the ability to self-propagate 
(Prusiner, 1991).  
To date, several studies have supported the Prion Protein-Only Hypothesis, 
including the successful induction of neurodegenerative diseases only from 
recombinant amyloid forms of prions (Castilla et al., 2005b; Colby et al., 2009; 
Legname et al., 2004) or in combination with certain lipids and RNA factors 
(Wang et al., 2010). Nevertheless, some findings suggest that the misfolded 
PrPres protein alone is not necessarily infectious and needs some cofactors to be 
able to self-propagate (Deleault et al., 2012; Saa et al., 2012; Telling et al., 1995); 
in this case, PrPres formation and infectious agent replication are two different 
processes. The existence of high infectivity when no or low amounts of PrPres 
are detected supports this view. On this basis, some authors have proposed that 
infectivity in prion diseases is caused by other non-prion structures such as the 
viruses of the vast metagenome (reviewed in reference (Manuelidis, 2013)). 
Despite these arguments, the conversion of PrPC into PrPSc is essential for prion 
disease development and prion diseases are entirely dependent on the 
expression of endogenous PrPC, as confirmed by the total resistance to TSEs of 
prnp knock-out mice (Bueler et al., 1993; Prusiner et al., 1993). 
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2.1. Cellular prion protein (PrPC)  
2.1.1. Prion protein gene (prnp) 
The prion gene family consists of three members: prnp gene that encodes the 
cellular prion protein (PrPC), prnd gene that encodes the Doppel protein, and 
sprn gene that encodes the Shadoo protein (Fig. 1).  
Prnp gene has been well conserved throughout evolution in mammals and 
paralog genes have been described in birds (Gabriel et al., 1992), amphibians 
(Strumbo et al., 2001), reptiles (Simonic et al., 2000), and fish (Cotto et al., 2005). 
Prnp is located on chromosome 2 in mice, 20 in humans, and 13 in ruminants 
(Sparkes et al., 1986). In mammalian species, prnp gene contains two (humans) 
or three (mice) exons; nevertheless, the complete PrPC protein is encoded by the 
terminal exon where the entire open reading frame (ORF) is located in all cases. 
The other exons harbor untranslated sequences such as promoter and 
termination sites. At the promoter level, prnp is characterized by the absence of 
a TATA box (Basler et al., 1986), which is substituted by a GC-rich repeats 
regulator sequence with potential binding sites for many transcription factors 
such as Sp1, AP1, and AP2 (Inoue et al., 1997; Mahal et al., 2001; McKnight and 
Tjian, 1986; Saeki et al., 1996; Westaway et al., 1994). 
Prnd gene lies 16 kb downstream of the murine prnp locus (Moore et al., 1999) 
and encodes a 179-residue PrP-like protein designated Doppel. Prnd 
postembryonic expression is nil in central nervous system (CNS) and 
principally confined to the testis, where Doppel seems to play a determinant 
role in spermatogenesis (Behrens et al., 2002). Doppel exhibits less than 25% 
homology with the PrPC; however, its upregulation in the CNS in the absence of 
the PrPC produces late-onset ataxia in transgenic mice, suggesting that this 
protein may be associated to neurodegeneration (Moore et al., 1999).  
Sprn gene is located on chromosome 7 in mice, 10 in humans, and 26 in 
ruminants. It encodes a protein of 130–150 amino acids named Shadoo, which 
harbors very similar domains to the PrPC protein (Fig. 1). While Doppel 
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resembles the α-helical C-terminal half of PrPC, Shadoo is reminiscent of the 
flexible N-terminal half. Sprn gene has partial homology to the PrPC 
hydrophobic domain, a series of N-terminal repeats, a C-terminal N-linked 
glycosylation, and a GPI anchor. Moreover, Shadoo is extracellular and GPI-
anchored and its pattern of expression in CNS seems to overlap that of PrPC 
(Watts et al., 2007; Young et al., 2009). These similarities may explain the 
functional analogy between Shadoo and PrPC (Passet et al., 2012; Young et al., 
2009). 
 
Figure 1. Schematic representation of mouse prnp, prnd, and sprn genes. The prn 
locus is located on chromosome 2 and contains prnp and prnd genes that encode PrPC 
and Doppel proteins, respectively. Sprn is located on chromosome 7 and encodes the 
Shadoo protein. E: Exon (adapted from (Watts et al., 2007)). 
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2.1.2. PrPC structure and biosynthesis 
Prnp transduction takes place in the endoplasmic reticulum (ER) where a 235–
264-amino-acid PrPC protein containing two glycosylation sites and a GPI 
anchor is produced (Colby and Prusiner, 2011). PrPC is post-translationally 
modified in the ER, a process that includes the cleavage of a 22-aa signal 
peptide, the removals of the 22-aa N-terminal signal peptide and a C-terminal 
hydrophobic segment, the formation of a single disulfide bond, glycosylation at 
one or two sites, and the attachment of a glycosyl phosphatidyl inositol (GPI) 
anchor (Stahl et al., 1987) (Fig. 2.A).  
After these post-translational modifications, the mature prion protein has ≈ 210 
amino acids and a molecular weight of around 26–37 kilodaltons (K) depending 
on its glycosylation state (un-, mono- or diglycosilated). Then, mature PrPC 
traffics through the Golgi apparatus to the cell surface where it is inserted and 
targeted in the detergent-resistant cholesterol-rich lipid domains (rafts) of the 
plasma membrane through its GPI anchor (Fig. 2B). 
Structural and biochemical studies in recombinant PrP or extracts have shown 
that the PrPC protein has two distinguishable parts: i) a long unstructured 
flexible N-terminal tail of ≈100 residues with the copper-binding octapeptide 
repeats (PHGGGWGQ), and ii) a globular domain of ≈100 residues that harbors 
the hydrophobic region and the short flexible C-terminal domain composed of 
three α-helices and two antiparallel β-sheets separated by short loops (Riek et 
al., 1998) with a single disulfide bond linking cysteine residues from α-helices 2 
and 3 (Fig. 2.A). 
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Figure 2. Mouse PrPC structure. A. Schematic representation of mouse PrPC primary 
structure. The PrPC structure consists of 1) an unstructured N-terminal tail 
encompassing a polybasic region (residues 23–27, yellow) and a tandem of five repeats 
of copper-binding octapeptide sequences (residues 51–90, orange) and a positively 
charged region (residues 90–112, white); and 2) a structured C-terminal domain that 
spans a highly conserved hydrophobic domain (residues 112–126, red); three α-helices 
(α1, α2 and α3; residues 144, 173 and 200, green), two short β-strands (β1 and β2; residues 
127 and 161, purple) and a disulfide bond linking cysteine residues from α-helices 2 
and 3 (S-S, residues 179 and 214). Signal peptide (residues 1–22, cyan) and a C-terminal 
peptide (residues 231–253, light blue) are removed during biosynthesis, followed by 
attachment of a glycosylphosphatidylinositol (GPI) moiety. PrPC also contains two N-
linked oligosaccharide chains (at Asn180 and Asn196, pink) and a disulfide bond 
between residues 178 and 231 in mouse numbering. Adapted from (Petit et al., 2013). B. 
PrPC anchored in lipid raft of cellular membrane (three-dimensional structure) 
extracted from (Petit et al., 2013).   
B 
A 
 Glycans                                     
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2.1.3. PrPC trafficking and metabolism 
PrPC half-life extends to one or two hours in a primary culture of neurons or 
splenocytes (Parizek et al., 2001) and five to six hours in neuroblastoma cells 
N2a (Borchelt et al., 1990). After its cleavage in the plasma membrane, PrPC is 
believed not to remain on the cell surface but cycles between the plasma 
membrane and an endocytic compartment (Fig. 3) (Shyng et al., 1993).  
PrPC is internalized into an endocytic compartment from which most of the 
molecules are recycled intact to the cell surface; a small percentage of the 
endocytosed molecules are proteolytically cleaved via late endosomes and 
lysosomes (Fig. 3). PrPC endocytosis lasts three to five min (Sunyach et al., 2003) 
and, depending on the cell type, may occur through clathrin-dependent 
pathways (Marella et al., 2002; Peters et al., 2003) or be mediated by “caveolae-
like” domains (Shyng et al., 1993) (Fig. 3).  
Cellular processing of PrPC involves two well-documented proteolytic cleavage 
events. α-cleavage occurs at residues His114 and Val115 for the ovine PrPC (Tveit 
et al., 2005) and produces a di- (25–27 K), mono- (21–23 K), or un-glycosylated 
(17 K) C-terminal fragment (C1) (Chen et al., 1995; Kuczius et al., 2007; Laffont-
Proust et al., 2005) and a 9 K N-terminal fragment (N1), which is mostly 
released from the cell by shedding (Vincent et al., 2000). On the other hand, β-
cleavage occurs within or adjacent to the octapeptide repeats (at Gly92 of the 
ovine PrPC) and generates a 21-K C-terminal fragment (C2) and the 
corresponding 7 K N-terminal fragment (N2) (Chen et al., 1995). This type of 
cleavage is less common in healthy animals than α-cleavage and appears to 
occur as a response to oxidative stress (Watt and Hooper, 2005), while α-
cleavage may be mediated by the ADAM family (Vincent et al., 2001).   
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Figure 3. PrPC trafficking in the cell. PrPC can be internalized into early endosomes via 
clathrin-coated pits (1) or via non-clathrin-coated pits (2) from which PrPC can be 
routed either for degradation (3) via late endosomes and lysosomes or for recycling (4) 
via recycling endosomes and Golgi apparatus (5). Adapted from (Rajendran et al., 
2012). 
. 
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2.1.4. PrPC functions 
PrPC has a high degree of conservation in mammalian species, which suggests 
that it has some important function maintained through evolution. PrPC is 
mostly expressed in the CNS, i.e. in the neurons and glia (Brown et al., 1990; 
Kretzschmar et al., 1986), but also in the lymphoreticular system (LRS), skeletal 
muscle, heart, kidney, digestive tract, skin, blood plasma, mammary gland, and 
endothelia (Nuvolone et al., 2009). Despite its ubiquitous expression and 
distribution, its physiological function is not yet clear.  
In an attempt to answer this question, several PrPC knockout (KO) mice lines 
were generated. In general PrPC KO mice are viable, fertile, and have no 
apparent gross developmental or anatomical abnormalities; the exception is one 
Tg mouse line that has late onset ataxia associated with a loss of Purkinje cells 
in the cerebellum, which was finally attributed to the artefactual upregulation 
of the adjacent Doppel gene (Moore et al., 1999). More recently, goats  – which 
naturally devoid PrPC – have been documented in Norway (Benestad et al., 
2012). These goats showed no apparent abnormal behavior or any other 
characteristics that differentiated them from their flock-mates.  
However, when studied in detail, PrPC KO mice exhibit dysfunctions in their 
circadian rhythms, memory, cognition, synaptic transmission, olfaction or 
immunologic alterations. Moreover, altered levels of nuclear factor NF-kappaB, 
Mn superoxide dismutase, and COX-IV, Cu/Zn superoxide dismutase activity, 
p53, and melatonin have also been detected in PrPC KO mice (Linden et al., 
2008; Nicolas et al., 2009; Steele et al., 2007).  
Some authors have associated PrPC with functions related to cell adhesion, 
enzymatic activity, copper metabolism, proliferation, survival, and 
differentiation and programmed cell death. In the nervous system, PrPC seems 
to actively participate in signal transduction (Collinge et al., 1994), synaptic 
plasticity (Prestori et al., 2008), neurogenesis, neurite outgrowth (Chen et al., 
2003), neuroprotection against pro-apoptotic stimuli, ischemic trauma, and 
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reactive oxygen species (Chiarini et al., 2002; McLennan et al., 2004), and copper 
metabolism (Brown et al., 2001). 
Outside the nervous system, PrPC may modulate the response of immune cell 
precursors to extracellular signaling molecules (Ballerini et al., 2006; Mattei et 
al., 2004) and also control the hematopoietic cell differentiation, which includes 
the self-renewal of bone marrow hematopoietic cells (Zhang et al., 2006), thymic 
differentiation (Jouvin-Marche et al., 2006), and the repression of phagocytosis 
and inflammatory response (de Almeida et al., 2005).  
Due to this ability to modulate cell proliferation and apoptosis, PrPC has been 
linked to cancer development and tumor progression, as well as to metastatic 
processes (Mehrpour and Codogno, 2010; Muras et al., 2009; Pan et al., 2006). 
Moreover, new findings suggest that PrPC may also modulate Alzheimer´s 
disease progression by promoting amyloid-β peptide production from amyloid 
precursor protein (APP) (Parkin et al., 2007) and by regulating effects of 
amyloid-β soluble oligomers on synapse alteration (Lauren et al., 2009). Hence, 
although it is known that PrPC participates in many fundamental biological 
processes, its physiological role still needs to be fully elucidated.  
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2.2 Misfolded prion protein (PrPSc) 
2.2.1. PrPSc structure 
PrPC conversion into PrPSc is a post-translational process, that is, both isoforms 
share an identical amino acid sequence within an individual but differ in their 
conformation. The structure of physiological PrPC was deduced in 1996 (Riek et 
al., 1996) (Fig. 4), but the high-resolution three-dimensional structure (3D) of the 
abnormal PrPSc remains unknown, along with the mechanistic details of 
PrPSc self-propagation. 
Deciphering the structural features of PrPSc is a key issue in understanding the 
molecular basis of prion formation and propagation. However, the insolubility 
and the propensity of the PrPSc isoform to aggregate prevent the use of high-
resolution techniques such as NMR or X-ray crystallography. Therefore, only 
partial structural information is available from low-resolution techniques that 
in general do not agree on a single feature or type of β-structure to explain the 
properties of the infectious prion (reviewed in (Requena and Wille, 2014)).  
Studies of the secondary structure of PrPSc suggest that PrPC conversion into the 
pathological isoform PrPSc mainly triggers changes in the N-terminal half of the 
protein such as the folding of a portion of the N-terminal tail from residues 90 
to 121 (and possibly part of the first a-helix) into 𝛽-sheet (Peretz et al., 1997). 
Thereby, unlike PrPC, which contains around 47% 𝛼-helices and 3% 𝛽-sheets 
(Riek et al., 1996), PrPSc is mostly folded into 𝛽-sheets, holding 17–30% 𝛼-helix 
and 43-54% extended 𝛽-structure (Pan et al., 1993) (Fig. 4). 
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Figure 4. Proposed structure of PrPC and PrPSc (adapted from (Prusiner, 2004)).  
 
2.2.2. PrPSc characteristics 
PrPC and PrPSc differ profoundly in their biochemical and biophysical 
properties. PrPC is monomeric, proteinase-sensitive, and soluble in non-ionic 
detergents, whereas conformational misfolding confers PrPSc with an increased 
tendency to aggregate, partial resistance to proteinase digestion, insolubility in 
non-ionic detergents, and high resistance to heat and chemical sterilization 
(Caughey and Chesebro, 2001; Collinge, 2001; Prusiner, 1998b).  
Indeed, PrPSc digestion with proteinase K (PK) produces a C-terminally non-
degraded fragment (PrP27-30 or PrPres) beginning around residues 81–89 (in the 
mouse PrP sequence), which is widely used as a biochemical marker for prion 
detection and characterization (Gielbert et al., 2009). Intriguingly, several 
studies have produced evidence of the existence of the involvement of PK 
sensitive PrPSc (PrPsen) in prion diseases (Gambetti et al., 2003; Pastrana et al., 
2006; Safar et al., 2005; Tzaban et al., 2002). PrPsen was first reported by 
Lasmézas, who observed the presence of clinical disease in the absence of 
detectable PrPres during the transmission of BSE to mice (Lasmezas et al., 1997. 
PrPsen has been observed in scrapie-infected sheep {Thackray, 2007 #26292). 
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PrPsen has also been observed in scrapie-infected sheep and hamsters (Safar et 
al., 1998). The extension of PrPsen involvement depends on the disease but can 
represent up to 90% of the total PrPSc in some sCJD cases (Safar et al., 2005). 
PrPsen is detected by conformation-dependent immunoassay (CDI), which 
provides the differential binding sites of prion proteins after denaturation (Safar 
et al., 1998).  
 
2.3. PrPC to PrPSc conversion site 
The exact site at which PrPC interacts with PrPSc remains unclear. Although 
analysis of the distribution pattern of PrPC and PrPSc in cell cultures has 
contributed to the search for this conversion site, the poor immunoreactivity of 
aggregated PrPSc and the difficulties to immunologically distinguish PrPC from 
PrPSc have hampered this task.  
Most evidence indicates that the interaction between PrPC and exogenous PrPSc 
takes place in detergent-resistant rafts, either extracellularly, on the plasma 
membrane where PrPC is GPI-anchored (Caughey and Raymond, 1991), and/or 
intracellularly in endosomal vesicles (Borchelt et al., 1992; Caughey et al., 2009; 
Caughey and Raymond, 1991; Manuelidis et al., 1976; Taraboulos et al., 1992; 
Vey et al., 1996).  These disagreements in proposed cellular models suggest that 
conversion may well occur along multiple pathways. 
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2.4. Cofactors involved in prion conversion  
Some authors have proposed that non-PrP molecules known as cofactors could 
be involved in the conversion of PrPC into PrPSc. The first evidence of the 
existence of cofactors arose from prion transmissions in transgenic mice that co-
express human and mouse PrPC. These mice were resistant to inoculation with 
human prions; on the other hand,  mice expressing only human PrPC developed 
the prion disease (Telling et al., 1994). These results suggest that mouse PrPC 
was able to inhibit the human PrPC by binding to another unknown factor. 
Nevertheless, the relatively low levels of specific infectivity obtained during in 
vitro studies using only pure PrPC molecules as a substrate (Colby et al., 2010; 
Kim et al., 2010; Makarava et al., 2010) also supports the involvement of 
cofactors in prion replication.  
Several compounds including RNA, homopolymeric nucleic acids such as 
poly(A) and poly(dT), and nonspecific DNA have shown in vitro capacity to 
promote prion replication (Adler et al., 2003; Cordeiro et al., 2001; Deleault et 
al., 2005; Deleault et al., 2003). By contrast, other molecules such as synthetic 
nucleic acids, heparin, albumin, fatty acids, and metal ions may attenuate prion 
replication in vitro (Abid et al., 2010). Although protein chaperones such as 
Hsp104 and GroEL (Parsell and Lindquist, 1993) are able to promote in vitro the 
conversion process of hamster PrPC, chemical chaperones including sucrose, 
trehalose, and dimethyl sulfoxide inhibit this conversion process (DebBurman 
et al., 1997). Heparan sulfate proteoglycans (HSPG) have been shown to be able 
to bring PrPC and PrPSc together and to act as a scaffold for the PrPSc 
fibrillization (Wong et al., 2001). HSPGs are able to bind PrPSc on the cell surface 
and facilitate its internalization by macropinocytosis (Horonchik et al., 2005; 
Wadia et al., 2008) and also to bind PrPC, thereby enhancing subcellular 
trafficking in clathrin-coated pits (Shyng et al., 1994). 
The specific identity and functions of cofactors have not yet been fully 
deciphered. Cofactors could act either as a catalytic molecule that binds both 
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PrPC and PrPSc and brings them together, thereby lowering the activation 
energy for the conversion process, or may just bind PrPSc and so stabilize its 
conformation. Cofactors might also play a pivotal role in the strain properties of 
newly generated PrPSc. The strain properties of recombinant PrPSc generated 
from recombinant PrPC by serial Protein Misfolding Cyclic Amplification in the 
presence of cofactors such as 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphoglycerol and RNA molecules were altered in subsequent in vitro 
passages by changing the cofactor element to phosphatidylethanolamine 
(Saborio et al., 2001). 
 The question remains whether the cofactor molecule is a component of the 
infectious particle or whether it is a molecule provided by the host. The latter 
case would suggest that the infectious agent causing prion diseases consists of a 
complex PrPSc-cofactor, a hypothesis that contradicts the Protein-Only 
Hypothesis. 
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2.5. Prion conversion models 
Prion diseases may occur as familial (inherited), spontaneous, or acquired 
(infectious) diseases. The mechanism of conversion from physiological PrPC to 
pathological PrPSc has not yet been clarified and two models have been 
proposed to explain it (Fig. 5):  
- Template-directed refolding model: this model postulates that the 
monomeric PrPSc acts as a conformational template, promoting the conversion 
of endogenous monomeric PrPC into a conformational intermediate 
(heterodimer) and finally originating further PrPSc (Fig. 5). The PrPSc dimer 
would then interact with other dimers and thus form larger aggregates. In 
healthy animals, a high-energy barrier exists that prevents the spontaneous 
conversion of PrPC into PrPSc. However, disease-linked mutations of the prnp 
could increase the stability of the PrPC mutated forms, either via the interaction 
between PrPC monomeric components and/or by abrogating the kinetic barrier 
that inhibits the conversion of PrPC into PrPSc, and so give rise to inherited or 
spontaneous prion diseases (Bradley and Wilesmith, 1993). In infectious forms 
of prion diseases, the exogenous PrPSc has been proposed as the element that 
leads the misfolding process (Safar, 1996). 
- Seeded nucleation-polymerization model: this model proposes that PrPC and 
PrPSc coexist in a reversible thermodynamic equilibrium that in a physiological 
state is shifted toward the PrPC conformation limiting the amount of PrPSc. 
Therefore, according to this model, the monomeric PrPSc would represent a 
minor and transient isoform of PrP and would only be destabilized in the event 
of the organization of several monomeric PrPSc into highly ordered seeds 
during the nucleation phase (Fig. 5). These infectious seeds would act as stable 
nuclei called amyloids that displace the equilibrium to the accumulation of the 
pathological isoform. The fragmentation of the amyloid aggregates increases 
the number of replication units, which can recruit further PrPSc and thus confer 
the infectious capacity of the prion (Glatzel and Aguzzi, 2001). Thermodynamic 
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disequilibrium toward PrPSc would be caused by disease-linked mutations that 
destabilize PrPC, thereby increasing its tendency to misfold (Apetri et al., 2004; 
Liemann and Glockshuber, 1999; Swietnicki et al., 1998; Zhang et al., 2000). The 
critical (rate-limiting) nucleation step is responsible for the “lag phase” 
observed in the spontaneous conversion reaction (Cobb and Surewicz, 2009) 
that would be shortened or even abolished by “seeding” exogenous preformed 
PrPSc aggregates in acquired TSEs (Collinge and Clarke, 2007).  
 
 
 
 
Figure 5. Models proposed for the PrPC conformational conversion into PrPSc (adapted 
from Aguzzi et al., 2004).  
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3. Pathogenesis of prion diseases 
Prion diseases may occur as either inherited or sporadic disorders, or be 
acquired by infection. In all forms, the key event in the pathogenesis of prion 
diseases is the conversion of the physiological PrPC into pathological PrPSc. 
While PrPC is expressed ubiquitously throughout the organism, the main target 
tissue for PrPSc replication is the brain.  
In acquired TSEs the most likely route of infection by prions is the ingestion of 
prion-contaminated products such as grass, soil, meat, or bones. Scarification of 
the skin and infection of mucous membranes/conjunctiva via direct contact 
with prion-contaminated excretions and secretions (saliva, feces, urine, blood, 
placenta, and milk) have also been suggested as alternative routes of infection 
(Mohan et al., 2004; Scott et al., 1993a; Taylor et al., 1996). The spread of prions 
from the infection site to the brain depends on several factors including entry 
site, dose, strain, and host genotype.  
When orally acquired, infectious prions penetrate the mucosal barrier of the 
stomach in one of three possible ways: the uptake of M-cells (Neutra et al., 
1996), via dendritic cells (not yet demonstrated), or endocytosed in vesicular 
structures by a ferritin-dependent mechanism (Mishra et al., 2004). Infectious 
prions reach the gut-associated lymphoid tissues (GALT) of the tonsil and the 
Peyer’s patches in the intestines, where they accumulate and replicate 
(Andreoletti et al., 2000; Hadlow et al., 1982; van Keulen et al., 2002).  
Cell tropism of prion strains seems to play a determinant role at this point. 
Scrapie is a clear lymphotropic prion agent, i.e. it colonizes lymphoid organs 
immediately after the peripheral infection and before CNS invasion. By 
contrast, BSE is neurotropic and invades the brain without any major 
replication in the LRS. Thus, in naturally infected cattle, replication of the BSE 
agent in the lymphoid tissues is minimal-to-absent. Only cattle experimentally 
infected with high doses have BSE infectivity in their ileum or tonsils (Espinosa 
et al., 2007b; Wells et al., 1994; Wells et al., 1998; Wells et al., 2005). 
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After replication in the GALT, prions are drained from the GALT-draining 
retropharyngeal and mesenteric lymph nodes (Andreoletti et al., 2000; van 
Keulen et al., 2002), from where neuroinvasion occurs through the enteric 
nervous system (ENS) of the gut (Andreoletti et al., 2000; Iwata et al., 2006; 
Schmerr et al., 1997). After the infection of the ENS, prions ascend along the 
parasympathetic (neurons of the dorsal motor nucleus of the nervus vagus, 
DMNV) and sympathetic efferent (neurons of the intermediolateral column 
neuronal, IMLC) pathways to the brain and to the spinal cord (Hoffmann et al., 
2007; van Keulen et al., 2002). From these sites in the CNS, the infection both 
ascends and descends and eventually affects the entire neuraxis.  
PrPSc spread to peripheral sites may take place before and/or after 
neuroinvasion. For example, in scrapie-infected sheep and goats, PrPSc 
deposition has also been observed in numerous peripheral structures such as 
nictitating membrane, muscles, placentas (Andreoletti et al., 2002), skin (Garza 
et al., 2014; Thomzig et al., 2007), mammary glands (Ligios et al., 2005), distal 
ilium, proximal colon (van Keulen et al., 2008a), pancreas, heart, and urinary 
bladder (Garza et al., 2014). The peripheral nervous system appears to be the 
main mechanism of PrPSc dissemination in hosts; however, inflammation or the 
presence of prions in the blood could underlie wider dissemination and more 
pronounced accumulation of PrPSc deposits in the body (Garza et al., 2014; 
Ligios et al., 2005). Indeed, prion infectivity has been reported in humans, 
primates (Bons et al., 2002), sheep (Houston et al., 2000), goats (Dassanayake et 
al., 2012), rodents (Brown et al., 1998), and cervids (Bannach et al., 2012; 
Dassanayake et al., 2012; Dassanayake et al., 2011; Jackman et al., 2006; Lacroux 
et al., 2012; Mathiason et al., 2010; Schmerr et al., 1997). 
Notably, the prnp genotype of the host modulates the PrPSc distribution in 
scrapie-infected sheep. For example, sheep carrying the V136R154Q171 or 
A136R154R171 genotypes exhibited minimal or no involvement of the lymphoid 
tissues in agent replication (van Keulen et al., 1996). Similar distribution 
modifications were observed in goats harboring the H154, Q211 or K222 prnp 
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mutations intracerebrally inoculated with scrapie (Lacroux et al., 2014a). Hence, 
both prion strain and host genotype strongly affect the distribution of infectious 
prions in the organism via a mechanism that is as yet unknown. 
4. Neurotoxicity 
The neurotoxic mechanism of pathological prions and the responsible toxic 
forms of PrP are not yet well established. PrPSc deposition appears as the 
earliest event in the pathological cascade of prion diseases, followed by 
microglial activation and the appearance of spongiform change or vacuolation. 
Different pathways including cellular systems associated with synapses, protein 
processing, oxidative stress, autophagy, and apoptosis (Kovacs and Budka, 
2009) seem to be involved in this tissue damage; nevertheless, the neurotoxic 
mechanism is still not well known.  
PrPSc aggregates are commonly designated as the primary cause of 
neurodegeneration due to the temporal and anatomical correlation between the 
accumulation of this pathological form and the development of 
neuropathological changes. However, in some cases significant pathology 
and/or clinical dysfunction develop even with little accumulation of PrPSc; in 
other cases, subclinical infections have abundant PrPSc but little 
symptomatology. Moreover, PrPSc is innocuous in the absence of GPI-linked 
PrPC, suggesting that PrP oligomers and fibrils are not toxic per se (and may 
require PrPC as a mediator of the toxic signal (Brandner et al., 1996)).  
On the other hand, growing evidence supports the neurotoxic role of multiple 
intermediate structures – mainly in an oligomeric state – prior to the fiber 
formation and/or their specific interaction with membranes (Caughey and 
Lansbury, 2003; Haass and Selkoe, 2007). Moreover, the physicochemical 
properties of these intermediate structures such as size, aggregation propensity, 
and glycosylation state seem to correlate with the clinicopathological features 
(Parchi et al., 2011), thereby suggesting that PrPSc fragments have variable 
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neurotoxicities and cause distinct lesions as a consequence of their different 
properties (Parchi et al., 1998).  
5. Prion strain 
Like conventional infectious agents, mammalian prions occur in a variety of 
different strains that are defined as natural isolates of infectious prions. Prion 
strains cause distinctive disease phenotypes (including incubation times, 
clinical signs, and the histopathological lesion profiles and PrPSc deposition 
patterns in the brain) that are faithfully recapitulated upon serial passage 
within the same host genotype (Beringue et al., 2008b; Collinge and Clarke, 
2007). Evidence of different prion strains was first reported in goats inoculated 
with a pool of scrapie-infected sheep brains. Scrapie transmission resulted in 
two clinically different disease phenotypes: ‘scratching’ or ‘drowsy’ (Pattison et 
al., 1959; Pattison and Millson, 1961).  
5.1. Molecular basis of prion strains 
The Prion Protein-Only Hypothesis postulates that the different prion disease 
phenotypes found in animals are due to differences in the genetic information 
triggered by the prion agent (Chesebro, 1998). However, prions are proteins 
and consequently do not harbor any genetic information. Experimental data 
available to date provides clear evidence that prion strains are encoded by the 
variety of conformations that PrPSc can adopt, which can affect its biological 
and biochemical properties. These molecular differences are thought to be the 
underlying cause of the widespread pathological range of prion diseases. 
The first evidence of the molecular basis of the diversity of prion strains came 
from a study in which scrapie-associated fibrils (SAF) from scrapie-infected 
mice and hamsters (ME7 and 139A in mice, and 263K in hamster) were isolated 
and their molecular properties compared (Kascsak et al., 1985). ME7 and 139A 
had different morphologies, erythrocyte sedimentation rates, and sensitivity to 
PK digestion from those in hamster 263K, differences that were associated with 
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the distinct biological and pathological properties of the prion strains. In 
another study, two biologically distinct strains, “hyper” (HY) and “drowsy” 
(DY), were distinguished after transmission of transmissible mink 
encephalopathy (TME) in hamsters, during which differences occurred in their 
PrPSc sedimentation in N-lauroylsarcosine, sensitivity to PK digestion, 
electrophoretic mobility, and even in their immunoreactivity in the N-terminus 
(Bessen and Marsh, 1992). These findings indicated that, although originating 
from the same host, the PrPSc molecules of different prion strains vary in 
conformation and/or composition.  
Studies of yeast have provided essential information for understanding the 
phenomenon of prion strains. A direct correlation between the frangibility 
(propensity to break up) of yeast PrPSc fibrils and their rate of replication have 
been reported (Immel et al., 2007; Tanaka et al., 2006; Tanaka et al., 2004) and 
extended to mammalian prions. A conformational stability assay of 30 different 
mammalian prion isolates revealed a linear relationship between the 
concentrations of guanidine hydrochloride (Gdn.HCl) required to denature 50% 
of PrPSc molecules and incubation times. This finding suggests that low PrPSc 
stability favors fragmentation of PrPSc molecules, thereby exposing more PrPSc 
surface able to bind to further PrPC and finally resulting in an increased rate of 
PrPSc formation and shorter incubation times (Legname et al., 2006). 
Besides the incubation time, prion stability has also been associated with the 
differential ability of prions to invade the CNS (Bett et al., 2012b). Thus, highly 
neuroinvasive prion strains seem to be conformationally unstable in denaturing 
conditions and efficiently form diffuse, non-fibrillar PrP aggregates in the CNS, 
which produces a rapid progression to terminal disease in mice. On the other 
hand, weakly neuroinvasive strains form dense, congophilic, fibrillar plaques 
and mice progress to terminal disease more slowly.  
  
 INTRODUCTION  
  
 
45 
 
 
5.2. Characterization of prion strains 
Prion strains can be characterized according to a number of different 
parameters: 
-Biological properties: prion strains produce specific disease phenotypes that 
can be identified by their incubation periods, clinical signs, and 
histopathological alterations such as PrPSc distribution and nature, lesion 
profiles (spongiosis), and tissue and cellular tropisms.  
-Biochemical properties:  each prion strain is associated with a specific cluster of 
biochemical features characterizing its PrPSc. Of these; the major hallmarks for 
prion differentiation are stability toward denaturing agents, glycosilation 
patterns and electrophoretic mobility after PK digestion, and resistance to 
proteolytic degradation.  Furthermore, differences between strains in their 
binding affinity for copper have also been described (Wadsworth et al., 1999). 
-Conformational properties:  distinct prion strains may display similar patterns 
of protease resistance but can be distinguished by their conformations. 
Differences in strain conformation can be revealed by sedimentation techniques 
(Bessen and Marsh, 1992), light scattering (Scheibel and Lindquist, 2001), both 
transmission electron microscopy and atomic force microscopy for assembly 
(Serio et al., 2000), through structural change studies, by circular dichroism 
(Safar et al., 1998) and dye binding (Nilsson, 2004; Sigurdson et al., 2006; 
Sigurdson et al., 2007), and through mapping binding sites by conformation-
dependent immunoassay (CDI) (Zou et al., 2003).  
6. Prion transmission 
Prion agents can be transmitted within or even between mammalian species. 
Although intra-species prion transmission is normally efficient and maintains 
disease features, the outcome of a cross-species transmission is unpredictable. 
In some cases, no TSE develops, while in others, although TSE does not develop 
clinically, silent/subclinical infection can occur. If transmission occurs, the TSE 
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agent can either remain identical to the original or evolve into a completely 
different prion strain as an adaptation to the new species (Bruce and Dickinson, 
1987; Kimberlin et al., 1987; Kimberlin et al., 1989; Pattison, 1965; Peretz et al., 
2002; Prusiner et al., 1990). In this latter case, some features of the newly 
generated prion are related to the original prion isolate, while others may be 
linked to the new host PrPC amino acid sequence or to other host factors.  In this 
second passage, the incubation periods decrease and the biochemical and 
neuropathological properties of the prion isolate are stabilized. This 
phenomenon is known as the “species barrier” and despite intensive 
investigation it still remains largely enigmatic.  
6.1. Factors governing prion transmission  
6.1.1. PrP genotype 
At molecular level, the transmission barrier was initially believed to be 
governed entirely by the degree of PrP amino acid sequence similarity between 
donor and recipient species. This assumption was derived from the fact that 
during prion infection a highly specific physical interaction between PrPC and 
PrPSc is required for the prion conversion. Thus, minimal changes in the PrPC 
amino acid sequence have a large impact on the susceptibility of a species to 
infection with a specific prion strain.  
Many studies have supported this assumption. For example, black weasel and 
the mink have shown different susceptibility when inoculated with the same 
mink-transmissible encephalopathy isolate (Bartz et al., 1994). The PrPC primary 
structures of these two mustelids only differ by two amino acid residues, which 
could be the cause of the differing susceptibilities.  
Besides interspecific variations in amino acid sequences, allelic variants in the 
prnp can affect the efficiency of prion disease transmission. In humans the 
susceptibility to vCJD and BSE is modulated by the V/M129 polymorphism. 
Cases of vCJD disease have only been observed in people who are homozygous 
for the M129 allele (Collinge and Clarke, 2007), while experiments using Tg mice 
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have demonstrated that the human V129 acts as a transmission barrier to the BSE 
prion agent, thereby producing alterations in the disease phenotype 
(Wadsworth et al., 2004). 
Prnp mutations can occur in different parts of the PrPC sequence, although not 
all influence transmission efficiency to the same degree. The amount of amino-
acid overlap between infectious PrPSc and endogenous PrPC substrate within 
the central region of the prion protein deeply affects the efficiency of the 
conversion process (Scott et al., 1993b; Scott et al., 1992; Telling et al., 1995). 
Above all, the β2–α2 loop region of the prion protein (residues 165–175 in the 
mouse prion protein) has been proposed as a critical region in the 
PrPC structure since minimal changes in its amino-acid sequence seriously 
influence mouse susceptibility to sheep scrapie, BSE, mouse-adapted scrapie, 
deer chronic wasting disease, and hamster-adapted scrapie prions (Bett et al., 
2012a; Sigurdson et al., 2011; Sigurdson et al., 2010).  
More recently, bank vole PrPC was proposed as a universal acceptor for prions 
(Watts et al., 2014) since Tg mice overexpressing this species’ PrPC are 
susceptible to a wide range of prion isolates from many different species 
(including humans, cattle, elk, sheep, guinea pigs, hamsters, mice, and meadow 
voles). This exceptional promiscuity of bank vole PrP Tg mice further indicates 
that only a small number of amino acid differences in the PrP influence the 
conversion efficiency of prions. 
6.1.2. Prion strain 
Transmission efficiency is also profoundly determined by the prion strain.  For 
example, bovinized Tg mice PrP can be infected with vCJD at ∼270 days but 
need over 500 days to succumb to sCJD subtype MM1 (Giles et al., 2010; Scott et 
al., 2005; Scott et al., 1999). Notably, the prion agents used in these transmission 
studies (vCJD and sCJD subtype MM1) harbored the same amino acid 
sequence, thereby supporting the idea that the differences in the sequences of 
PrPSc in the inoculum and PrPC in the host are insufficient to explain all aspects 
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of prion transmission from one host to another. Similarly, Tg mice expressing 
porcine PrP are susceptible to sheep-BSE but not to scrapie (Espinosa et al., 
2009). 
Recently, our group has compared the properties of BSE prions after 
transmission to different species with other non-BSE related prions, and has 
shown that the BSE agent was able to cross the trans-species barrier without 
any fundamental alteration of their strain specific features; on the other hand, a 
high species barrier was observed for non-BSE related prions harboring an 
identical PrP amino acid sequence (Torres et al., 2014). These results confirm 
that BSE is a highly promiscuous prion agent and supports the contention 
that prion transmission barriers might be modulated by strain properties 
(presumably conformation-dependent) rather than by PrP amino acid sequence 
differences existing between host and donor.  
6.2. Emergence of prion strains: “adaptation” vs. “selection” 
The emergence of new prion strains occurs when a propagated prion does not 
maintain the same biochemical and pathogenic characteristics as the original 
strain. This phenomenon can occur either during cross-species transmission or 
within a single species (Falsig et al., 2008). In the first case, the sequence of the 
PrPC of the host is different from that of the donor (prion agent) and, due to the 
species barrier, the conversion process can lead to a different strain (Collinge et 
al., 1996). In the second case, the prnp gene, coding for the PrPC, is identical in 
the donor and the host, suggesting that other mechanisms such as cofactors or 
host cellular environment or polymorphisms of the PrPC sequence (see below) 
may be involved in strain selection.  
Two theories have been proposed to explain the emergence of prion strains: 
strain “mutation” and strain “selection”. The former postulates that strains 
exist as a single clone that can suffer a change into one or multiple new strains 
after transmission into a host (Fig. 6B2). This shift results in new biochemical, 
biological, or histological properties. By contrast, the latter theory proposes that 
 INTRODUCTION  
  
 
49 
 
 
strains exist as a mixture of PrPSc conformers in a relative proportion, which 
varies upon transmission to different species (Angers et al., 2010). This process 
would lead to the emergence of new strain properties but not to the emergence 
of new prion strains (Fig. 6D). 
6.3. Conformational Selection model 
The “conformational selection” model was postulated to explain how the host 
PrPC sequence influences the ability to propagate strain features. This model 
proposes that a prion strain would consist of a cloud of possible PrPSc 
conformations, i.e. a dominant PrPSc species plus other less abundant 
PrPSc structures, and that its transmission would be determined by the degree 
of overlap between the range of PrPSc conformers that the prion strain harbors 
and the conformational constraints imposed by the sequence and conformation 
of the host PrPC (Fig. 6D) (Beringue et al., 2008b; Collinge and Clarke, 2007). 
According to this model, depending on their PrPC properties and the PrPSc 
conformations in the infecting inoculum, each mammal species could be 
infected by a range of possible PrPSc conformations. In this way, the relative 
composition of this cloud is maintained in its original host but upon passage to 
a new host it may adopt a different ratio of conformations and thus a new strain 
is formed (Fig. 6D). Therefore, the emergence of the new strain would result 
from an inability of the new host PrPC sequence to adopt the dominant PrPSc 
structure and so a different subset of PrPSc conformers are propagated instead.  
 INTRODUCTION  
  
 
50 
 
 
 
Figure 6. Models for the emergence of prion strains and transmission barrier. The 
transmission barrier is determined by the degree of overlap between the range of PrPSc 
conformers (represented by different shapes: stars, triangles, and circles) and the 
diverse sequences of the PrPC in the host (represented by different colors) (adapted 
from (Beringue et al., 2008b; Collinge and Clarke, 2007). Several possibilities may 
occur: 
A. The infection of PrPC A with a prion strain from its species resulting in the 
propagation of the original phenotypic properties of the strain.  
B. The heterologous transmission of the prion strain from species A may result in two 
different outcomes. PrPC B may not be able to adopt the conformation of the prion 
strain from species A and so transmission is not possible (B1). Conversely, PrPC C can 
replicate this prion strain, although its properties are modified by a phenomenon 
known as mutation (B2). 
C. Further passage of the newly formed strain may result in the maintenance of the 
properties formed during previous passage (C1). Nevertheless, transmission to the 
PrPC species of origin may rescue the original properties of the prion strain from 
species A (C2).  
D. Conformational selection: Strains harbor a range of conformations that interact with 
PrPC. Only the most compatible PrPSc conformations with the conformational 
constraints imposed by the host PrPC sequence are replicated by the PrPC species, 
thereby giving rise to a variety of strain characteristics. 
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Alternatively, multiple PrPSc types might be produced de novo during 
heterologous transmission (C). Independently of the mechanism, mutation, or 
selection, the establishment of the new strain properties might be gradual upon 
serial transmissions within the host. 
The molecular mechanism by which the range of PrPSc conformers is produced 
and selected during the process of strain “adaptation” or “selection” is as yet 
unknown. One possibility is that each PrPSc conformer requires a unique set of 
cofactors to propagate efficiently, and that the distribution of these cofactor 
molecules varies between animal species and even between cell types. In line 
with this view, different cell types within the same host can offer unique 
environments and selective pressures, each resulting in the emergence of 
different mutants as major constituents of the evolving population (Aguzzi and 
Sigurdson, 2004; Li et al., 2010; Mahal et al., 2007; Tremblay et al., 2004). 
Lymphotropism is a prion characteristic that varies greatly depending on the 
strain (Bartz et al., 2005). For example, scrapie, CWD, and vCJD are able to 
replicate in lymphoid tissues, while cattle BSE agent is only poorly 
lymphotropic but increases this ability when adapted to sheep PrP sequence 
(reviewed in (Beringue et al., 2008b)).  
Selective metal binding could be another mechanism of prion strain generation. 
In an in vitro conversion study performed with two different human prion 
strains isolated from two clinically different cases of sCJD, one sCJD strain 
could have converted into the other merely by changing its metal ion 
occupancy, thereby indicating that copper and zinc binding can influence PrPSc 
conformation (Wadsworth et al., 1999).  
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7. Human transmissible spongiform encephalopathies 
Human prion diseases are classified according to their origin as sporadic, 
familial, or inherited, and as infectious or acquired. Polymorphism M/V at 
codon 129 of the human prnp appears to be a key factor in human prion 
susceptibility and to act as a modifier of the disease phenotype in human prion 
diseases (Alperovitch et al., 1999; Collinge et al., 1991; Doh-ura et al., 1991; 
Palmer et al., 1991; Zeidler et al., 1997). In Caucasians, 52% of individuals are M 
homozygous (MM), 36% are heterozygous (MV), and 12% are V homozygous 
(VV) (Alperovitch et al., 1999; Collinge and Palmer, 1994). Approximately 95% 
of the sCJD patients who carry M/M129 prnp genotype develop a PrPSc type 1 or 
sCJD, whereas 86% of the patients harboring either the V/V129 or M/V129 
develop a PrPSc type 2 sCJD or ataxic sCJD (Parchi et al., 1996; Parchi et al., 
1999). Furthermore, M/M129 patients who harbor the N/D178 mutation develop 
a Fatal Familial Insommia (FFI)-like syndrome, while V/V129 patients develop a 
familial CJD (Lloyd et al., 2011). In familial CJD cases, the codon 129 
polymorphism seems to modulate the age of onset and duration of the illness 
(Gambetti et al., 1995). 
7.1. Inherited transmissible spongiform encephalopathies 
Familial CJD forms comprise 10–15% of all human prion diseases. All these 
forms are inherited as autosomal dominant traits and most are linked to point 
mutations in the ORF of the prnp gene, including 24 missense point mutations, 
27 octapeptide repeat mutations with insertions of 1, 2, and 4–9 additional 
repeats, 2 octapeptide repeat mutations with deletion of two repeats, and two 
nonsense mutations (Fig. 7). Most are located at the C-terminal domain on α2 
and α3 helices. Each mutation has been linked with a specific disease 
phenotype and familial CJD cases are commonly classified as one of three 
phenotypes: Gerstmann-Sträussler-Scheinker disease (GSS), familial CJD (fCJD), 
and fatal familial insomnia (FFI). 
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GSS has an average age of onset of 50–60 years and is characterized by a slowly 
progressive cerebellar dysfunction, ataxia, nystagmus, dysarthria, and cognitive 
decline. GSS has been associated with numerous mutations but mainly with 
P/L102 (Glatzel et al., 2005; Kovacs and Budka, 2009; Piccardo et al., 1998). fCJD 
presents very similar clinical features to sCJD and prnp sequencing is required 
to guarantee correct identification (Glatzel et al., 2005). FFI has an average age 
of onset of around 49 years and can be associated with the D/N178 mutation in 
combination with M/M129. It causes sleep disturbance, oneiric or stuporous 
episodes characterized by hallucinations and confusion, autonomic 
dysfunction, and often myoclonus, spasticity, and seizures (Glatzel et al., 2005; 
Kovacs and Budka, 2009).  
 
 
Figure 7. PrP mutations and polymorphisms of human PrPC. Schematic 
representation of full-length human PrPC, including disease-associated mutations (in 
red) and non-synonymous non-pathogenic genetic variants (in green). (OPRD: 
octapeptide repeat deletion; OPRI: octapeptide repeat insertion). Cleaved signal 
sequences (in grey) and octapeptide repeat region (in purple) are shown (extracted 
from (Lloyd et al., 2013).  
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7.2. Sporadic transmissible spongiform encephalopathies 
sCJD represents ≈85% of all CJD cases (Masters et al., 1979) and occurs at a rate 
of 1–2 cases/million population (Mead et al., 2003). sCJD has a peak age of 
onset at 55–75 years (Glatzel et al., 2005), although some younger (under 20 
years) and older (over 90 years) cases have been reported. The etiology of sCJD 
is unknown. The transmission of human or animal prions, the somatic mutation 
of the prnp, or spontaneous PrPC into PrPSc conversion have all been proposed 
as possible origins (Prusiner, 1998a).  
The disease is characterized by rapidly progressive dementia, cerebellar 
dysfunction including muscle incoordination, and visual, speech, and gait 
abnormalities, spontaneous or induced mioclonia, extrapyramidal or pyramidal 
dysfunction with reflexes, tremors, spasticity, and rigidity, behavioral 
alterations such as agitation, confusion, and depression, and a state of akinetic 
mutism at the end of the course of the disease (Belay, 1999). The illness usually 
lasts 3–6 months (Glatzel et al., 2005; Kovacs and Budka, 2009).  
The clinicopathological and molecular phenotypes of sCJD are profoundly 
influenced by mutations in the prnp genotype. In this way, M129 homozygotes 
account for approximately 70% of all sCJD cases (Kovacs and Budka, 2009). 
Current classifications of CJD are mainly based on the combination of genotype 
(polymorphism at codon 129 of prnp) and PrPres molecular characteristics 
(Collinge et al., 1996; Hill and Collinge, 2003Head, 2004 #966; Parchi et al., 1999; 
Wadsworth et al., 1999; Zanusso et al., 2001). 
7.3. Infectious transmissible spongiform encephalopathies 
7.3.1 Kuru  
Kuru is a neurological disorder endemic to the Fore linguistic tribal regions 
of Papua New Guinea (Gajdusek and Zigas, 1957). The term "kuru" derives 
from the Fore word kuria/guria ("to shake") and refers to the body tremors 
exhibited by patients. The clinical stage lasts for between 3 months to 2 years 
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(on average of 12 months) and has three clearly different stages: ambulant 
(infected people can still walk), sedentary (can only sit up), and terminal 
(unable to sit up independently). Cerebellar ataxia, tremors, deterioration of 
speech, and dysarthria are other distinctive clinical signs. Kuru was the first 
human TSE transmitted to chimpanzees (Gajdusek et al., 1967). The etiology of 
the disease was soon linked to endocannibalistic funeral practices and, after a 
ban on ritualistic cannibalism imposed by the Australian authorities in the mid-
1950s, the incidence of the disease started to decline steadily (Alpers, 2008).  
7.3.2 Iatrogenic CJD (iCJD)  
Iatrogenic transmission of CJD occurs due to the use of stereotactic intracerebral 
electrodes or neurosurgical instruments that have been inadequately sterilized, 
cadaveric dura mater grafts, or intramuscular injections of contaminated 
cadaveric pituitary-derived human growth hormone (hGH) and gonadotrophin 
hormone. Clinical signs are similar to sCJD, although in some cases due to 
hormone treatment cerebellar symptomatology may dominate (Brown et al., 
1992; Glatzel et al., 2005; Kovacs and Budka, 2009).  
7.3.3 Variant CJD  
The first variant CJD (vCJD) cases were reported in 1996 in UK in teenagers and 
young adults with psychiatric symptoms instead of the cerebellar ataxia or 
progressive dementia that is typical of CJD (Will et al., 1996). Soon after the first 
reports of these cases, epidemiological studies along with the experimental 
transmission of the disease to cynomologous macaques and mice and 
biochemical strain-typing managed to link the etiology of vCJD to exposure to 
BSE-infected meat products (Bruce et al., 1997; Hill et al., 1997; Will et al., 1996). 
As of June 2014, 226 vCJD diagnoses have been reported worldwide, most of 
them in the UK (Table 2) 
(http://www.cjd.ed.ac.uk/documents/worldfigs.pdf). Once again, M/V129 
human polymorphism has a determinant influence on vCJD cases and, to date, 
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all except one clinical case have been homozygous M/M129 (Kaski et al., 2009; 
Kovacs and Budka, 2009). 
The psychiatric symptoms of vCJD include agitation, aggression, depression, 
anxiety, apathy, sensory disturbance (paresthesia, diesthesia, and pain), and 
paranoid delusions. Neurologic symptoms begin at least six months after the 
onset of psychiatric symptoms and comprise cerebellar ataxia, cognitive 
impairment, and involuntary movements that may be dystonic, choreiform, or 
myoclonic (Spencer et al., 2002). The mean age at the onset of symptoms is 29 
years, and the total duration of the disease is on average 18 months (Belay, 1999; 
Will, 2003). Neuropathological hallmarks of vCJD are florid plaques that 
predominantly occur in the cerebellum and cerebrum (Belay, 1999). vCJD PrPres 
glycoprofile is similar to that observed in cattle BSE but is different from that 
observed in sCJD (Collinge et al., 1996; Hill et al., 1997).  
Importantly, at least four cases of vCJD in UK have been associated with 
secondary human-to-human transmission due to blood transfusions (Wroe et 
al., 2006), which has raised serious public health concerns (Hewitt et al., 2006; 
Llewelyn et al., 2004; Sibbald, 2004). As a consequence, in 2004 the UK Blood 
Service banned transfusion recipients from donating blood. 
Table 2. vCJD cases worldwide (June 2014) 
Country 
Total number of 
primary cases 
Total number of 
secondary cases  
Residence in UK 
>6 months 
during 1980-1996 
UK 174 4 177 
France 27 - 1 
Spain 5 - 0 
Republic of 
Ireland 
4 - 2 
USA 4 - 2 
Netherlands 3 - 0 
Canada 2 - 1 
Italy 2 - 0 
Portugal 2 - 0 
Japan 1 - 0 
Saudi Arabia 1 - 0 
Taiwan 1 - 1 
 INTRODUCTION  
  
 
57 
 
 
8. Transmissible spongiform encephalopathies in animals 
8.1 Scrapie 
8.1.1. Classical scrapie 
Scrapie is a TSE naturally affecting sheep, goats, and mouflons (Jeffrey and 
Gonzalez, 2007) that is today endemic in many countries worldwide. Scrapie is 
characterized by its long incubation periods (2–5 years) and survival times 
ranging from two weeks to six months. Clinical signs include behavioral 
changes (fixed stare, isolation, hyperexcitability, loss of inquisitiveness), 
trembling, incoordination of gait, weight loss or emaciation, pruritus (the main 
symptom in sheep, which usually leads to wool loss), and impaired vision 
(Bellworthy et al., 2008; Dickinson, 1976; Hadlow et al., 1982).  
Associated neurological lesions depend deeply on the scrapie strain but 
generally include neuronal degeneration, non-inflammatory spongiform 
changes, and astrogliosis, which are detected mainly in the diencephalon, 
midbrain, pons, medulla oblongata, and cerebellar cortex (Hadlow et al., 1982). 
Apart from the nervous system, PrPSc deposition has also been observed in the 
tonsils (Andreoletti et al., 2000), spleen (Hadlow et al., 1982), lymph nodes (van 
Keulen et al., 2008a), nicitating membrane, muscles, placentas (Andreoletti et 
al., 2002), skin (Garza et al., 2014; Thomzig et al., 2007), mammary glands 
(Ligios et al., 2005), distal ilium, proximal colon (van Keulen et al., 2008a), and, 
more recently, in the pancreas, heart, and urinary bladder (Garza et al., 2014).  
Although there is some evidence of vertical transmission (Spiropoulos et al., 
2014), the most likely route of prion infection seems to be contact transmission 
between ewes and their lambs around the time of birth (Imran and Mahmood, 
2011). The presence of scrapie infectivity in blood (Bannach et al., 2012; 
Dassanayake et al., 2012; Dassanayake et al., 2011; Lacroux et al., 2012), saliva 
(Gough et al., 2011; Tamguney et al., 2012), milk (Ligios et al., 2011), and 
colostum (Konold et al., 2013) in conjunction with the high resistance of this 
prion agent against denaturizing factors contribute to its permanence in the 
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environment, i.e. in the soil (Saunders et al., 2012b), and consequently favors 
horizontal transmission within sheep and goats herds.  
To date, epidemiological and transmission studies have failed to demonstrate 
any link between scrapie disease and any human prion disease despite 
worldwide endemicity ((BIOHAZ), 2011; Wadsworth et al., 2013). More 
recently, some classical scrapie isolates from infected sheep have been 
transmitted to humanized Tg mice expressing either the M129 or V129 
polymorhic variants with similar efficacy as in cattle-BSE (Lacroux et al., 2014b). 
Interestingly, after serial transmission in these humanized Tg mice, the scrapie 
isolates were phenotypically identical to either sCJD type 1 or sCJD type 2. 
These results demonstrate the zoonotic potential of classical scrapie agents and 
are an argument for their prompt control and eradication. 
8.1.2 Scrapie strains: classical scrapie vs. atypical scrapie 
Increased surveillance over the past two decades has led to the identification of 
a wide variety of scrapie disease phenotypes, which differ in terms of their 
incubation periods, clinical signs, PrPres WB profile, PrPSc distribution, and 
pathogenesis. These differences are suggestive of a number of scrapie strains 
and highlight the tremendous heterogeneity of the scrapie disease. In addition, 
an unusual type of scrapie was identified in 1998 in Norway and was named 
atypical scrapie Nor-98 (Benestad et al., 2003). Currently, an increasing number 
of atypical/Nor98 scrapie cases are being reported from many European 
countries, as well as from the USA (Benestad et al., 2008) and New Zealand 
(Kittelberger et al., 2010). Its clinical signs are similar to classical scrapie disease, 
albeit are generally less pronounced. Pruritus is uncommon and the major 
clinical symptoms are ataxia and incoordination (Imran and Mahmood, 2011). 
Unlike classical scrapie, the PrPSc deposition pattern in atypical scrapie 
infections is mild and restricted to the obex but is more intense throughout the 
cerebellum, substantia nigra, thalamus, and basal nuclei (Moore et al., 2008). 
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Despite the increasing number of atypical scrapie cases, no evidence of strains 
have appeared so far for this TSE and so no major differences have been 
determined in incubation periods, clinical signs, PrPres WB profile, PrPSc 
distribution, or pathogenesis in the reported natural and experimental cases 
(Gotte et al., 2011; Griffiths et al., 2010; Le Dur et al., 2005; Pirisinu et al., 2010; 
Pirisinu et al., 2013). This fact clearly contrasts with the high heterogeneity 
registered for classical scrapie and further supports the contention that atypical 
scrapie is a homogenous entity (Gotte et al., 2011; Griffiths et al., 2010; Le Dur et 
al., 2005; Pirisinu et al., 2010; Pirisinu et al., 2013).  
On the other hand, atypical scrapie has been proposed as spontaneous in origin 
since is quite widespread and often occurs in older animals as single cases in a 
whole flock (Benestad et al., 2008; Fediaevsky et al., 2010; Hopp et al., 2006). 
Nevertheless, some findings have demonstrated the oral transmissibility of the 
atypical scrapie agent (Simmons et al., 2007; Simmons et al., 2011) and this fact, 
together with the presence of prion infectivity in different tissues (including 
lymphoid tissues, nerves, and muscles (Andreoletti et al., 2011; Simmons et al., 
2011)), seems to indicate that natural transmission may be possible in atypical 
scrapie. 
8.1.3 Factors determining scrapie occurrence 
Scrapie occurrence is mainly determined by the host prion protein encoding 
gene (prnp) (Agrimi et al., 2003; Baylis et al., 2004) and the prion strain (Aguzzi 
et al., 2007) and thus results in distinct disease phenotypes with differences in 
the incubation period, pathogenesis, clinical signs PrPres WB profile, and PrPSc 
deposition pattern.  
Sheep and goats share the same PrPC amino acid sequence but with a variety of 
polymorphism (Fig. 8). Sheep prnp genotypes V136R154Q171 and A136R154Q171 are 
associated with a high susceptibility to classical scrapie, while the A136R154R171 
genotype is linked to resistance (Belt et al., 1995; Bossers et al., 1996; Hunter, 
1996, 1997). Interestingly, atypical scrapie more frequently affects sheep 
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carrying resistant genotypes (such as A136R154Q171, A136H154Q171) than 
susceptible animals (i.e. V136R154Q171). Indeed, atypical scrapie seems to be 
strongly modulated by R/H154 and F/L141 polymorphisms (reviewed in 
(Benestad et al., 2008)).  
In goats, around 50 polymorphisms in the open reading frame (ORF) of the prnp 
gene have been described (Acin et al., 2013; Fragkiadaki et al., 2011; Vaccari et 
al., 2009a), including some silent mutations, a three octapeptide repeats variant 
(Goldmann et al., 1998), and a nonsense mutation at codon 32 (Benestad et al.) 
(Fig. 8). Although several polymorphisms are shared by sheep and goats, to 
date only some correlations between variants of the goat PrPC and susceptibility 
to TSE have been published.  
The I/M142 amino acid substitution is associated with a slightly lower risk of 
developing scrapie (Barillet et al., 2009; Goldmann et al., 2011; Gonzalez et al., 
2010) and prolonged incubation times after challenges  from scrapie and BSE 
prions (Goldmann et al., 1996). In natural outbreaks, goats carrying the H/R143 
polymorphism showed a partial decrease in their susceptibility to scrapie 
prions (Barillet et al., 2009; Billinis et al., 2002). Likewise, a low susceptibility to 
scrapie has also been linked to the R/H154 and R/Q211 variants of the goat PrPC 
(Barillet et al., 2009; Bouzalas et al., 2010), although the R/H154 polymorphism 
also arose as a risk factor for goat atypical scrapie (Colussi et al., 2008). Other 
PrPC variants such as the N/D146 and N/S146 polymorphisms have been linked 
to resistance to scrapie (Papasavva-Stylianou et al., 2011). 
 
  
 
    
 
 
Figure 8. PrP polymorphisms of sheep and goat PrPC. A schematic representation of full-length sheep/goat PrPC including all the PrP 
polymorphisms reported and their effect on increasing resistance (in red) to classical scrapie. 
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However, the most encouraging results are those related to the Q/K222 
polymorphism. The absence or marked under-representation of scrapie-positive 
goats expressing the K222 variant in herds from many different countries (Acin 
et al., 2013; Acutis et al., 2006; Barillet et al., 2009; Bouzalas et al., 2010; Corbiere 
et al., ; Fragkiadaki et al., 2011; Papasavva-Stylianou et al., 2011; Vaccari et al., 
2006) suggests that the K222- PrPC variant strongly influences goat susceptibility 
to TSE agents.  
Most of these associations have been determined as a result of the intense 
epidemiological surveillance program for TSE in small ruminants implemented 
by the European Union (EU) in 2002, which has subsequently been adopted by 
non-EU countries such as Canada and the USA. This program consists of both 
passive and active surveillance through post-mortem testing of a fraction of 
small ruminants at abattoirs or rendering plants (Corbiere et al., 2013a). 
Currently, scrapie control regulations in the EU consist of 1) culling all animals 
of a susceptible genotype in infected flocks (if no genetic testing is carried out, 
all animals are culled) and 2) the genetic testing of rams intended for breeding 
in scrapie-free flocks of "high genetic merit", followed by the culling of the 
susceptible rams (EC Regulation No 999/2001).  
This system provides an estimate of scrapie occurrence in the EU and enables 
both the trend of classical scrapie evolution in populations over the past decade 
and the genotypes governing susceptibility to scrapie to be monitored. 
Although this epidemiological data is highly valuable for controlling scrapie, 
experimental confirmation is still necessary to obtain conclusive results. 
8.1.4 Selective breeding programs 
Epidemiological studies provide highly valuable information about the 
potential role of certain polymorphic variants of goat and sheep PrPC and these 
animals’ susceptibility to both classical and atypical scrapie. This work is 
normally based on case-control studies. Unfortunately, the low frequency of 
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certain polymorphisms in goat and sheep populations prevents us from 
drawing conclusions regarding their effect on susceptibility to prion infection.  
Experimental studies in sheep have demonstrated a clear link between the 
A136R154R171 genotype and resistance to classical scrapie (Belt et al., 1995; Bossers 
et al., 1996; Hunter, 1996, 1997). On this basis, selective breeding programs have 
been implemented in some EU member states in order to promote the 
A136R154R171 haplotype within ovine herds (Dawson et al., 1998). This strategy 
has resulted in the rapid control of scrapie outbreaks (Nodelijk et al., 2011) and 
has lowered the risk of scrapie infection even in animals with susceptible 
genotypes (Hagenaars et al., 2010; Kanata et al., 2014). 
Unfortunately, atypical scrapie is more common in genotypes such as 
A136R154R171 and A136H154R171 sheep than in genotypes associated with high 
susceptibility to classical scrapie such as V136R154Q171 (Benestad et al., 2008). 
Hence, selective breeding programs could have indirectly favored the incidence 
of atypical scrapie in sheep herds, which has prompted a search for new 
resistant genotypes to control and eradicate both classical and atypical scrapie 
in sheep herds.  
Epidemiological and in vitro studies are of great use in this task. However, 
results must be confirmed by experimental inoculations in sheep and goats 
before drawing definitive conclusions. Due to the high number of prnp 
genotypes, their low frequencies in sheep and goat populations, and the 
unknown number of scrapie strains currently in circulation, experimental 
challenges in sheep and goats are not feasible. In this sense, Tg mice may be a 
good alternative. The generation of Tg mice, each expressing either a sheep or 
goat PrPC variant, would help clarify their role in scrapie and BSE susceptibility 
and decide which is the most suitable for breeding programs. 
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8.2. Bovine Spongiform Encephalopathy (BSE) 
BSE, commonly known as “Mad Cow Disease”, was firstly diagnosed in UK in 
1986 (Wells et al., 1987). It soon spread worldwide and became epidemic. BSE-
infected cattle have incubation periods of over two years and clinical signs 
including cachexia, alopecia, apprehension, lethargic or aggressive behavior, 
hyper-responsiveness to stimuli, and abnormalities in movement (i.e. ataxia, 
particularly of the hind-limbs).  
Histolopathological lesions consist of vacuolation, predominantly in the 
medulla oblongata at the level of the obex (Jeffrey and Gonzalez, 2004), and also 
in the central grey matter, rostral colliculus, and hypothalamus (Simmons et al., 
1996; Wells et al., 2005). Unlike scrapie, PrPSc deposition in BSE-infected 
animals is mostly confined to the nervous system. However, low infectivity in 
Peyer’s patches of the small intestine, distal ileum, jejunum, ileocecal juction 
(Hoffmann et al., 2011), and tonsils (Buschmann and Groschup, 2005; Espinosa 
et al., 2007b; Hoffmann et al., 2011; Stack et al., 2011; Terry et al., 2003; Wells et 
al., 2005) have also been described.  
More recently, BSE infectivity in skeletal muscles has been determined and 
associated with a probable centrifugal spread of the agent from central nervous 
tissues through the somatic motor and/or sensory pathways to peripheral 
muscle tissues (Okada et al., 2014). This observation is extremely relevant for 
redefining the Specified Risk Materials as stated by the Food Standards Agency 
to prevent the entry of BSE-contaminated material into the foodchain.  
To date, there is no evidence of BSE infectivity in semen, embryos, placenta, or 
milk, (Bradley and Wilesmith, 1993; Buschmann and Groschup, 2005; Taylor et 
al., 1995; Wrathall et al., 2002), although an increased risk of BSE development 
has been reported in the offspring of infected cows. The practice of feeding 
cattle with meat and bone meal (MBM) contaminated with infectious prions 
was initially proposed as the most likely cause of the BSE epidemic (Wilesmith 
et al., 1991). A number of hypotheses regarding the origin of BSE have been 
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considered, including i) the primary existence of sporadic or genetic BSE in 
cattle before its transmission via MBM (Baron et al., 2011; Capobianco et al., 
2007; Nicholson et al., 2008; Richt and Hall, 2008; Torres et al., 2013); ii) sheep or 
goat-scrapie transmission to cattle through MBM (Hill et al., 1998), and iii) 
human CJD (Colchester and Colchester, 2005). The European ban on the feeding 
of MBM to ruminants has sharply decreased the incidence of the disease, 
although it has still not been completely eradicated.  
The BSE agent has demonstrated a high capacity to cross species barriers. 
During the BSE epidemic in the 1980s, the disease spread not only to humans 
with the emergence of variant Creutzfeldt-Jacob disease (vCJD) (Bruce et al., 
1997; Hill et al., 1997) but also to cats and a variety of zoo animals, which 
probably gave rise to Feline Spongiform Encephalopathy (FSE), Exotic Ungulate 
Spongiform Encephalopathy (EUE), and TSE in non-human primates (NHP) 
(reviewed in (Sigurdson and Miller, 2003)). Furthermore, BSE has been 
experimentally transmitted with great efficiency to mice, hamsters, sheep, 
goats, pigs, mink, and non-human primates (Brown et al., 2003; Holznagel et al., 
2013; Hunter, 2003; Lasmezas et al., 2005; Wells et al., 2003).  
Upon passage in sheep, BSE becomes more lymphotropic (Foster et al., 2001b) 
but also increases its transmissibility to humans (Padilla et al., 2011; Plinston et 
al., 2011; Priem et al., 2014). These facts have important implications for public 
health, especially after two “natural” BSE cases in goats were reported (Eloit et 
al., 2005; Jeffrey et al., 2006). Consequently, political regulations were changed 
to prioritize biochemical differentiation between BSE and scrapie agents in 
sheep and goats (European and Council, 2005). Several biochemical tests have 
been approved for differentiating BSE and scrapie, while immunohistochemical 
procedures have been established with the same purpose for lymphoid tissues 
(Thuring et al., 2005) and the central nervous system (Siso et al., 2010). 
Unlike scrapie, little is known about the factors determining the susceptibility 
of goats and sheep to BSE. Some authors report prolonged incubation times in 
BSE-infected goats harboring the I/M142 polymorphism (Goldmann et al., 1996), 
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although L/F141 polymorphism seems to produce the same effect in BSE-
infected sheep (Tan et al., 2012). It has also been demonstrated that the 
ARR/ARR genotype (promoted by selective breeding programs for 
controlling/eradicating scrapie in sheep populations) does not protect sheep 
against BSE infection (Andreoletti et al., 2006; Bencsik and Baron, 2007). These 
findings support the view that sheep and goat-BSE are new potential risks for 
human health and that strategies for their control are lacking. 
8.2.1 Atypical BSE 
In recent years, active surveillance of BSE in cattle has led to the discovery of 
two “atypical” BSE variants named H-type (Biacabe et al., 2004) and L-type BSE 
(Casalone et al., 2004). These variants are often detected in fallen cattle and 
slaughtered old animals, and differ from classical BSE in their biochemical 
properties and histopathological lesions. Their low prevalence worldwide is 
consistent with a sporadic origin. However, their experimental transmission to 
bovinized, ovinized, and wild type mice suggest a potentially infectious nature 
(Beringue et al., 2007; Buschmann et al., 2006; Capobianco et al., 2007; Torres et 
al., 2011). Unlike the classical BSE agent, several changes occur in the biological 
and biochemical properties of atypical BSE variants when transmitted to other 
species. Many of these changes result in the emergence of classical BSE features, 
which suggests a possible relationship between atypical BSE variants and the 
origin of the BSE epidemic (Beringue et al., 2007; Beringue et al., 2006; 
Capobianco et al., 2007; Torres et al., 2011). 
Although no epidemiological link between atypical BSE and any human prion 
disease has yet been determined, it has been reported that the L-type BSE agent 
can propagate into humanized mice overexpressing the M129-PrPC variant 
without any significant transmission barrier, and is even more infectious for 
humans than epidemic classical BSE (Beringue et al., 2008a). Similar outcomes 
have been obtained in non-human primates, in which the L-type BSE agent is a 
noted zoonotic risk (Comoy et al., 2008; Ono et al., 2011). Conversely, 
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transmission studies have failed to transmit H-type BSE to humanized mice 
(Beringue et al., 2008a; Wilson et al., 2012).  
8.3 Chronic Wasting Disease (CWD) 
CWD is a naturally occurring TSE affecting farmed and free-ranging cervids. Its 
main symptoms are marked weight loss, rough dry coat, excessive salivation, 
pacing, sudden death after handling, lowered head and drooping ears, and 
behavioral changes such as a loss of fear of humans. Survival times range from 
seven to eight months in deer (Williams and Young, 1980) but can be longer in 
elks (Miller et al., 1998). In CWD-affected animals, PrPSc can be widely 
distributed throughout the nervous system but also in the lymphoreticular and 
hematopoietic systems, pancreas, muscles, fat, retina, placenta, and the adrenal 
and salivary glands (Race et al., 2009a; Seelig et al., 2010; Sigurdson, 2008; 
Sigurdson and Miller, 2003; Spraker et al., 2010). It is unknown whether CWD 
arises spontaneously or was transmitted from other species. Scrapie would be a 
possible origin since the intracerebral inoculation of elks with this agent has 
induced CWD features (Hamir et al., 2004). 
Since the first case was recorded in 1967 in Colorado (Williams and Young, 
1980), CWD has spread unchecked throughout at least 15 states in the USA and 
two Canadian provinces (Saunders et al., 2012a), and has even reached South 
Korea due to the importation of CWD-infected animals. Horizontal 
transmission is the most likely infection route. It can be efficiently transmitted 
by contact with affected animals since CWD prions are secreted and excreted in 
urine, feces, saliva, and blood, or through environmental exposure to CWD-
contaminated graze, soil, and water (Almberg et al., 2011; Kuznetsova et al., 
2014; Mathiason et al., 2006; Miller et al., 2004; Nichols et al., 2009; Safar et al., 
2008; Sigurdson, 2008; Sigurdson and Miller, 2003; Tamguney et al., 2009). 
Limited maternal transmission has also been proposed (Nalls et al., 2013).  
In contrast to its high transmissibility among cervids, to date no natural 
transmission to any other species has been described. Moreover, it has been 
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experimentally determined that CWD is unable to cross the species barrier via 
the oral route (Sigurdson, 2008; Sigurdson and Miller, 2003; Tamguney et al., 
2006; Wilson et al., 2012). Nevertheless, it is transmissible to cattle, sheep, goats, 
ferrets, hamsters, bank voles, minks, raccoons, and squirrel monkeys when 
intracerebrally inoculated (Sigurdson, 2008). Recent studies have provided 
evidence of the capacity in vitro of this CWD to convert human PrPC after either 
passage in Tg mice expressing cervid PrPC or serial PMCA amplification in deer 
PrPC substrate (Barria et al., 2011). In addition, CWD has been successfully 
transmitted to squirrel monkeys, albeit less efficiently than the epidemic BSE 
(Marsh et al., 2005; Race et al., 2009b). Despite these findings, there is no 
epidemiological evidence to date for a zoonotic role of the CWD agent.  
CWD surveillance and control measures have been implemented across the 
USA and Canada to reduce disease spread, mitigate the economic losses due to 
less recreational hunting, and control its potential cross-species transmission 
(Williams, 2005; Joly et al., 2009; Wasserberg et al., 2009). Challenges associated 
with CWD include i) the high prion contamination of the environment due to 
the excretion of the agent by multiple vias and the high persistence of its 
infectivity (Saunders et al., 2008; Saunders et al., 2011; Smith et al., 2011), ii) the 
geographical spread of the agent as a result of the natural migration of cervids 
and scavengers, and iii) the existence of different CWD strains (Angers et al., 
2010).  
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The general objective of this thesis is to improve our understanding of the 
molecular mechanisms underlying susceptibility/resistance to prion 
infection. To address this task a number of specific aims were pursued:  
1. To study the individual role of the polymorphic variants found naturally in 
goat and sheep prnp in the susceptibility/resistance to scrapie and BSE infection 
in transgenic mice.  
1.1 To generate a panel of transgenic mouse lines each expressing either the 
goat wild type prnp or one goat (M142, H154, Q211 and K222) or sheep (R171 and 
K176) polymorphic variant of this wild type prnp. 
1.2. To determine the suitability of the transgenic mouse line expressing the 
goat/sheep wild type prnp for analyzing the susceptibility of goats and sheep 
to different prion strains. 
1.3. To compare individual susceptibility to different prion strains in the 
different mouse lines expressing each polymorphic variant with the mouse 
line expressing the wt-PrPC. 
1.4. To analyze the protective effect of the prnp polymorphic variants 
associated with prion resistance over the prion replication of the wild type 
allele. 
2. To confirm in a natural host (goats) the reliability of the results from mouse 
models: 
2.1. To analyze the effect of prnp polymorphic variants on the susceptibility 
of goats to oral and intracerebral infection with classical scrapie. 
2.2. To evaluate the effect of prnp polymorphic variants on the susceptibility 
of goats to oral infection with goat-BSE.   
The experimental design uses two complimentary models, Tg mice and goats. 
The Tg model permitted us to analyze from a molecular point of view the role 
of polymorphic variants of the prion protein in infection with scrapie and BSE. 
Transmission studies in goats – the natural host for scrapie and, potentially, for 
BSE – allowed us to evaluate the ability of our Tg models to predict prion 
infection in goats. 
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1. Studies in goat and sheep PrP transgenic mice 
1.1 Mouse model  
1.1.1 Generation of transgenic mouse lines  
1.1.1.1 Plasmid construction 
A schematic representation of the generation of all Tg mouse lines is given in 
Fig. 9. Transgenic mouse lines expressing either the goat wild type-PrPC or the 
K222-PrPC variant were previously generated by our group.  Briefly, the Open 
Reading Frame (ORF) of goat wild type (wt) PrP gene (prnp) (GenBank 
accession number AF117316.1) was isolated by PCR amplification and 
subcloned into the pGEM-T Easy vector system (Promega) (Fig. 9). The 
obtained goat wt prnp ORF was excised from the cloning vector and inserted 
into the expression vector MoPrP.Xho (Borchelt et al., 1996), resulting in the 
plasmid pMo-GoPrP.Xho. This vector contains the murine PrP (muPrP) 
promoter, exon 1, intron 1, exon 2, and 3’-untranslated sequences flanked by 
two XhoI restriction sites but could be distinguished from the wt murine PrP 
gene because of the absence of intron 2.  pMo-GoPrP.Xho plasmid was 
directedly mutated to generate a K222-PrP plasmid (pMo-GoK222-PrP.Xho) by 
using a QuikChange II XL kit (Stratagene, CA) with specific oligonucleotides 
(5´-GTGCATCACCCAGTACAAGAGAGAATCCCAGGC-3´ and 3´-
GCCTGGGATTCTCTCTTGTACTGGGTGATGCAC-5´), following the 
manufacturer’s instructions. 
M142, H154, R171, K176, and Q211-PrP plasmids were new-generated for the present 
study by directed mutation of the plasmid pMo-GoPrP.Xho, as previously 
carried out for the K222-PrP plasmid. Mutations consisting of single nucleotide 
substitutions were obtained using the same QuikChange II XL kit (Stratagene, 
CA) with other specific oligonucleotides (Table 1). 
 
  
  
 
 
 
 
 
 
 
 
Figure 9. Schematic representation of the generation of the goat and sheep PrP transgenic mice.
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Table 3. Oligonucleotides used for generating the different PrPC variants-plasmids 
PrPC  
variant 
Nucleotide 
substitutio
n 
aa 
exchange 
Oligonucleotide used for directed 
mutagenesis PrPC variant-plasmids 
K222 
CAG to 
AAG 
Q to K 
Forward: 5’-
GTGCATCACCCAGTAC 
AAGAGAGAATCCCAGGC-3’  
Reverse: 5’- GCCTGGGATTCTCTCT 
TGTACTGGGTGATGCAC-3 
pMo-GoK222-PrP.Xho 
M142 
ATA to 
ATG 
I to M 
Forward: 5’- 
GCCATGAGCAGGCCTC 
TTATGCATTTTGGCAATGAC -3’ 
Reverse: 5’- 
GTCATTGCCAAAATGC 
ATAAGAGGCCTGCTCATGGC -3’ 
pMo-GoM142-PrP.Xho 
H154 
CGT to 
CAT 
R to H 
Forward: 5’- 
CTATGAGGACCGTTAC 
TATCATGAAAACATGTACCGTT
ACC -3´ 
Reverse: 5’-
GGTAACGGTACATGTT 
TTCATGATAGTAACGGTCCTCAT
AG - 3’ 
pMo-GoH154-PrP.Xho 
R171 CAG to 
CGG 
Q to R 
Forward: 5’-
CTACAGACCAGTGGAT 
CGGTATAGTAACCAGAACAAC-
3’ 
Reverse: 5’-
GTTGTTCTGGTTACTAT 
ACCGATCCACTGGTCTGTAG-3’ 
pMo-GoR171-PrP.Xho 
K176 
AAC to 
AAA 
N to K 
Forward: 5’-
GTGGATCAGTATAGTA 
ACCAGAAAAACTTTGTGCATGA
CTGTGTC-3’ 
Reverse: 5’-
GACACAGTCATGCACA 
AAGTTTTTCTGGTTACTATACTG
ATCCAC-3’ 
pMo-GoK176-PrP.Xho 
Q211 
CGA to 
CAA 
R to Q 
Forward: 5’-
CATCAAGATAATGGAG 
CAAGTGGTGGAGCAAATGTGC-3’ 
Reverse: 5’-
GCACATTTGCTCCACCA 
CTTGCTCCATTATCTTGATG-3’ 
pMo-GoQ211-PrP.Xho 
 
1.1.1.2 Microinjection of DNA constructions 
All different transgenes (M142, H154, R171, K176, and Q211) were excised from their 
respective expression vectors (pMo-GoM142-PrP.Xho, pMo-GoH154-PrP.Xho, 
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pMo-GoR171-PrP.Xho, pMo-GoK176-PrP.Xho, and pMo-GoQ211-PrP.Xho) 
using the restriction endonuclease NotI, which gave DNA fragments of 
approximately 12 kb corresponding to the murine promoter and the goat PrP 
ORF (Fig. 9).  
The transgenes of each variant were recovered from a 0.7% agarose gel 
(Pronadisa) using a DNA purification kit (Elu-Quik; Schleicher & Schuell). 
Then, DNAs were dissolved in TE (10mM Tris, pH 7.4, 0.1mM EDTA) at a final 
concentration of 2–6 ng/ml. Finally, DNAs were microinjected into pronuclear-
stage embryos collected from superovulated B6CBAF1 females mated with 
129/Ola males carrying a null mutation in their endogenous prnp (Manson et 
al., 1994). For each transgene, multiple embryos were microinjected at the 
Centro Nacional de Biotecnología (CNB-CSIC) and different number of 
founders was obtained (see Results, Table 7). 
1.1.1.3 Screening of founders 
DNAs were extracted from founders’ tail biopsy specimens using an Extract-N-
Amp tissue PCR kit (Sigma-Aldrich) following the manufacturer’s instructions. 
The presence of the goat or sheep transgene in these founders was identified by 
PCR amplification using specific primers for mouse PrP exon 2 and the goat PrP 
ORF. The primers used were 5’-CATTCTGCCTTCCTAGTGGTACC-3’ and 5’-
GCTTGTTCCACTGACTGTGGC-3’. muPrP+/- goPrP+/- founders were 
backcrossed with homozygous PrP null animals (muPrP-/-) to obtain mice 
homozygosis for the null mutation (muPrP-/- goPrP+/-). The absence of the 
murine PrP ORF in the generated transgenic mice was confirmed by PCR 
amplification using the primers 5’-ATGGCGAACCTTGGCTACTGGC-3’ and 
5’-GATTATGGGTACCCCCTCCTTGG-3’. 
1.1.1.4 Analysis of transgene transmission to the offspring 
The offspring obtained from breeding each founder (muPrP+/- goPrP+/-) with 
prnp null mice (prnp mu-/- goPrP-/-) (Manson et al., 1994) was studied for the 
presence of the goat or sheep transgene by PCR as described above. Transgene 
 MATERIALS AND METHODS  
  
79 
transmission to ≤50% of the progeny (following Mendel´s principle of 
segregation) indicated that only one set of transgene copy was inserted in the 
mice genome (Fig. 10). Founders with more than one integration site were 
discarded.  
1.1.1.5 Analysis of brain PrPC expression in hemizygous transgenic mouse lines 
Whole brains from mice, goats, and sheep were homogenized in extraction 
buffer (1% (w/v) NP40, 1% (w/v) sodium deoxycholate, and 10mM EDTA in 
PBS pH 7.4 + complete™ cocktail of protease inhibitors (Roche). Samples were 
precleared by centrifugation at 2,000 X g for 5 min, after which an equal volume 
of 2X SDS reducing sample loading buffer was added to all samples, and each 
was boiled for 5 min. 20 µl of each sample were loaded into a 12% Criterion XT 
Bis-Tris Gel (BioRad). Electrophoresis was performed in XT MES running buffer 
(BioRad) at 150V for 80 min. Proteins were electrophoretically transferred to 
PVDF membranes (Millipore) at 400 mA for 90 min. Membranes were blocked 
O/N with 2% (w/v) Bovine Serum Albumin (BSA) fraction V (Sigma-Aldrich) 
in PBS-Tween (BSA-PBST).  
For the immunoblotting experiments, membranes were incubated for an hour 
with monoclonal antibodies (mAbs) FH11 (Foster et al., 1996b) or 12B2 (Yull et 
al., 2006) at a final concentration of 1µg/ml in BSA-PBST. FH11 recognizes the 
goat PrP amino-terminal region (amino acids 23–85), while 12B2 recognizes the 
93WGQGG97 epitope of the goat PrP sequence. Membranes were washed three 
times for 5 min with PBST to minimize background and remove unbound Ab. 
Immunocomplexes were detected with horseradish peroxidase-conjugated anti-
mouse IgG (Amersham GE Life Sciences) at a final concentration of 1µg/ml in 
BSA-PBST after incubating the membranes for an hour. Membranes were 
washed again three times for 5 min with PBST, and immunoreactivity was 
visualized using chemiluminescence with Pierce® ECL 2 (Thermo Scientific) in a 
Gel imaging system (Bio-Rad ChemiDoc™ XRS). The signal was recorded 
during 15 min of exposure time.  
1.1.1.6 Analysis of animal health and physiological behavior 
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All the founders, as well as 6–7 animals from each progeny, were housed until 
the end of their lifespans and monitored for the presence of any signs of 
neurological or other physiological alterations. Their brains were 
histopathologically analyzed to discard the possibility of neurological 
alterations. 
1.1.1.7 Obtaining homozygous goat and sheep PrPC transgenic mice 
Homozygosity for each goat or sheep PrP transgene (WT, K222, M142, H154, R171, 
K176, and Q211) was obtained by interbreeding hemizygous goat or sheep PrP 
mice (muPrP-/- goPrP+/-) from the same transgenic mouse line rendering 
muPrP-/- goPrP+/- (50%), muPrP-/- goPrP+/+ (25%), and muPrP-/- goPrP-/- (25%) 
(Fig. 10). Homozygosity was confirmed by backcrossing potential homozygous 
transgenic mice (muPrP-/- goPrP+/+) with homozygous PrP null animals 
(muPrP-/-) and rendering 100% of hemizygous (muPrP-/- goPrP+/-) animals. 
PrPC expression in the brain of homozygous mice was analyzed using Western 
blot as for hemizygous mice (see section 1.1.1.5). The brains of homozygous 
mice should express twice as much PrPC as those of their hemizygous 
counterparts. 
 
Figure 10. Hemizygous and homozygous transgenic mice generation. Schematic 
representation of the generation of hemizygous and homozygous mice for each 
different goat and sheep PrP transgenic mouse lines. 
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1.1.1.8 Obtaining heterozygous Q/K222 transgenic mice 
Heterozygous Q/K222 transgenic mice were obtained by mating homozygous 
K222-Tg516 (muPrP-/- goK222PrP+/+) and homozygous Wt-Tg501 (muPrP-/- 
goQ222PrP+/+) mice, which rendered 100% Q/K222 (muPrP-/- goQ222PrP+/- 
goK222PrP+/-). 
1.2 Transmission studies in mice 
1.2.1 TSE isolates collection and characterization 
Transgenic mice expressing different genotypes of goat and sheep prnp were 
challenged with a wide variety of TSE agents, including both classical and 
atypical scrapie isolates, as well as BSE isolates (see Tables 2–5 for isolates 
information). Inocula were prepared from infected brains as 10% 
(weight/volume) homogenates in 5% glucose. Brain homogenates from PrPres 
positive mice were pooled for further passaging. When all mice were scored 
negative for PrPres on the primary passage, PrPres-negative brain homogenates 
were used for the second passage. 
1.2.1.1. Molecular characterization (genotyping) 
The prnp ORF was amplified from the purified genomic DNA in the brain 
homogenate of each isolate by PCR using specific oligonucleotides (5’-
CTCGAGATCATGGTGAAAAGCCACATAGGC-3’ and 3’- 
CTCGAGCTATCCTACTATGAGAAAAATGAG-5’). Then, the prnp ORF was 
sequenced by the department of Sequencing Services of the Centro de 
Investigación en Sanidad Animal (CISA, INIA). The polymorphic variants that 
each isolate harbors are indicated in tables 2–5, “PrPSc genotype”. 
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Table 4. Description of the goat classical scrapie isolates used in this work 
Isolate Origin (local code) PrP
Sc 
genotype
 
Description and references Supplier 
Goat-Sc F2 Fr (CP40) wt
a
; S/P240 Classical scrapie from an experimentally infected goat INRAN
1
 
Goat-Sc F3 Fr (CDP1028) wt; P/P240 Classical scrapie from a naturally infected goat INRAN 
Goat-Sc F6 Fr (CP2119) wt; S/P240 Classical scrapie from a naturally infected goat INRAN 
Goat-Sc F10 Fr (2143) wt; S/P240 Classical scrapie from a naturally infected goat INRAN 
Goat-ScF11 Fr (2154) wt; I/M142; P/P240 Classical scrapie from an experimentally infected goat INRAN 
Goat-Sc F14 Fr (9041) wt; I/M142; S/P240 Classical scrapie from a naturally infected goat INRAN 
Goat-ScF16 Fr (9135) wt; I/M142; S/P240 Classical scrapie from a naturally infected goat INRAN 
Goat-Sc I2 It (114921/1/1) wt; S/S240 Classical scrapie from a naturally infected goat IZSTO
2
 
Goat-Sc I3 It (121429/1/1) wt; P/P240 Classical scrapie from a naturally infected goat IZSTO 
Goat-Sc I4 It (128710/1/1) wt; R/Q211; S/P240 Classical scrapie from a naturally infected goat IZSTO 
Goat-Sc I9 It (85792/1/1) wt; R/H143; S/P240 Classical scrapie from a naturally infected goat IZSTO 
Goat-Sc I12 It (144508/1/1) wt; S/P240 Classical scrapie from a naturally infected goat IZSTO 
Goat-Sc G2 Gr (1883) wt; P/P240 Classical scrapie from a naturally infected goat CERTH
3
 
Goat-Sc G3 Gr (1878) wt; R/H143; P/P240 Classical scrapie from a naturally infected goat CERTH
3
 
Goat-Sc N1 Ne (1) wt; R/H143; S/P240 Classical scrapie from a naturally infected goat CIDC
4
 
Goat-Sc N2 Ne (2) wt; R/H143; S/P240 Classical scrapie from a naturally infected goat CIDC 
Goat-Sc N3 Ne (3) wt; P/P240 Classical scrapie from a naturally infected goat CIDC 
Goat-Sc S2 Sp (C-163) wt; S/P240 Classical scrapie from a naturally infected goat UNIZAR
5 
Goat-Sc S3 Sp (C-645) wt; P/P240 Classical scrapie from a naturally infected goat UNIZAR
 
Goat-Sc UKA2 UKA2 wt; S/P240 Classical scrapie from a naturally infected goat UEDIN
6 
Goat-Sc UKB2 UKB2 wt; G/S127; P/P240 Classical scrapie from a naturally infected goat UEDIN
6 
Goat-Sc UKD2 UK D2 wt; G/S127; P/P240 Classical scrapie from a naturally infected goat UEDIN 
Goat-Sc ZYP13 C1 wt; P/P240 Classical scrapie from a naturally infected goat TVCN
7 
Goat-Sc ZYP21 C2 wt; P/P240 Classical scrapie from a naturally infected goat TVCN 
Healthy goat brain - wt; P/P240 Brain from a non-infected goat INRAN 
a Wild type (wt) goat prion protein genotype: A136R154Q171/ A136R154Q171. // 1 French National Institute for Agricultural Research (INRA), Nouzilly, France.  
2 Istituto Zooprofilattico Sperimentale del Piemont, Italy. // 3 CERTH-INA, Thessaloniki, Greece. // 4 Central Veterinary Institute of Wageningen UR, Lelystad, The 
Netherlands. // 5 Universidad de Zaragoza, Spain. // 6 Roslin Institute, University of Edinburgh (UEDIN-Roslin), Edinburgh, UK. // 7 Toumazos Veterinary 
Center, Nicosia, Cyprus. 
MATERIALS AND METHODS 
 
 
Table 5. Description of the sheep classical scrapie isolates used in this work 
Isolate Origin (local code) PrP
Sc 
genotype
 Description and references Supplier 
Sheep-Sc21 Fr (CH0064) wt
a
; S/S240 Classical scrapie from a naturally infected sheep INRAN
1
 
Sheep-Sc Langlade PD377 wt; S/S240 Classical scrapie from a naturally infected sheep INRAT
2 
Sheep-Sc 09  - wt; F/F141;S/S240 
Pool of terminally ill mice TgOV IX infected with one classical 
scrapie isolate 
FLI
3 
a Wild type (wt) goat prion protein genotype: A136R154Q171/ A136R154Q171. // 1 French National Institute for Agricultural Research (INRA), Nouzilly, France. 
2 French National Institute for Agricultural Research (INRA), Toulouse, France. // 3 Friedrich-Loeffler-Institut, InselRiems, Germany.  
 
Table 6. Description of the atypical isolates used in this work 
Isolate Origin (local code) PrP
Sc 
genotype
 
Description and references Supplier 
Goat-Sc I15 It (87016/1/1) wt
a
; H/R154 S/P240 Atypical scrapie from a naturally infected goat IZSTO
1
 
Sheep-Sc M45 - wt; S/S240 Atypical scrapie from a naturally infected sheep NEIKER
2
 
Sheep-Sc engavagen Sc3080 wt; F/F141;S/S240 Atypical scrapie from a naturally infected sheep NVT
3 
Sheep-Sc TOA4 TOA4 wt; H/Q171;S/S240 Atypical scrapie from a naturally infected sheep CReSA4 
Sheep-Sc Nor98/Tg338 - wt;V/V136;S/S240 Pool of cerebellum from terminally ill mice Tg338 infected with 
an atypical scrapie isolate (Laude et al., 2002) 
NVT 
a Wild type (wt) goat prion protein genotype: A136R154Q171/ A136R154Q171. // 1 Istituto Zooprofilattico Sperimentale del Piemont, Italy. // 2 Instituto Vasco de 
Investigación y Desarrollo Agrario (NEIKER), Vizcaya, Spain. // 3 Norwegian Veterinary Institute, Oslo, Norway. // 4 Centre de Recerca en Sanitat Animal (CReSA-
PRIOCAT), Barcelona, Spain.  
Table 7. Description of the BSE isolates used in this work 
Isolate Origin (local code) PrP
Sc 
genotype
 
Description and references Supplier 
Goat-BSE1 Fr (CH0064) wt
a
; S/S240 Terminally ill goat intracerebrally inoculated with Ca-BSE isolate INRAN
1
 
Goat-BSE2 Fr (CH1075) wt; S/P240 Terminally ill goat intracerebrally inoculated with Ca-BSE isolate INRAN 
Sheep-BSE Fr (ARQ0) wt;S/S240 Pool of terminally ill ARQ/ARQ sheep inoculated with Ca-BSE 
isolate cow (Espinosa et al., 2007a) 
INRAN 
Cattle-BSE Fr (139) Cattle wt BSE from a naturally infected cow (Espinosa et al., 2007a) INRAN 
Cattle-BSE L 02.2528 Cattle wt BSE from a naturally infected cow INRAN 
a Wild type (wt) goat prion protein genotype: A136R154Q171/ A136R154Q171. // 1 French National Institute for Agricultural Research (INRA), Nouzilly, France.  
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1.2.1.2. PrPres biochemical characterization 
PrPres was analyzed for each isolate using Western blotting (WB), as previously 
described (Padilla et al., 2011). Briefly, 100 µl of the isolate (10% brain 
homogenate) was diluted in a 10% (w/v) negative sheep brain homogenate to 
obtain a 200 μl final volume. Homogenates were incubated for 15 min at 37ºC 
with 200 μl of a 2% proteinase K solution (in buffer A). PrPres was recovered as a 
pellet following the addition of 200 μl of buffer B (Bio-Rad) and a centrifugation 
at 15,000 x g for 7 min at 20ºC. Supernatants were discarded and pellets were 
dried over absorbent paper for 5 min. Pellets were solubilized in 50 μl of 
Laemmli buffer and samples were incubated for 5 min at room temperature, 
solubilized, and heated at 100ºC for 5 min. Samples were centrifuged at 20,000 x 
g for 15 min at 20ºC and supernatants were recovered and loaded into a 12% 
Criterion XT Bis-Tris Gel (BioRad). Electrophoresis was performed in XT MES 
running buffer (BioRad) at 150V for 80 min. Proteins were electrophoretically 
transferred to PVDF membranes (Millipore) at 400 mA for 90 min. Membranes 
were blocked O/N with BSA-PBST.  
For immunoblotting, membranes were incubated for an hour with Sha31 mAb 
(Feraudet et al., 2005), which recognizes the 148YEDRYYRE155 epitope of the goat 
PrP sequence, at 1µg/ml dilution in BSA-PBST. Membranes were washed three 
times for 5 min with PBST. Immunocomplexes were detected with horseradish 
peroxidase-conjugated anti-mouse IgG (Amersham GE Life Sciences) at 1µg/ml 
dilution in BSA-PBST after incubating the membranes for an hour. Membranes 
were washed again three times for 5 min with PBST and immunoreactivity was 
visualized by chemiluminescence with Pierce® ECL 2 (Thermo Scientific) in a 
Gel imaging system (Bio-Rad ChemiDoc™ XRS). Signal was recorded during 15 
min of exposure time.  
For detecting atypical scrapie PrPres, the same WB procedure was followed 
(Padilla et al., 2011), although the membranes were incubated with 9A2 mAb 
(Yull et al., 2006), which recognizes the 102WNK104 epitope of the goat PrP 
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sequence, at 1µg/ml dilution in BSA-PBST for immunoblotting, and the signal 
was recorded for 30 min of exposure time.  
1.2.2 Mice inoculation 
Groups of 6–9 individually identified animals (6–7-weeks old) were 
anesthetized with isoflurane (Isoba vet Schering-Plough S.A.) and were 
intracerebrally inoculated using a 25-gauge disposable hypodermic needle with 
20 µl of 10% brain homogenate in the right parietal lobe. As a control, 6 or 7 
animals of each line were inoculated with healthy goat brain to rule out the 
possibility of spontaneous prion disease developing.  
1.2.3 Clinical status monitoring 
After inoculation, mice were observed daily and their neurological status 
assessed twice a week. When the progression of the disease was evident or at 
the end of their life span (≈650 days), mice were humanely euthanized by 
cervical dislocation. A mouse was considered positive for neurological disease 
when it displayed two or three out of the previously described 10 signs of 
neurological dysfunction (Scott et al., 1989; Scott et al., 1993b). Definitive 
diagnoses were made when one confirmatory sign of prion disease (ataxia, 
generalized tremor, loss of righting reflex, limb paralysis, extensive pilo-
erection, or sustained hunched posture) was observed, at which point the 
animals were culled.  
1.2.4 Euthanasia and tissue sampling 
During necropsy, part of each brain was immediately fixed in neutral-buffered 
10% formalin (4% 2-formaldehyde) for determining PK resistant PrP 
accumulations using immunohistochemistry (IHC) and/or Paraffin-embedded 
Tissue (PET) blot and spongiform degeneration by histopathology. The other 
part was homogenized as 10% (w/v) in sterile 0.9 NaCl and harvested at -20ºC 
for detecting the presence of PrPres by Western blot (WB) and/or further 
passaging. Survival time (ST) was expressed as the mean number of survival 
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days postinoculation (dpi) for all the PrPres-positive mice, with the standard 
error of the mena (SEM) included. Attack rate (AR) was determined as the 
proportion of PrPres-positive mice among all the mice inoculated. 
1.2.5 Brain PrPres detection by Western blot 
A total of 175 mg of whole brain tissue was homogenized in 5% glucose in 
distilled water in grinding tubes (Bio-Rad) and adjusted to 10% (w/v) by using 
a TeSeETM Precess 48TM homogenizer (Bio-Rad) following the manufacturer’s 
instructions. Homogenates were pressed through 0.4 mm needles of a 
calibration syringe and immediately frozen at -20ºC. The presence of PrPres in 
transgenic mouse brains was determined by Western blotting following the 
same procedure as in section 1.2.1.2. In all, 100 µl of 10% brain homogenate 
were analyzed in each WB experiment.  For immunoblotting, membranes were 
incubated with Sha31 and immunocomplexes were detected with horseradish 
peroxidase-conjugated anti-mouse IgG (Amersham GE Life Sciences). For 
detecting atypical scrapie PrPres, the same WB procedure was followed, 
although the membranes were incubated with 9A2 mAb and the signal was 
recorded for 30 min of exposure time.  
1.2.6 Histopathological analysis 
All procedures involved in the histopathological analysis of infected mouse 
brains were performed in the laboratory of Dr. Olivier Andréoletti at the École 
Nationale Vétérinaire in Toulouse, France. 
Brain samples were immediately fixed in neutral-buffered 10% formalin (4% 2-
formaldehyde) during necropsy. Later, samples were dehydrated in a HMP 110 
processor for 16 hours, paraffin-embedded in cassettes using a Tissue-Tek® 
TEC III Embedding Center System and harvested at -20ºC. 
1.2.6.1 Hematoxylin-Eosin staining 
Paraffin-embedded (paraplast plus Kendall) brain samples were cut into 3μm 
thick sections using a microtome and collected onto adhesive-treated slides 
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(adhesive-treated ChemMate Capillary Gap microscope slides (DAKO)). Slides 
were dried overnight at 37ºC and then deparaffinated and rehydrated. Finally, 
brain samples were stained with hematoxylin (Mayer´s hemalum solution: RAL 
320550-2500/320554) and eosin (HE) and dried before microscopic analysis. 
Lesion profiles in the different coronal sections of the brain samples were 
established following the standard method described by Fraser and Dickinson 
(Fraser and Dickinson, 1968). This method scores the degree of vacuolation in 
the range 0–4 in nine gray and three white areas of the brain: dorsal medulla 
(G1), cerebellar cortex (G2), superior colliculus (G3), hypothalamus (G4), medial 
thalamus (G5), hippocampus (G6), septum (G7), medial cerebral cortex at the 
level of the thalamus (G8), and at the level of the septum (G9), cerebellum (W1), 
mesencephalic tegmentum (W2), and pyramidal tract (W3).  
1.2.6.2 Paraffin-embedded Tissue blot 
Paraffin-embedded brain samples were cut 3μm thick sections using a Leica® 
RM 2135 microtome and collected onto 0.45 μm nitrocellulose membranes for 
Paraffin-embedded Tissue (PET) blotting. Membranes were dried O/N at 56ºC 
before being deparaffinated and rehydrated. For PK digestion, membranes 
were incubated with PK 250 μg/ml (PK recombinant, PCR Grade, Roche) for 
two hours at 55°C. Then, membranes were denaturated in guanidium 
isothiocyanate 3 M solution for 10 min at room temperature and blocked with 
0.2% BSA (Sigma Aldrich) in PBST dilution. For immunodetection, membranes 
were incubated with Sha-31 mAb (4 μg/ml saturation buffer) for an hour at 
room temperature. Immunocomplexes were detected with an alkaline 
phosphatase-coupled secondary Ab (Polyclonal rabbit antimouse 
Inmunoglobuline, Dako) at 2µl/ml dilution in a saturation buffer. 
Immunoreactivity was revealed using NBT/BCIP substrate chromogen (Sigma 
B-5655).  
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2. Goat models  
All procedures involving the goat transmission studies (goat mating, 
sequencing and inoculation, clinical status monitoring, euthanasia, tissue 
sampling, and histopathological analysis) were performed either in the 
laboratory of Dr. Olivier Andréoletti at the École Nationale Vétérinaire in 
Toulouse (France) or in the laboratory of Dr. Martin Groshup at the Institute for 
Novel and Emerging Infectious Diseases, Friedrich-Loeffler-Institut (FLI), Insel 
Riems (Germany) in the framework of the StrepBSE in goat EU project (UE-FP6-
2005-FOOD4B-036353). These procedures are described below and will help in 
the understanding of the experiments. 
2.1 Goat mating and sequencing 
The goats kids used in the experiment were produced by direct mating of prnp-
sequenced Alpine and Saanen female goats and bucks. Parents were selected 
from three herds managed by the French National Agronomic Institute (INRA). 
Selection was based on the prnp polymorphisms at codons 142 (I/M), 154 
(R/H), 211 (R/Q), and 222 (Q/K). Animals were then naturally mated to 
produce the goats used in the experimental inoculation.  
The Exon3 of the prnp of each goat kid was sequenced as previously described 
(Arsac et al., 2007). Briefly, DNA was directly recovered from the brain stem (30 
mg) using a commercial DNA extraction kit (Qiaprep DNeasy Minikit 
(QIAGEN, Courtaboeuf, France) following the manufacturer’s 
recommendations. The complete ORF sequence of the prnp was determined 
using several oligonucleotides: 3´-GTGGGCATTTGATGCTGACAC-5´; 5´-
TGGTTGGGGTAACGGTACATG-3´; 5´-TCAGCCCCATGGTGGTGGCT-3´ and 
3´-CTGCAGGTAGACACTCCCTCC-5´.  
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2.2 Transmission studies in goats 
2.2.1 Goat inoculation 
Goat bioassay with scrapie at INRA 
Within 48 hours of birth a group of goat kids received 1.5g of brain-equivalent 
material through natural suckling (1% diluted stock inoculum in glucose 5%). A 
second inoculation (same material and route) was performed at the age of 30 
days. In parallel, a second group of goat kids were housed until they were six 
months of age. At this age, all the goats were anesthetised (Ketamine/Valium) 
and 400µL of the stock inoculum was injected into their temporal cortex. The 
inoculum was derived from a single natural field scrapie case (clinical) obtained 
from a 3.5-year-old goat with the wt prnp genotype.  
Goat bioassay with BSE at FLI 
At 6–7 months of age goats harboring WT (R211Q222/RQ), R/Q211, or Q/K222 
genotypes received a total dose of approximately 1g brain-equivalent material 
from BSE first passaged in goat. This goat BSE material was obtained by 
pooling brainstems from three WT goats experimentally inoculated with a 
mixture of four cattle BSE field cases (Foster et al., 1993; Goldmann et al., 1996). 
The inoculum was orally administered at 1:5 (w/v) dilution in sterile 0.9 NaCl; 
each goat received 5ml of pooled goat brain homogenate. 
2.2.2 Clinical status monitoring, euthanasia, and tissue sampling 
Goats were regularly monitored for the presence of clinical signs, i.e. cachexia, 
alopecia, lethargy, and abnormalities in sensations and movements. Goats were 
euthanatized at the clinical stage or at scheduled times (Tables 6 and 7) using 
Ketaminhydrochlorid (10-15 mg/kg) and Xylazinhydrochlorid for anesthesia 
followed by euthanasia with T61 (4-6ml/50 kg body weight). During necropsy, 
a set of tissues including brain, lymph node poplitealis, psoas major, and 
retractor bulbi muscles was collected under TSE sterile conditions and 
harvested at -80ºC. 
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2.2.3 Histological analysis 
A part of each sample was immediately fixed in neutral-buffered 10% formalin 
(4% formaldehyde). Subsequently, these samples were treated for one hour 
with 98% formic acid and rinsed in tap water for 40 min before dehydration and 
embedding in paraffin. After rehydration, 3-µm-thick brain slices were stained 
with hematoxylin and eosin (HE) and a histopathological examination was 
carried out. For detecting PrPSc deposits, immunohistochemistry (IHC) analyses 
were performed as previously described (Kaatz et al., 2012), using 6C2 (Central 
Veterinary Institute of Wageningen UR, Lelystad, Netherlands) and F99 
(VMRD, Pullman, USA) monoclonal antibodies (mAb).  
Subsequently, the sections were pretreated by incubation with 98% formic acid 
(15 min), followed by autoclaving in citrate buffer for 20 min at 121°C. The 
endogenous peroxidase was inhibited using 3% H2O2 in methanol for 30 min. 
The primary antibodies were diluted in goat serum: the 6C2 at 1:50 to 1:150 and 
the F99 at 1:4000, and then incubated for two hours at room temperature. 
Negative control sections were treated only with goat serum. As a secondary 
Ab the EnVision™ reagent (Dako, Hamburg, Germany) containing a 
peroxidase-conjugated polymer backbone was used. The incubation time for 
these sections was 30 min at room temperature. The slides were finally 
developed in diaminobenzidine tetrahydrochloride (Fluka, Steinheim, 
Germany) and counterstained with Mayer’s haematoxylin. All sections were 
examined by light microscopy. 
2.2.4 PrPres detection in different goat tissues by Western blot 
PrPres was detected in tissues from goat BSE orally inoculated goats by WB as 
mentioned above (see section 1.2.1.2). In all, 100 µl of each tissue 10% (w/v) 
homogenate were analyzed. For immunoblotting, membranes were incubated 
with Sha31 mAb and immunocomplexes were detected with horseradish 
peroxidase-conjugated anti-mouse IgG (Amersham GE Life Sciences). 
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2.3 Prion infectivity in goat tissues 
2.3.1 Prion infectivity in Goat BSE inoculum 
Wt-Tg501 and BoPrP-Tg110 mouse lines were used for titration of the Goat BSE 
isolate. The BoPrP-Tg110 mouse line was established and has been described 
elsewhere (Castilla et al., 2003). BoPrP-Tg110 transgenic mice express bovine 
PrP protein under the murine PrP promoter in a murine PrP null (muPrP-/-) 
background. PrPC expression levels in this mouse line are approximately 8-fold 
higher than the PrPC levels found in cow brain homogenates. 
Groups of 6–9 individually identified Wt-Tg501 and BoPrP-Tg110 (6–7-weeks 
old) mice were intracerebrally inoculated with 10-fold serial dilution of the 
Goat-BSE isolate (Foster et al., 1993; Goldmann et al., 1996). Mice inoculation, 
clinical status monitoring, euthanasia, tissue sampling, and brain PrPres 
detection by Western blot were performed as previously described (see sections 
1.2.2–1.2.5). The survival time was expressed as the mean number of survival 
days postinoculation (dpi) for all the PrPres-positive mice, with the standard 
error included. The attack rate was determined as the proportion of PrPres-
positive mice out of all the inoculated mice. 
The Infective Dose50 (ID50) of the Goat-BSE isolate (Foster et al., 1993; 
Goldmann et al., 1996) was assessed using the Reed-Muench method. The 
proportionate distance was calculated with the Reed-Muench formula ((percent 
of infected mice at dilution immediately above 50%) -50% / (percent of infected 
mice at dilution immediately above 50%) – (percent of infected mice at dilution 
immediately bellow 50%)) and applied to the dilution that produced the 
percentage of infection immediately above 50%. The infectious titer of the Goat-
BSE isolate was expressed in ID50 per gram (ID50 g-1) of tissue. 
A regression curve was drawn with dilutions that produced 100% attack rates. 
The equation fit to the data was obtained (y = ex) and used to determine the 
infectious titers in each different goat tissue from their survival time values. 
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2.3.2 Assesment of infectivity in goat tissues  
Brain, lymph node poplitealis, psoas major, and retractor bulbi muscles were 
obtained from WT (R211Q222/RQ), R/Q211, and Q/K222 goats orally inoculated 
with a Goat-BSE isolate (Foster et al., 1993; Goldmann et al., 1996) at the 
Institute for Novel and Emerging Infectious Diseases, Friedrich-Loeffler-Institut 
(FLI), InselRiems, Germany. Samples were homogenized as 10% (w/v) in sterile 
0.9 NaCl and some were pooled. 
Groups of 6–9 individually identified BoPrP-Tg110 mice were intracerebrally 
inoculated with 20µl of each tissue homogenate and monitored for the presence 
of neurological signs. Euthanasia, tissue sampling, and brain PrPres detection by 
WB analysis were performed as previously described (see sections 1.2.2–1.2.5).  
The relative infectivity of the different goat tissues was calculated as a function 
of the survival times obtained after their inoculation in BoPrP-Tg110 mice. 
Hence, survival times were interpolated into the equation fitting the data (y = 
ex) previously obtained in the goat-BSE inoculum titration (see section 2.3.1).  
3. Statistical analysis 
A non-parametric Mann-Whitney-U test was applied to establish statistically 
significant differences in survival times of the M142-Tg541 and K176-Tg570 
mouse lines and of the Wt-Tg501 mouse line inoculated with the same scrapie 
and BSE isolates. Statistical analyses were performed using PAST software 
(PAlaeontological STatistics, version 1.81). A difference of P<0.05 was 
considered as significant. 
4. Buffers 
- 4% 2-formaldehyde: 10% formaldehyde (w/v)  (Carlo Erba 310358), 0.4% 
(w/v)  NaH2PO4-H2O (Carlo Erba 480086), 0.4% (w/v) Na2HPO4 (Carlo 
Erba 480141), 0.4% (w/v) NaHO 4 N in H20. 
- BSA blocking buffer: 2% (w/v) Bovine Serum Albumin (BSA) fraction V 
(Sigma-Aldrich) in PBST.  
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- Eosin: 10% (w/v) Eosine Y (RAL 312717), 10% (w/v) Erythrosine 239 for 
histology (RAL 312827) in distilled H2O. 
- Extraction buffer: 1% (w/v) NP40, 1% (w/v) sodium deoxycholate, 10mM 
EDTA in PBS (pH 7.4) + complete™ cocktail of protease inhibitors (Roche).  
- Laemmli buffer: 5% (v/v) β-mercaptoethanol, 2% (w/v) SDS, 125mM Tris-HCl 
(pH 6.8), 10% (v/v) glycerol, 0.01% (w/v) bromofenol blue in H2O.  
- Loading buffer: 50mM ditiotreitol (DTT), 1.5% Sodium Dodecyl Sulfate (SDS), 
125mM Tris-HCl (pH 6.8), 10% (v/v) glycerol, 0.01% (w/v) bromofenol blue in 
H2O.  
- PBS + IP: 1X Phosphate Buffered Saline (PBS) + complete™ cocktail of 
protease inhibitors (Roche).  
- Phosphate Buffered Saline (PBS): 137 mM NaCl, 2.7 mM KCl, 1.5 mM KH2PO4, 
8.5 mM Na2HPO4 (pH 7.4) in H2O. 
- Phosphate Buffered Saline with Tween (PBST): PBS, 0.1% (v/v) Tween 20 
(Merck  822184).  
-  TE: 10 mM Tris (pH 7.4), 0.1 mM EDTA.  
- Transferring buffer: 25mM Tris, 192mM glycine, 10% (v/v) metanol in H2O.  
- Running buffer (for 12% polyacrylamide gels): 1.6% (v/v) acrylamide, 0.8 M 
Tris (pH 6.8), 5% (w/v) SDS, 5% (w/v) PSA and 0.2% (v/v) TEMED in H2O.  
- Saturation buffer: PBST, 0.2% BSA 30% (Sigma Aldrich A3299).  
-  Stacking buffer (for 12% polyacrylamide gels): 2% (v/v) acrylamide (BioRad), 
13 mM Tris (pH 6.8), 1% (w/v) SDS, 1% (w/v) ammonium persulfate (PSA) and 
0.1% (v/v) Tetramethylethylenediamine (TEMED) (BioRad) in H2O.
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1. Assessment of the resistance/susceptibility of polymorphic 
variants of the prion protein to prion infection in transgenic mice 
1.1. Generation of transgenic mice expressing different goat and sheep PrPC 
polymorphic variants 
1.1.1. Obtaining mouse founders 
Transgenic mouse lines (Tg) expressing either the goat wild type PrPC (Wt-
Tg501 mice) or the K222-PrPC variant (K222-Tg516 mice) were previously 
generated by our group and the results related to their generation are included 
here for the purposes of comparison. In the present study, Tg lines expressing 
the M142, H154, R171, K176, or Q211-PrPC polymorphic variants were new-generated 
following the same procedure used for obtaining goat wt- and K222-PrPC mice.  
The Wt-Tg501 mouse line was obtained from the DNA of a wild type goat 
whose prnp was identical to that of a goat previously reported (GenBank 
accession number AF117316.1). Its ORF was subcloned into the pGEM-T Easy 
Vector System (Promega) and later inserted into a MoPrP.Xho plasmid 
(Borchelt et al., 1996) containing the murine PrP promoter, and exon 1, intron 1, 
exon 2, and 3’ untranslated sequences, and named as pMo-GoPrP.Xho (see 
Materials and Methods section, Fig. 9).  
Transgenes containing different polymorphic variants of the prnp (M142, H154, 
R171, K176, Q211, and K222) were generated by directed mutation of the 
aforementioned pMo-GoPrP.Xho plasmid with specific primers (see Table 3 in 
Materials and Methods section). Mutations consisted of single nucleotide 
substitutions that gave rise to amino acid exchanges (Fig. 11). In this way, all 
these transgenes harbor the same PrPC sequence except for a single amino acid 
exchange corresponding to the desired PrPC polymorphic variant (see Materials 
and Methods section, Fig. 9).  
Finally, these DNA constructions were purified and microinjected into 
pronuclear stage embryos collected from super-ovulated B6CBAF1 females in 
collaboration with Dr. Belén Pintado at the Centro Nacional de Biotecnología 
(CNB-CSIC). These female mice were mated with 129/Ola males carrying a null 
mutation in their endogenous PrP (Manson et al., 1994), and their progeny were 
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analyzed by PCR for the presence of the goat or sheep transgene (Table 8). 
Those carrying the transgene (founders) were selected for further 
characterization. 
Table 8. Summary of the generation of the different transgenic mouse lines 
Trans
gene 
Microinjecte
d embryos 
Mice 
born 
Transgene 
positive  
mice (Founders) 
Transgenesis 
rate (%) 
Transgenic 
mouse 
lines 
WTa 667 41 6 14.6 
G500 
G501 
G502 
G503 
G504 
G505 
K222a 503 30 4 13.3 
G514 
G515 
G516 
G517 
M142 440 57 7 12.28 
G540 
G541 
G542 
G543 
G544 
G545 
G546 
H154 560 39 6 15.38 
G560 
G561 
G562 
G563 
G564 
G565 
Q211 1049 85 3 3.53 
G580 
G581 
G582 
R171 379 25 2 8 
G550 
G552 
K176 262 43 4 9.30 
G570 
G571 
G572 
G574 
a Transgenic mouse lines expressing the WT PrPC or the K222-PrPC variant were 
previously generated by our group and are included for comparison. 
 
  
 
 
 
ATG GTG AAA AGC CAC ATA GGC AGT TGG ATC CTG GTT CTC TTT GTG GCC ATG TGG AGT GAC GTG GGC CTC TGC AAG AAG CGA CCA AAA CCT GGC GGA GGA TGG AAC ACT 
 M   V   K   S   H   I   G   S   W   I   L   V   L   F   V   A   M   W   S   D   V   G   L   C   K   K   R   P   K   P    G   G   G   W   N   T 36 
 
GGG GGG AGC CGA TAC CCG GGA CAG GGC AGT CCT GGA GGC AAC CGC TAT CCA CCT CAG GGA GGG GGT GGC TGG GGT CAG CCC CAT GGA GGT GGC TGG GGC CAA CCT CAT  
 G   G   S   R   Y   P   G   Q   G   S   P   G   G   N   R   Y   P   P   Q   G   G   G   G   W   G   Q   P   H   G   G   G   W   G   Q   P   H   
72 
GGA GGT GGC TGG GGT CAG CCC CAT GGT GGT GGC TGG GGA CAG CCA CAT GGT GGT GGA GGC TGG GGT CAA GGT GGT AGC CAC AGT CAG TGG AAC AGG CCC AGT AAG CCA  
 G   G   G   W   G   Q   P   H   G   G   G   W   G   Q   P   H   G   G   G   G   W   G   Q   G   G   S   H   S   Q   W   N   K   P   S   K   P   
108 
AAA ACC AAC ATG AAG CAT GTG GCA GGA GCT GCT GCA TCA GGA GCA GTG GTA GGG GGC CTT GGT GGC TAC ATG CTG GGA AGT GCC ATG AGC AGG CCT CTT ATA CAT TTT  
 K   T   N   M   K   H   V   A   G   A   A   A   A   G   A   V   V   G   G   L   G   G   Y   M   L   G   S   A   M   S   R   P   L   I   H   F   
                                                                                                                                   M142 (ATG)   144 
GGC AAT GAC TAT GAG GAC CGT TAC TAT CGT GAA AAC ATG TAC CGT TAC CCC AAC CAA GTG TAC TAC AGA CCA GTG GAT CAG TAT AGT AAC CAG AAC AAC TTT GTG CAT 
 G   N   D   Y   E   D   R   Y   Y   R   E   N   M   Y   R   Y   P   N   Q   V   Y   Y   R   P   V   D   Q   Y   S   N   Q   N   N   F   V   H                                                  
                                   H154 (CAT)                                                          R171 (CGG)           K176 (AAA)           180 
GAC TGT GTC AAC ATC ACA GTC AAG CAA CAC ACA GTC ACC ACC ACC ACC AAG GGG GAG AAC TTC ACC GAA ACT GAC ATC AAG ATA ATG GAG CGA GTG GTG GAG CAA ATG 
 D   C   V   N   I   T   V   K   Q   H   T   V   T   T   T   T   K   G   E   N   F   T   E   T   D   I   K   I   M   E   R   V   V   E   Q   M      
                       Q211 (CAA)                    216 
TGC ATC ACC CAG TAC CAG AGA GAA TCC CAG GCT TAT TAC CAA AGG GGG GCA AGT GTG ATC CTC TTT TCT TCC CCT CCT GTG ATC CTC CTC ATC TCT TTC CTC ATT TTT  
 C   I   T   Q   Y   Q   R   E   S   Q   A   Y   Y   Q   R   G   A   S   V   I   L   F   S   S   P   P   V   I   L   L   I   S   F   L   I   F     
                                              K222 (AAG)                                                                                                                                                              252 
CTC ATA GTA GGA TAG 
 L   I   V   G  end  255 
Figure 11. Nucleotide sequence of the open reading frame (ORF) encoding the goat wild type prion protein (Capra hircus tissue-type PBL 
prion protein (PrP) gene; GENBANK ACCESSION NUMBER: AF117316.1); the polymorphic variants studied in this work are highlighted. 
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1.1.2. Selection of mouse founders 
Several mouse lines (founders) were obtained for each transgene (Table 8). Founder 
animals also expressing the endogenous murine prnp gene (prnp mu+/- go+/-) were 
crossed with prnp null mice (prnp mu-/-) (Manson et al., 1994) to obtain transgene 
hemizygous lines in a murine prnp null background (prnp mu-/- go+/-), thereby 
preventing any possible interference by the endogenous murine PrPC in the 
susceptibility of goat and sheep Tg mice to TSEs (Kobayashi et al., 2009).  
For each mouse line, transgene transmission ability, PrPC level of expression in the 
brain, and animal health and physiological behavior were analyzed (Table 9) in order 
to select the most suitable founders for the transmission studies.  
All the offspring obtained from breeding the founders with prnp null mice (prnp mu-
/-) (Manson et al., 1994) were analyzed by PCR to confirm the presence of the 
transgene. The majority of the founders were able to transmit the transgene to their 
progeny (Table 8), which, following Mendel´s principle of segregation (≤50% of 
transgene transmission when hemizygous founders were crossed with prnp null 
mice), thus suggests the existence of a single transgene insertion site in the mice 
genome. Founders with transgene transmission rates over 50% (indicative of 
multiple insertion sites), were discarded.  
Then, the PrPC level of expression in the brain was determined in those mouse lines 
that transmitted the transgene (Table 9). Several animals from each progeny were 
sacrificed at 60 days of age and their whole brains were sampled. The amount of 
PrPC in their brains was assessed by Western blot (WB) and compared to the PrPC 
expressed in the brain of a wt goat or sheep (Fig. 12). Given that a directly 
proportional influence of the PrPC level of expression in the TSEs incubation times 
has been described (Castilla et al., 2003), mouse lines expressing the brain PrPC at 
goat and sheep physiological levels were selected in order to mimic as closely as 
possible the prion infection in goat and sheep.  
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Table 9. Summary of the characterization of the different transgenic mouse lines 
Trans 
gene 
Tg mouse 
lines 
Transgene 
transmission 
ability 
Brain PrPC level of 
expression in 
hemizygosisb 
Animal 
health and 
behavior 
WTa 
G500 
G501 
G502 
G503 
G504 
G505 
+ 
+ 
+ 
+ 
+ 
+ 
1X 
1X 
0.75X 
0.75X 
0.75X 
0.75X 
Normal 
Normal 
Normal 
Normal 
Normal 
Normal 
K222a 
G514 
G515 
G516 
G517 
+ 
+ 
+ 
+ 
0.5X 
1X 
1X 
0.25X 
Normal 
Normal 
Normal 
Normal 
M142 
G540 + 0.5X Normal 
G541 + 1X Normal 
G542 + 0.5X Normal 
G543 - NA Normal 
G544 + 0.25X Normal 
G545 + 0.25X Normal 
G546 - NA Normal 
H154 
G560 + 0.25X Normal 
G561 + 0.25X Normal 
G562 - NA Normal 
G563 + 0.25X Normal 
G564 + 0X Normal 
G565 + 0X Normal 
Q211 
G580 + 0.5X Normal 
G581 - NA Normal 
G582 - NA Normal 
R171 
G550 + 1X Normal 
G552 + 1X Normal 
K176 
G570 + 2X Normal 
G571 -c NA Normal 
G572 + 0.25X Normal 
G574 + 0.75X Normal 
a Characterization of the transgenic mouse lines expressing the WT PrPC or the K222-PrPC 
variant that were previously generated by our group, and are here included for comparison. 
b Brain PrPC expression in hemizygous Tg mouse lines related to that in goat or sheep brains. 
c This founder had no progeny. 
NA: Not analyzed. 
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A similar PrPC level of expression in the different Tg mouse lines was also pursued to 
ensure that the comparative study of their susceptibilities to prion infection was as 
accurate as possible. Thus, the PrPC expression in the brain of Wt-Tg501 and K222-
Tg516 (Aguilar-Calvo et al., 2014) was also compared with that of each of the new-
generated transgenic mouse lines (Fig. 12A and D).  
Brain PrPC electrophoretic profiles for all the goat and sheep Tg mouse lines were 
similar to those taken for goat and sheep brain PrPC (Fig. 12). M142-Tg541 and R171-
Tg552 lines were selected on the basis of the similarity in the PrPC expression levels 
in their brains to those of goat, sheep, Wt-Tg501, and K222-Tg516 mice brains (Fig. 12B 
and F). By contrast, we found no K176 or Q211 mouse line expressing their brain PrPC 
with similar levels to those of goat, sheep, Wt-Tg501, or K222-Tg516 mice brains. 
Hence, K176-Tg570 mouse line was selected due to its expression of the PrPC, twice 
the PrPC in goat brains (2X) (Fig. 12G), which is comparable to the expression of Wt-
Tg501 mice in homozygosis. Q211-Tg580 mouse line was chosen because it was the 
only Q211 founder able to transmit the transgene to their progeny, even if its 
expression was slightly lower than in Wt-Tg501 mice (Fig. 12D). Finally, H154-Tg563 
was used for transmission studies even though its PrPC expression in the brain was 
four times lower than in the goat brain (0.25X) (Fig. 12C). 
All the founders and a number of their progeny were monitored until the end of their 
lifespans to see whether any health or behavior abnormalities developed. None of 
these animals showed any sign of disease or physiological alteration. Neither were 
any histological lesions suggestive of prion disease found in their brains using 
Hematoxylin-Eosin staining (HE) or Paraffin-embedded Tissue blots (PET-Blot). 
Therefore, spontaneous disease development due to the expression of the mutated 
PrPC could also be ruled out for all the transgenic mouse lines (Table 9). 
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Figure 12. Brain PrPC expression in hemizygous goat and sheep PrP transgenic mouse 
lines in comparison to goat and sheep brains. Immunoblotting of brain PrPC of Wt-Tg501 
(A), M142-Tg541 (B), H154-Tg563 (C), Q211-Tg580 (D), K222-Tg516 (E), R171-Tg552 (F), and K176-
Tg570 (G) mice detected with 12B2 mAb. Direct sample (10% brain homogenates) and ½ 
serial dilutions were loaded on 12% Bis-Tris gels. The figure illustrates a representative set of 
three independent experiments. The relative molecular mass in kilodaltons is shown on the 
left-hand side of each blot.  
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In conclusion, M142-Tg541, H154-Tg563, Q211-Tg580, R171-Tg552, and K176-Tg570 Tg 
mouse lines, all expressing similar levels of the same goat wt PrPC as Wt-Tg501 mice 
but with a single amino acid exchange, were generated in this work (Fig. 13). These 
mouse lines, together with previously generated Wt-Tg501 and K222-Tg516 mice, 
were then used for transmission studies with a wide variety of scrapie and BSE 
isolates in order to study the role of each PrPC polymorphic variant on the 
resistance/susceptibility to prion infection. 
 
Figure 13. Brain PrP
C
 expression level of the different transgenic mouse lines in 
comparison to goat and sheep brains. Immunoblotting of brain PrP
C
 from M
142
-Tg541, Q
211
-
Tg580, H
154
-Tg563, K
222
-Tg516, Wt-Tg501, R
171
-Tg552 and K
176
-Tg570 mice, goat, and sheep 
detected with 12B2 mAb.  Identical amounts of brain material (10% brain homogenate) were 
loaded on 12% Bis-Tris gels. The relative molecular mass in kilodaltons is given on at the 
right-hand side of the blot. 
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1.2 Susceptibility of goat wild type-PrPC transgenic mice to a wide diversity of 
prion isolates 
Goat Wt-Tg501 mice were previously generated and initially challenged with a 
limited number of scrapie isolates by our group. These mice resulted fully 
susceptible to these scrapie transmissions, thereby suggesting that this mouse line is 
a promising tool for studying this infectious agent in goats and sheep. However, the 
low number of isolates tested prevented us from drawing further conclusions at this 
point.In order to fully assess the susceptibility of this mouse line to the prion 
infection, Wt-Tg501 mice were challenged with a broad panel of scrapie and BSE 
isolates (see Tables 4-7 in Materials and Methods for more information).  
1.2.1 Characteristics of prion isolates 
A collection of scrapie isolates were selected on the basis of heterogeneity according 
to the following factors: i) geographical origin, ii) PrPSc amino acid sequence, iii) 
brain PrPres glycoprofile, and iv) transmission features in BoPrP-Tg110 mice. Table 10 
summarizes the characteristics of the scrapie isolates. Scrapie isolates were obtained 
from numerous outbreaks from different European countries (see Tables 4-6 in 
Materials and Methods for more information). All the isolates were sequenced to 
determine the PrPSc amino acid sequence according to the procedures described in 
Materials and Methods, section 1.2.1.1. The polymorphic variants found in the 
isolates are given in Table 10, column “PrPSc genotype”.  
Brain PrPres glycoprofile for all the scrapie isolates were analyzed by Western blot 
(WB) following the procedures described in Materials and Methods, section 1.2.1.2. 
The apparent molecular mass of the PrPres unglycosilated band of each isolate is 
given in kilodaltons (K) in Table 10, column “PrPres profile”. Most of the classical 
scrapie isolates exhibited a single 21K PrPres unglycosilated band (Fig. 14A). Only 
Goat-Sc F14 and Goat-Sc UKB2 isolates were distinguishable by their double 19-21K 
PrPres unglycosilated band (Fig. 14A), thereby suggesting the presence of more than 
one scrapie agent in these isolates. In contrast, all atypical scrapie isolates showed a 
similar Nor98 PrPres WB glycoprofile characterized by a ladder pattern and a low 
unglycosilated band of around 7K (Fig. 14B).  
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Table 10. Characteristics of the panel of scrapie and BSE isolates 
 
Isolate 
Transmission in BoPrP-Tg110 
1st passage 2nd passage 
Name Origin PrPSc genotypea 
PrPres 
profileb 
ST ± SEM 
(n/n0)c 
PrPres 
profile 
ST ± SEM 
(n/n0)d 
PrPres 
profile 
C
la
ss
ic
al
 s
cr
ap
ie
 
Goat-Sc I2 
Italy 
wt; S/S240 21K 453 (1/6) 21K 167±9 (7/7) 21K 
Goat-Sc I3 wt; P/P240 21K 464 (1/7) 21K 163±16 (7/7) 21K 
Goat-Sc I4 wt; R/Q211; S/P240 21K >650 (0/5) - NA NA 
Goat-Sc I9 wt; R/H143; S/P240 21K 324±90 (6/6) 21K 174±8 (5/5) 21K 
Goat-Sc I12 wt; S/P240 21K >650 (0/7) - NA - 
Goat-Sc F2 
France 
wt; S/P240 21K 343±163 (4/5) 19K 198±13 (6/6) 19K 
Goat-Sc F3 wt; P/P240 21K 290±48 (3/6) 19K 191±3 (6/6) 19K 
Goat-Sc F6 wt; S/P240 21K 523±166 (6/6) 19K 178±13 (5/5) 19K 
Goat-Sc F10 wt; S/P240 21K 556±68 (4/4) 19K 575±43 (5/5) 19K 
Goat-ScF11 wt; I/M142; P/P240 21K >650 (0/6) - NA NA 
Goat-ScF14 wt; I/M142; S/P240 19-21K >650 (0/6) - NA NA 
Goat-Sc F16 wt; I/M142; S/P240 21K 348±58 (3/6) 21K 177±9 (6/6) 21K 
Goat-ScG2 
Greece 
wt; P/P240 21K 610 (1/6) 19K 348±85 (6/6) 19K 
Goat-ScG3 wt; R/H143; P/P240 21K >650 (0/6) - NA - 
Goat-Sc N1 
Netherlands 
wt; R/H143; S/P240 21K 649±9 (3/3) 19K 
>450 
(ongoing)  
- 
Goat-Sc N2 wt; R/H143; S/P240 21K >650 (0/6) - NA - 
Goat-Sc N3 wt; P/P240 21K 324, 703 (2/6)* 19K 
203±7 (5/5) 19K 
493±72 (6/6) 19K 
Goat-Sc S2 
Spain 
wt; S/P240 21K 384±149 (6/6) 19K 237±39 (9/9) 19K 
Goat-Sc S3 wt; P/P240 21K 271±19 (6/6) 19K 254±52 (4/4) 19K 
Goat-Sc UKA2 
United 
Kingdom 
wt; S/P240 21K 255±69 (5/5) 19K 187±6 (6/6) 19K 
Goat-Sc UKB2 wt; G/S127; P/P240 19-21K 205±12 (7/7) 19K 196±5 (6/6) 19K 
Goat-Sc UKD2 wt; G/S127; P/P240 21K >650 (0/7) - NA NA 
Goat-Sc Zyp13 
Cyprus 
wt; P/P240 21K >650  (2/2) 19K 371±51 (6/6) 19K 
Goat-Sc Zyp21 wt; P/P240 21K >650 (2/5) 19K 387±12 (3/3) 19K 
Sheep-Sc 21 
France 
wt; S/S240 21K 244±13 (6/6) 19K 187±2 (4/4) 19K 
Sheep-Sc 
Langlade 
wt; S/S240 21K 504±47 (6/6) 19K 229±37 (4/4) 19K 
Sheep-Sc 09 wt; F/F141;S/S240 21K 230±66 (4/6) 19K 168±6 (6/6) 19K 
A
ty
p
ic
al
 s
cr
ap
ie
  
Goat-Sc I15 Italy wt; H/R154;S/P240 Nor98e >650 (1/6) 19K NA NA 
Sheep-Sc 
engavagen 
Norway wt; F/F141;S/S240 Nor98 395±44 (3/5) 19K NA NA 
Sheep-Sc M45 
Spain 
wt; S/S240 Nor98 >650 (0/6) - NA NA 
Sheep-Sc TOA4 wt; H/Q171; S/S240 Nor98 >650 (0/6) - NA NA 
B
S
E
 
Goat-BSE1 
France 
wt S/S240 19K 255±7 (5/5) 19K  242±3 (5/5) 19K 
Goat-BSE2 wt P/S240 19K 289±24 (6/6) 19K 277±10 (6/6) 19K 
Sheep-BSE wt; S/S240 19K 246±9 (5/5) 19K 237±5 (5/5) 19K 
Cattle-BSE Cattle wt 19K 282±41 (6/6) 19K 245±26 (5/5) 19K 
Cattle-BSE L Cattle wt 19K-Lf 214±15 (6/6) 19K-L 188±1 (6/6) 19K-L 
See next page for footnotes 
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a Scrapie isolates were sequenced following the procedures described in Materials and 
Methods, section 1.2.1.1. Wild type (wt) PrPSc sequence (A136R154Q171/ A136R154Q171) and the 
polymorphic variants observed are indicated.  
b Brain PrPres was detected by Western blot using Sha31 or 9A2 mAb (Fig. 14–15). The 
apparent molecular mass of the PrPres unglycosilated band is given in kilodaltons (K).  
c n/n0: diseased, PrPres: positive/inoculated animals.  
d Isolates were considered fast (in red) if survival times were <300 days post-inoculation 
(dpi) at second passage, or slow (in blue) when survival times were >300 dpi at second 
passage. 
 e Nor98: PrPres Western blot glycoprofile characterized by a ladder pattern and a low 
unglycosilated band of around 7K. 
f 19K-Ltype: PrPres Western blot glycoprofile characterized by a predominant 
monoglycosylated moiety and a smaller molecular size of the nonglycosylated fragment 
compared to the classical BSE agent. 
* Among the Goat-Sc N3 infected BoPrP-Tg110 mice one exhibited very long survival times 
of 703 dpi. The brain from this animal was further passaged in BoPrP-Tg110 mice (in blue) 
separately from the other mouse (in red). 
Orange cells: isolates transmitted with no apparent transmission barrier. 
Green cells: isolates transmitted with a moderate-to-high transmission barrier. 
White cells: isolates not transmitted.  
NA: Not analyzed 
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Figure 14. PrP
res
 of scrapie and BSE isolates. Immunoblots of brain PrP
res
 detected in 
classical scrapie (A), atypical scrapie (B), and BSE (C) isolates. PrPres was detected with Sha31 
mAb for classical scrapie and BSE isolates, and with 9A2 mAb for atypical scrapie isolates. 
Similar quantities of sample (10% brain homogenate) were loaded for adequate comparison. 
Molecular weights in kilodaltons are shown on the right-hand side of the blot.  
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Table 10 also shows the results of the prion transmission experiments in BoPrP-Tg110 
mice, and includes survival times (ST) and attack rates (AR) at first and second 
passage, and brain PrPres WB profile. These transmission studies were conducted in 
the framework of the StrepBSE in goat EU project (UE-FP6-2005-FOOD4B-036353) 
and permitted us to analyze the behavior of scrapie isolates in the bovine species 
context. 
For these transmission experiments, groups of 6–9 BoPrP-Tg110 mice were 
intracerebrally (IC) inoculated with the complete panel of prion isolates described 
above. When the progression of the disease was evident or at the end of their lifespan 
(≈650 days), BoPrP-Tg110 mice were euthanized and their brains sampled for 
detecting the presence of PrPres using Sha31 mAb (Fig. 15), following the procedures 
described in Materials and Methods, section 1.2.1.2.  
Brain homogenates from mice scoring positive for PrPres were used for further 
passaging. When all mice scored negative for PrPres on primary passage, PrPres-
negative brain homogenates were used for second passage (see Materials and 
Methods, section 1.2.1). ST and AR were assessed following the procedures described 
in Materials and Methods, section 1.2.4 to determine the susceptibility of BoPrP-
Tg110 mice to scrapie infection. ST are expressed as the mean number of survival 
days postinoculation (dpi) for all the PrPres-positive mice, including the standard 
error (SM), while AR were assessed as the proportion of PrPres-positive mice out of 
all the inoculated mice. 
Taking into account the transmission efficiency in BoPrP-Tg110 mice at first and 
second passage, classical scrapie isolates can be classified in three groups:  
i) Classical scrapie isolates transmitted to BoPrP-Tg110 mice with low or no apparent 
transmission barrier. Seven out of the 27 isolates showed 100% AR at first passage 
and a weak decrease in their ST after second passage in these bovinized Tg mice (in 
orange in Table 9), suggesting a low or no transmission barrier in BoPrP-Tg110 mice. 
ii) Classical scrapie isolates transmitted to BoPrP-Tg110 mice with a moderate-to-
high apparent transmission barrier. Thirteen out of the 27 isolates showed less than 
100% AR and/or very long ST at first passage, but were fully transmitted (100% AR) 
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to these bovinized Tg mice at second passage (in green in Table 10). This drastic 
decrease in ST is suggestive of a high transmission barrier. 
iii) Classical scrapie isolates that were not transmitted to BoPrP-Tg110 mice. BoPrP-
Tg110 mice did not succumb to the primary transmission of seven out of the 27 
classical scrapie isolates tested (in white in Table 10), suggesting that an absolute 
transmission barrier for these agents exists in this mouse model. However, low 
infectious titers cannot be ruled out as the cause of these negative results in these 
cases, in which no second passage was performed. 
All the atypical scrapie isolates had poor transmission efficiencies at primary passage 
in BoPrP-Tg110 mice showing long ST and/or low AR (Table 9). Moreover, two out 
of the four isolates inoculated were not transmitted at first passage.  
On the basis of the PrPres glycloprofile, two kinds of classical scrapie isolates were 
observed: those that showed a 21K PrPres unglycosilated band upon passage in 
BoPrP-Tg110 mice, and those that produced a 19K PrPres unglycosilated band in this 
mouse model (Fig. 15A). Although all Italian scrapie isolates exhibited a 21K PrPres 
unglycosilated band in BoPrP-Tg110 mice, only one non-Italian isolate (Goat-Sc F16) 
shared this property, a finding that thus supports the idea of a regional distribution 
of scrapie strains. The rest of the panel produced a 19K PrPres unglycosilated band 
regardless of their geographical origin. Contrary to classical scrapie isolates, atypical 
scrapie isolate switched its Nor98 PrPres glycoprofile to a classical three banded PrPres 
pattern undistinguishable from classical BSE upon passage in BoPrP-Tg110 mice (Fig. 
15B). 
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Figure 15. PrPres of scrapie and BSE isolates after transmission in BoPrP-Tg110 mice. 
Immunoblots of brain PrPres from BoPrP-Tg110 mice infected with classical scrapie (A), 
atypical scrapie (B), and BSE, BSE L isolates (C) detected with Sha31 mAb. Similar quantities 
of sample (10% brain homogenate) were loaded for adequate comparison. Molecular weights 
in kilodaltons are shown on the right-hand side of the blot. 
 
Finally, given the ST at second passage in BoPrP-Tg110 mice, this panel of scrapie 
isolates could be classified as either fast (<300 dpi, in red in Table 10) or slow (>300 
dpi, in blue in Table 10). Intriguingly, all the isolates that produced a 21K PrPres 
unglycosilated band in BoPrP-Tg110 mice (Italian isolates and Goat-Sc F16) were also 
similar in terms of the other transmission features in BoPrP-Tg110 mice, i.e. they all 
exhibited a moderate transmission barrier and behaved as fast strains. For the rest of 
the panel, fast and slow isolates could be identified independently of their 
geographical origin. 
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Besides this panel of scrapie isolates, three BSE isolates naturally or experimentally 
obtained from cattle, sheep, or goat species (see Table 7 in Materials and Methods for 
more information) were selected to study the susceptibility of Wt-Tg501 mice to BSE 
infection. In addition, a natural case of an atypical BSE agent, cattle BSE L, was also 
tested to analyze its transmission features in the goat context. 
As previously reported (Castilla et al., 2005a; Castilla et al., 2003; Espinosa et al., 
2007a), all the BSE isolates were transmitted to BoPrP-Tg110 mice that had no 
transmission barrier (Table 11). Brain PrPres WB glycoprofiles of both classical and 
atypical BSE isolates were maintained in these bovinized Tg mice (Fig. 14C and 15C). 
Cattle, sheep, and goat-BSE isolates produced a characteristic BSE-like WB profile 
characterized by a predominant diglycosilated band and an apparent molecular mass 
of the unglycosilated band of 19K. By contrast, the atypical BSE L isolate showed a 
PrPres “light pattern”, with a lower molecular weight than classical BSE and no 
predominant band (Figs. 14C and 15C).  
1.2.2 Prion transmission features in transgenic mice expressing goat wild type-PrPC  
Groups of 6–9 goat Wt-Tg501 mice were IC inoculated with the complete panel of 
prion isolates described above. When the progression of the disease was evident or at 
the end of their lifespan (≈650 days), the Wt-Tg501 mice were euthanized and their 
brains sampled for both detecting the presence of PrPres by WB analysis and studying 
the PrPSc deposition and histopathological alterations using Hematoxylin-Eosin 
staining (HE) and Paraffin-embedded Tissue blots (PET-Blot), following the 
procedures described in Materials and Methods, section 1.2.6). Brain homogenates 
from PrPres positive mice were used for further passaging. ST and AR were assessed 
as previously described (see section 1.2.4 in Materials and Methods) to determine the 
susceptibility of the Wt-Tg501 mouse line to the prion infection. As well, 6–7 Wt-
Tg501 mice were IC inoculated with healthy goat brains to act as controls for the 
appearance of a spontaneous prion disease. 
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1.2.2.1 Survival times and attack rates in Wt-Tg501 mice 
Homozygous Wt-Tg501 mice were fully susceptible (100% AR) to the primary 
transmission of all the classical scrapie isolates except for two isolates (Goat-Sc G2 
and Goat-Sc UKB2) which displayed 13% and 20% AR, respectively. ST greatly 
varied at first passage, ranging from 200 to 650 dpi (Table 11). These differences in 
transmission efficiencies could be due to: i) differences in infectious titers, ii) PrP 
amino acid differences between host and donor, or iii) transmission strain 
differences. To study further the origin of these differences, second passages were 
performed (Table 11). After second passage, Wt-Tg501 mice were fully susceptible 
(100% AR) to the whole panel of classical scrapie isolates (Table 11). A reduction in 
ST was observed in some isolates (in green in Table 11), thereby suggesting the 
presence of an apparent transmission barrier. In terms of the ST at second passage, 
fast (<300 dpi, in red in Table 12) and slow (>300 dpi, in blue in Table 11) scrapie 
isolates could be distinguished. Notably, Italian isolates differed from the rest of the 
isolates due to their very long ST (550-650dpi).  
Atypical scrapie isolates were also fully transmitted (100% AR) to Wt-Tg501 mice 
(Table 11). Despite the high level of expression of homozygous Wt-Tg501 mice (twice 
the PrPC in the goat brain), all inoculated mice exhibited very long ST >400 dpi.  
Homozygous Wt-Tg501 mice were also fully susceptible (100% AR) to the 
inoculation with all the BSE isolates tested. Mice had very similar ST of around 350-
400 dpi regardless of the BSE species of origin—cattle, sheep, or goat (Table 11). 
Moreover, cattle-BSE registered very similar ST at second passage, thereby 
suggesting a low transmission barrier to the classical cattle-BSE in Tg mice 
expressing goat wt-PrPC. Atypical cattle BSE L agent was also transmitted to Wt-
Tg501 mice with high efficiency (100% AR). However, ST were longer than those 
obtained with Cattle-BSE infections at first passage (Table 11), and clearly decreased 
after second passage which indicates the presence of an apparent transmission 
barrier to Cattle-BSE L.  
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Table 11. Transmission of scrapie and BSE isolates to goat Wt-Tg501 mice 
Isolate 
Transmission in Wt-Tg501 mice
 
1
st
 passage 2
nd
 passage 
 
Name Origin PrP
Sc
 genotype
a
 
PrP
res
 
profile
b
 
ST ± SEM 
(n/n0)
c 
PrP
res
 
profile 
ST ± SEM 
(n/n0)
d 
PrP
res
 
profile 
C
la
ss
ic
al
 s
cr
ap
ie
 
Goat-Sc I2
 
Italy 
wt; S/S240 21K
 
526±123(6/6) 21K >600 (ongoing) - 
Goat-Sc I3 wt; P/P240 21K
 
>650 (5/5) 21K >600 (ongoing) - 
Goat-Sc I4 wt; R/Q211; S/P240 21K
 
582±20 (6/6) 21K >350 (ongoing) - 
Goat-Sc I9 wt; R/H143; S/P240 21K
 
578±25 (5/5) 21K 547±25 (6/6) 21K 
Goat-Sc I12 wt; S/P240 21K
 
591±42 (4/4) 21K >350 (ongoing) - 
Goat-Sc F2 
France 
wt; S/P240 21K 259±28 (4/4) 21K 212±16 (6/6) 21K 
Goat-Sc F3 wt; P/P240 21K 287±14 (6/6) 21K 228±7 (6/6) 21K 
Goat-Sc F6 wt; S/P240 21K 468±15 (4/4) 21K 299±6 (6/6) 21K 
Goat-Sc F10 wt; S/P240 21K 449±19 (5/5) 21K 372±14 (6/6) 21K 
Goat-Sc F11 wt; I/M142; P/P240 21K >650 (6/6) 21K >330 (ongoing) - 
Goat-Sc F14 wt; I/M142; S/P240 19-21K 526±46 (4/4) 19-21K 287±94 (4/4) 19-21K 
Goat-Sc F16 wt; I/M142; S/P240 21K 551±89 (3/3) 21K 242±26 (5/5) 21K 
Goat-ScG2 
Greece 
wt; P/P240 21K >650 (1/4) 21K >400 (ongoing) - 
Goat-ScG3 wt; R/H143; P/P240 21K 466±35 (4/4) 21K 375±25 (4/4) 21K 
Goat-Sc N1 
Netherlands 
wt; R/H143; S/P240 21K 535±8 (4/4) 21K 339±19 (5/5) 21K 
Goat-Sc N2 wt; R/H143; S/P240 21K 555±4 (4/4) 21K >350 (ongoing) - 
Goat-Sc N3 wt; P/P240 21K 451±9 (4/4) 21K 254±50 (6/6) 21K 
Goat-Sc S2 
Spain 
wt; S/P240 21K 228±15 (6/6) 21K 233±4 (6/6) 21K 
Goat-Sc S3 wt; P/P240 21K 221±16 (6/6) 21K 233±64 (5/5) 21K 
Goat-Sc UKA2 
United 
Kingdom 
wt; S/P240 21K 245±36 (5/5) 19-21K 252±8 (6/6) 19-21K 
Goat-Sc UKB2 wt; G/S127; P/P240 19-21K 381 (1/5) 19-21K 214±34 (7/7) 19-21K 
Goat-Sc UKD2 wt; G/S127; P/P240 21K 547±100(5/5) 21K >450 (ongoing) - 
Goat-Sc Zyp13 
Cyprus 
wt; P/P240 21K 483±15 (4/4) 21K 301±10 (4/4) 21K 
Goat-Sc Zyp21 wt; P/P240 21K 475±31 (5/5) 21K 324±9 (4/4) 21K 
Sheep-Sc 21 France wt; S/S240 21K 194±5 (6/6) 21K 205±18 (6/6) 21K 
Sheep-Sc 
Langlade 
France wt; S/S240 21K >650 (3/3) 21K 222±5 (6/6) 21K 
Sheep-Sc 09 France wt; F/F141;S/S240 21K 277±31 (5/5) 21K NA NA 
A
ty
p
ic
al
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ie
 Goat-Sc I15
 
Italy wt; H/R154 S/P240 Nor98
e 
557±73(6/6) Nor 98 NA NA 
Sheep-Sc 
NOR98/Tg338 
Norway wt; V/V136; S/S240 Nor98 601±50 (4/4) Nor 98 NA NA 
Sheep-Sc 
engavagen 
France wt; F/F141;S/S240 Nor98 623±48 (6/6) Nor 98 NA NA 
Sheep-Sc M45 
Spain 
wt; S/S240 Nor98 453±12 (5/5) Nor 98 NA NA 
Sheep-ScTOA4 wt; Q/H 171; S/S240 Nor98 407±17 (5/5) Nor 98 NA NA 
B
S
E
 
Goat-BSE1
 
France 
wt; S/S240 19K-BSE
f
 
 366±24 (5/5) 19K-BSE - - 
Goat-BSE2 wt; S/P240 19K-BSE 346±16 (7/7) 19K-BSE - - 
Sheep-BSE wt; S/S240 19K-BSE 405±37 (7/7) 19K-BSE - - 
Cattle-BSE Cattle wt
 
19K-BSE 357±9 (6/6) 19K-BSE 326±26 (5/5) 19K-BSE 
Cattle-BSE L Cattle wt
 
19K-Ltype
g
 581±36 (5/5) 19K-BSE 300±41 (5/5) 19K-BSE 
 Healthy goat 
brain 
France wt; P/P240 - >650 (0/6) - NA NA 
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a Scrapie isolates were sequenced following the procedures described in Materials and 
Methods (see section 1.2.1.1). Wild type (wt) PrPSc sequence (A136R154Q171/A136R154Q171) and 
the polymorphic variants observed are given.  
b Brain PrPres was detected by Western blot using Sha31 or 9A2 mAb (Fig. 14-16). The 
apparent molecular mass of the PrPres unglycosilated band is given in kilodaltons (K).  
c n/n0: diseased, PrPres: positive/inoculated animals.  
d Isolates were considered fast (in red) when survival times were <300 days post-inoculation 
(dpi) at second passage, or slow (in blue) when survival times were >300 dpi at second 
passage. 
e Nor98: PrPres Western blot glycoprofile characterized by a ladder pattern and a low 
unglycosilated band of around 7K. 
f 19K-BSE: PrPres Western blot glycoprofile characterized by a predominant diglycosylated 
moiety and a 19K unglycosylated band. 
g 19K-Ltype: PrPres Western blot glycoprofile characterized by a predominant 
monoglycosylated moiety and a lower molecular size of the nonglycosylated fragment than 
in the classical BSE agent. 
Orange cells: isolates transmitted with no apparent transmission barrier. 
Orange cells: isolates transmitted with no apparent transmission barrier. 
Green cells: isolates transmitted with a moderate-to-high transmission barrier. 
NA: Not analyzed. 
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Finally, no evidence of prion disease was determined in Wt-Tg501 mice IC inoculated 
with healthy goat brain (Table 11). These mice were euthanized at 650 dpi without 
showing any clinical signs and their brains were scored as PrPres negative, which thus 
rules out any spontaneous development of a prion disease in this mouse line. 
1.2.2.2 Brain PrPres Western blot profile 
Brains from all of the challenged Wt-Tg501 mice were routinely analyzed for the 
presence of PrPres using WB. Sha31 mAb was used for detecting brain PrPres in 
classical scrapie and BSE-challenged mice, whereas 9A2 mAb was used for detecting 
brain PrPres in atypical scrapie-infected animals. Their PrPres signature was then 
compared to those of the original isolates (Fig. 16). 
In general, the electrophoretic motilities observed for the original prion isolates were 
conserved upon transmission to Wt-Tg501 mice regardless of whether they were 21K 
or 19K (Fig. 16) scrapie isolates. In particular, Goat-Sc UKB2-infected mice had in 
their brains the double 19-21K PrPres unglycosilated band observed in the 
corresponding original isolates (Fig. 16A). Intriguingly, inoculation with the Goat-Sc 
UKA2 isolate, which originally harbored a 21K PrPres unglycosilated bands, gave rise 
to variable PrPres WB glycoprofiles: some mice exhibited a 19-21K double 
unglycosilated band (Fig. 16A, Goat-Sc UKA2 in Tg501(1)), while in others a 21K 
single unglycosilated band was observed (Fig. 16A, Goat-Sc UKA2 in Tg501(2)). 
Goat-Sc F14-infected mice exhibited the double 19- 21K PrPres unglycosilated bands 
observed in the original isolate. These particular cases suggest the coexistence of two 
different agents in each of these isolates. PrPres WB profile of atypical scrapie isolates 
was also maintained upon transmission in goat Wt-Tg501 mice.  In all cases, atypical 
PrPres was characterized by a ladder pattern with a low predominant band of around 
7K (Fig. 16B).  
On the other hand, WB analysis of brain-PrPres from goat-BSE isolates revealed a 
typical PrPres banding pattern, characterized by small fragments (19K fragment for 
the unglycosylated-band) and prominent diglycosylated species. This pattern was 
indistinguishable from that observed in Wt-Tg501 mice infected with sheep-BSE 
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isolate. Moreover, an identical PrPres banding pattern was observed in Wt-Tg501 
mice inoculated with Cattle-BSE isolate (Fig. 16C). By contrast, PrPres WB profile of 
the atypical BSE L, commonly characterized by a predominant monoglycosylated 
moiety and a smaller molecular size in the unglycosylated fragment than in classical 
cattle-BSE, was changed into a BSE-like WB profile upon passage in Wt-Tg501 mice 
(Fig. 16C). 
 
Figure 16. PrP
res
 of scrapie ad BSE isolates both before and after transmission in Wt-Tg501 
mice Immunoblots of brain PrPres from Wt-Tg501 mice infected with classical scrapie (A), 
atypical scrapie (B), and BSE, BSE L isolates (C). PrPres was detected with Sha31 mAb for 
classical scrapie-infected and BSE-infected mice and with 9A2 mAb for atypical scrapie-
infected mice. Similar quantities of sample (10% brain homogenate) were loaded for 
adequate comparison. Molecular weights in kilodaltons are shown on the right-hand side of 
the blot. Goat-Sc UKA2 in Tg501 (1): some Goat-ScUKA2-infected Wt-Tg501 mice exhibited a 
19K-21K double unglycosilated band in their brains.  Goat-Sc UKA2 in Tg501 (2): some Goat-
ScUKA2-infected Wt-Tg501 mice had a 21K single unglycosilated band. Sheep-Sc M45 
passaged in VRQ-OvTg338 mice was used as positive control in atypical scrapie WBs. C-: 
non-inoculated Wt-Tg501 mouse brain.  
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1.2.2.3 Histopathological analysis 
Brains from all of the challenged Wt-Tg501 mice were routinely analyzed for the 
presence of PrPSc deposition and neurodegenerative lesions by Paraffin-Embedded 
Tissue blotting (PET-blot) and hematoxilyn-eosin (HE) staining, respectively.  
PET-blot analysis confirmed the presence of PrPSc deposits in all the scrapie- or BSE-
inoculated Wt-Tg501 mice (Fig. 17A-C). PrPSc deposits were widely detected in the 
grey and white matter of all the studied coronal brain sections, including medulla 
oblongata, cerebellum, and brain stem. By contrast, no PrPSc deposits or neurological 
lesions were detected in Wt-Tg501 mice inoculated with healthy goat brains. Only a 
few vacuolar changes were observed in areas of white matter, probably due to the 
advanced age of these animals (650 dpi).  
Scrapie-infected mice had an extensive PrPSc topographical distribution characterized 
by the presence of PrPSc deposits throughout the dorsal medulla, cerebellum, 
thalamus, hippocampus, and septum (Fig. 17A and B). The cochlear and dorsal 
medial nuclei, raphe, dorsal colliculus, habenula, pyramidel tract, medial septal 
nucleus, and cuadoputamen were greatly affected. The cortex was also involved in 
the different studied brain sections and PrPSc was mainly detected in its granular 
layer but also in its molecular layer. PrPSc deposition was accompanied by high 
spongiform degeneration (Fig. 17C), above all at the level of white matter areas, as 
determined by HE staining. 
Differences between scrapie isolates in the histopathological analysis were observed. 
Interestingly, these differences coincided with the three kinds of scrapie isolates 
identified in Wt-Tg501 mice in terms of their ST at second passage (Table 11): Italian 
isolates, non-Italian fast isolates, and non-Italian slow isolates. Non-Italian fast 
isolates (Goat-Sc F2 in Fig. 17) and non-Italian slow isolates (Goat-Sc F10 in Fig. 17) 
both had very similar PrPSc deposition patterns (Fig. 17A and B) but clearly different 
spongiosis profiles (Fig. 17C). Among non-Italian fast isolates, those that had a 
doubled unglycosilated band (Goat-Sc F14, Goat-Sc UKA2 and Goat-Sc UKB2) 
showed no major differences in their histopathological alterations than the rest of the 
isolates of their group. Italian isolates showed very homogenous histopathological 
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outcomes which clearly differed from those of non-Italian isolates. In general, Italian 
isolates had lower levels of PrPSc deposition with less involvement of the superior 
colliculus, dorsal raphe, lateral dorsal nucleus, and cortex (Fig. 17A and B). 
 
 
Figure 17. PrPSc distribution and lesion profile in brain of scrapie-inoculated Wt-Tg501 
mice. PET-blots of representative coronal sections at the level of the thalamus (A) and 
medulla (B) of Wt-Tg501 mice inoculated with Goat-Sc F2, Goat-Sc UKA2, Goat-Sc F10, and 
Goat-Sc I3 inocula. 20x magnification level was used. Vacuolar lesion profiles in brains (C) 
from Wt-Tg501 mice inoculated with Goat-Sc F2 (light blue squares, n = 3 animals), Goat-Sc 
UKA2 (light green rhombuses, n = 3 animals), Goat-Sc F10 (dark blue squares, n = 3 animals), 
and Goat-Sc I9 (pink triangles, n = 3 animals). Lesion scoring was carried out for nine areas 
of gray matter (G) and white matter (W) in mouse brains: dorsal medulla (G1), cerebellar 
cortex (G2), superior colliculus (G3), hypothalamus (G4), medial thalamus (G5), 
hippocampus (G6), septum (G7), medial cerebral cortex at the level of the thalamus (G8) and 
the septum (G9), cerebellum (W1), mesencephalic tegmentum (W2), and pyramidal tract 
(W3). Error bars indicate the standard error of the mean.  
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On the other hand, PET-blot studies in BSE-infected Wt-Tg501 mice revealed 
very similar PrPSc distribution patterns (Fig. 18A) and lesion profiles (Fig. 18B) 
in animals inoculated either with classical cattle-BSE or goat-BSE isolates. PrPSc 
deposits in these BSE-infected Wt-Tg501 mice had a more restricted distribution 
than in the scrapie-infected Wt-Tg501 mice and were mostly observed at the 
level of the cerebellum, ventral septum, and thalamus, with little involvement 
of the hippocampus (Fig. 18A). Spongiosis was in general less evident in BSE-
infected mice than in scrapie-infected mice, and was mainly limited to the 
cerebellum, dorsal medulla, and white matter areas (Fig. 18B). Cattle-BSE L-
infected mice differed from the rest of BSE-infected mice in their 
histopathological outcomes. PrPSc deposits were more intense and abundant at 
the level of the thalamus and hippocampus (Fig. 18A) and spongiosis was 
noticeably more severe (Fig. 18B). 
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Figure 18. PrPSc distribution and lesion profile in brains of BSE-inoculated Wt-Tg501 
mice. PET-blots of representative coronal sections at the level of the thalamus (A) of 
Wt-Tg501 mice inoculated with Goat-BSE1, Cattle-BSE, and Cattle-BSE L inocula. 20x 
magnification was used. Vacuolar lesion profile (B) in brains from Wt-Tg501 mice 
inoculated with Cattle-BSE (black triangles, n = 6 animals), Goat-BSE1 (grey triangles, n 
= 3 animals), and Cattle-BSE L (blue rhombuses, n = 1 animal). Lesion scoring was 
undertaken for nine areas of gray matter (G) and white matter (W) in mouse brains: 
dorsal medulla (G1), cerebellar cortex (G2), superior colliculus (G3), hypothalamus 
(G4), medial thalamus (G5), hippocampus (G6), septum (G7), medial cerebral cortex at 
the level of the thalamus (G8) and the septum (G9), cerebellum (W1), mesencephalic 
tegmentum (W2), and pyramidal tract (W3). Error bars indicate the standard error of 
the mean.  
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1.3 Susceptibility of transgenic mice expressing different goat-PrPC 
polymorphic variants to prion infection 
After confirming the suitability of the goat wt-PrPC Tg mouse line (Wt-Tg501) as 
a model for studying the susceptibility of goats to TSEs, transmission studies 
were carried out with the Tg mouse lines expressing different goat-PrPC 
polymorphic variants (M142-, K222-, H154-, and Q211-PrPC variants) in order to 
evaluate the individual role of each of these PrPC variants in 
resistance/susceptibility to prion infection. In this way, K222-Tg516, H154-Tg563, 
Q211-Tg580, and M142-Tg541 mouse lines were IC inoculated with a selection of 
scrapie and BSE isolates and their relative susceptibilities were assessed in 
comparison to those obtained in Wt-Tg501 mice. 
A number of classical scrapie isolates from Spain, France, and Italy were 
selected from the wide range of scrapie isolates tested to maintain the 
geographical diversity. Nevertheless, only one atypical scrapie isolate was used 
for these transmission studies since all of the atypical scrapie isolates exhibited 
similar properties when transmitted to Wt-Tg501 mice (Tables 11). Sheep-Sc 
M45 was the atypical isolate selected because it produced the lowest ST and 
highest AR in Wt-Tg501 mice and harbors a sheep wild type PrPSc primary 
sequence.  
1.3.1 Prion transmission features in goat K222-PrPC transgenic mice 
Of all the PrPC variants in goats, K222 has yielded the most promising results in 
terms of resistance against TSEs. Its low susceptibility to classical scrapie 
infection has been documented in numerous epidemiological studies in several 
European countries (Acin et al., 2013; Acutis et al., 2006; Barillet et al., 2009; 
Bouzalas et al., 2010; Corbiere et al., 2013b; Fragkiadaki et al., 2011; Papasavva-
Stylianou et al., 2011; Vaccari et al., 2006). However, this evidence has not yet 
been analyzed in detail by experimental inoculations. Taking into account these 
data, K222-Tg516 mice were challenged with a broad panel of classical scrapie 
isolates to study the role of this polymorphism in susceptibility to scrapie 
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infection. In addition, K222-Tg516 mice were inoculated with an atypical scrapie 
agent and a number of BSE isolates (including an atypical BSE L isolate). 
K222-Tg516 mice expressing the K222-PrPC at around 1-fold the PrPC in the goat 
brain were resistant to the primary transmission of all the inoculated classical 
scrapie isolates (Table 12). These animals were sacrificed at the end of their 
lifespans (650 dpi) without any apparent clinical signs of the disease and their 
brains were scored as PrPSc negative by WB and IHC (Andreoletti et al., 2000) 
analysis.  
 
Table 12. Transmission of a panel of scrapie and BSE isolates to Wt-Tg501 and K222-
Tg516 mice 
Isolate 
Mean survival time in days ± SEM (n/n0)a 
Wt-Tg501 (Q222/-) 
1Xb 
K222-Tg516 (K222/-) 
1X 
Goat-Sc F2 250±36 (4/4) >650 (0/7) 
Goat-Sc F10 465±19(7/7) >650 (0/5) 
Goat-Sc I3 >650 (5/5) >650 (0/5) 
Goat-Sc I9 600±43 (5/5) >650 (0/5) 
Goat-Sc S2 449±62 (9/9) >650 (0/6) 
Goat-Sc S3 298±22 (6/6) >650 (0/6) 
Sheep-Sc 21  500±23 (4/4) >650 (0/6) 
Sheep-Sc Langlade >650 (3/3) >650 (0/5) 
Sheep-Sc M45c 453±12 (5/5) 416±12 (4/4) 
Goat-BSE1  497±31 (5/5) 519±42 (5/5) 
Goat-BSE2  484±34 (7/7) 478±31 (4/4) 
Sheep-BSE 485±62 (7/7) 418±11 (4/4) 
Cattle-BSE  583±57 (6/6) >650 (0/6) 
Cattle-BSE/Tg516d NA >650 (0/6) 
Cattle-BSE/Tg501e 326±26 (6/6) 434±30 (5/5) 
Cattle-BSE L 618±41 (4/4) >650 (0/6) 
Healthy goat brain >650 (0/6) >650 (0/6) 
a n/n0: diseased, PrPres: positive/inoculated animals. 
b PrPC level of expression in the brain compared to PrPC in goat and sheep brains as 
assessed by Western blot analysis (see Fig. 13A and E). 
c Atypical scrapie isolate inoculated in homozygous Wt-Tg501 (2X) and K222-Tg516 
mice (2X). 
d Pool of K222-Tg516 mice inoculated with Cattle-BSE isolate. 
e Pool of terminally ill Wt-Tg501 mice inoculated with Cattle-BSE isolate. 
NA: Not analyzed 
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Conversely, K222-Tg516 mice succumbed to the IC inoculation of the atypical 
scrapie isolate (Table 12). These mice had 100% AR and similar ST to the Wt-
Tg501 mice inoculated with the same isolate.  
The K222-Tg516 mouse line was fully susceptible (100% AR) to goat and sheep 
BSE isolates and had similar mean ST (in the range 400–500 dpi) to Wt-Tg501 
mice (Table 12). Nevertheless, K222-Tg516 mice did not succumb to either 
classical Cattle-BSE or to atypical Cattle-BSE L. These mice were sacrificed at 
the end of their lifespans (650 dpi) without any apparent clinical signs or PrPres 
in the brain. Moreover, the resistance in K222-Tg516 mice to classical cattle BSE 
was even maintained after second passage (Cattle-BSE/Tg516, Table 12). 
Surprisingly, K222-Tg516 mice were fully susceptible to the cattle BSE agent after 
passage in Wt-Tg501 mice (Cattle-BSE/Tg501), with a mean ST of 434±30 dpi.  
None of the K222-Tg516 mice inoculated with healthy goat brain showed any 
evidence of neurological disease until the end of their lifespan (Table 12) and 
their brains were scored as PrPSc negative by WB, PET-blot and IHC analysis, 
which discards any spontaneous development of a prion disease in these mice. 
Western blot analysis of brain PrPres in goat- and sheep-BSE-infected K222-Tg516 
mice showed the typical PrPBSE banding pattern previously described for Wt-
Tg501 mice inoculated with goat, sheep, or cattle-BSE agents (Fig. 19A). 
Likewise, the PrPres WB profile of the atypical scrapie isolate was also 
maintained after passage in K222-Tg516 mice (Fig. 19B). 
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Figure 19. PrP
res
 of scrapie ad BSE isolates both before and after transmission in 
either Wt-Tg501 mice or K222-Tg516. (A) Immunoblots of brain PrPres from Wt-Tg501 
and K222-Tg516 mice infected with goat- and sheep-BSE isolates. (B) Immunoblots of 
brain PrPres from Wt-Tg501, K222-Tg516, Q211-Tg580, R171-Tg552 and K176-Tg570 mice 
infected with atypical scrapie isolate. PrPres was detected with Sha31 mAb for BSE-
infected mice and with 9A2 mAb for atypical scrapie-infected mice. Similar quantities 
of sample (10% brain homogenate) were loaded for adequate comparison. Molecular 
weights in kilodaltons are shown on the right-hand side of the blot. Sheep-Sc M45 
passaged in VRQ-OvTg338 mice was used as positive control in atypical scrapie WBs. 
C-: non-inoculated Wt-Tg501 mouse brain. 
 
The absence of PrPSc in the brains of classical scrapie-challenged K222-Tg516 
mice was confirmed by PET-blot (Fig. 20A). These animals exhibited some 
vacuolation, mainly at the level of the dorsal medulla and mesencephalic 
tegmentum. However, these alterations were also observed in the same areas in 
old Wt-Tg501 and K222-Tg516 mice inoculated with healthy goat brain, probably 
due to the advanced age of these animals. 
PrPSc deposits or spongiform changes were not detected in the brains of Cattle-
BSE-infected K222-Tg516 mice (Fig. 20A). These K222-Tg516 mice exhibited some 
spongiosis, mainly at the level of the dorsal medulla and the mesencephalic 
tegmentum, that coincided with the vacuolation observed in old Wt-Tg501 and 
K222-Tg516 mice inoculated with healthy goat brain, which again indicates that 
the old age of the animals was the cause of these lesions. However, when K222-
Tg516 mice were infected with goat BSE isolates, they exhibited PrPres deposits 
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and vacuolation that were very similar to those observed in Wt-Tg501 mice 
infected with either cattle or goat BSE isolates (Fig. 20 A and B). 
 
Figure 20. PrPSc distribution and lesion profile in brain of scrapie and BSE-
inoculated K222-Tg516 mice in comparison with Wt-Tg501 mice. PET-blots of 
representative coronal sections (A) at the level of the thalamus of Wt-Tg501and K222-
Tg516 mice inoculated with Goat-Sc F10, Goat-BSE, and Cattle-BSE. 20x magnification 
level was used. Vacuolar lesion profile (B) in brains from K222-Tg516 (green circles, n = 
4 animals) mice and Wt-Tg501 (grey circles, n = 3 animals) mice inoculated with Goat-
BSE1. Lesion scoring was carried out for nine areas of gray matter (G) and white matter 
(W) in mouse brains: dorsal medulla (G1), cerebellar cortex (G2), superior colliculus 
(G3), hypothalamus (G4), medial thalamus (G5), hippocampus (G6), septum (G7), 
medial cerebral cortex at the level of the thalamus (G8) and the septum (G9), 
cerebellum (W1), mesencephalic tegmentum (W2), and pyramidal tract (W3). Error 
bars indicate SE. 
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1.3.2 Prion transmission features in goat Q211-PrPC transgenic mice 
R/Q211 polymorphisms have been epidemiologically linked to low 
susceptibility to classical scrapie (Barillet et al., 2009; Bouzalas et al., 2010); 
however, little is known about their role in BSE infection. In these experiments, 
Q211-Tg580 mice were bred to homozygosis in order to obtain similar brain PrPC 
levels of expression than Wt-Tg501 mice (1X). Homozygous Q211-Tg580 mice 
were challenged with a variety of scrapie and BSE isolates.  
Homozygous Q211-Tg580 mice expressing the Q211-PrPC at around 1-fold the 
PrPC in the goat brain did not succumb to the primary transmission of any of 
the classical scrapie isolates that were inoculated (Table 13). These mice were 
euthanized without showing any apparent neurological sign of prion disease or 
PrPSc in their brains after analysis by WB or PET-blot. However, Q211-Tg580 
mice did succumb to the infection with atypical scrapie isolate (Table 13). These 
animals were euthanized showing no sign of prion disease but were scored 
PrPres positive in their brains by WB analysis (Fig. 19). Brain PrPres WB profile of 
infected Q211-Tg580 mice was very similar to that previously observed for Wt-
Tg501 mice (Fig. 19B). 
Table 13. Transmission of a panel of scrapie and BSE isolates to Wt-Tg501 and Q211-
Tg580 mice 
Isolate 
Mean survival time in days ± SEM (n/n0)a 
Wt-Tg501 (Q211/-) 
1Xb 
Q211-Tg580 (Q211/ Q211) 
1X 
Goat-Sc F2 250±36 (4/4) >650 (0/7) 
Goat-Sc F10 465±19(7/7) >650 (0/5) 
Goat-Sc I3 >650 (5/5) >650 (0/5) 
Sheep-Sc Langlade >650 (3/3) >650 (0/5) 
Sheep-Sc M45c 453±12 (5/5) >650 (4/4) 
Goat-BSE2  484±34 (7/7) >550 (ongoing) 
Sheep-BSE 485±62 (7/7) >550 (ongoing) 
Cattle-BSE  583±57 (6/6) >550 (ongoing) 
Healthy goat brain >650 (0/6) >650 (0/6) 
a n/n0: diseased, PrPres: positive/inoculated animals. 
b PrPC level of expression in the brain compared to PrPC in goat and sheep brains as 
assessed by Western blot analysis (Fig. 13A and D). 
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c Atypical scrapie isolate Sheep-Sc M45 inoculated in homozygous Wt-Tg501 (2X) and 
Q211-Tg580 mice (1X). 
Q211-Tg580 mice have not yet succumbed to any of the BSE isolates inoculated. 
These mice surpass the ST previously observed in BSE-infected Wt-Tg501 mice. 
Again, no prion disease was evidenced in Q211-Tg580 mice inoculated with 
healthy goat brain (Table 13). WB and PET-blot analysis discarded the presence 
of PrPSc in their brains. 
1.3.3 Prion transmission features in goat H154-PrPC transgenic mice 
R/H154 polymorphism have also been associated to low susceptibility to 
classical scrapie in natural outbreaks (Barillet et al., 2009; Billinis et al., 2002), 
even though this polymorphism has also been reported to be a risk factor for 
atypical scrapie (Benestad et al., 2008; Colussi et al., 2008). In these experiments, 
H154-Tg563 mice were challenged with some classical scrapie and BSE isolates. 
The lower PrPC levels of expression in the brain of this mouse line compared to 
goat Wt-Tg501 mice (0.25-fold the PrPC in the brain of Wt-Tg501 mice, 
respectively) were taken into account when performing the comparative 
susceptibility of H154-PrPC variant to the prion infection. 
H154-Tg563 mice did not succumb to the primary transmission of any classical 
scrapie isolate except for Goat-Sc F2 (Table 14). H154-Tg563 mice were 80% 
susceptible to this scrapie isolate and had much longer ST than Wt-Tg501 mice. 
When inoculated with BSE, H154-Tg563 mice only succumbed to Goat-BSE2 
isolate that had very long ST (582 dpi) and very low AR (20%).  
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Table 14. Transmission of a panel of scrapie and BSE isolates to Wt-Tg501 and H154-
Tg563 mice 
Isolate 
Mean survival time in days ± SEM (n/n0)a 
Wt-Tg501 (H154Q211/-) 
1Xb 
H154-Tg563 (H154/-) 
0.25X 
Goat-Sc F2 250±36 (4/4) 650±9 (5/6) 
Goat-Sc F10 465±19(5/5) >650 (0/5) 
Goat-Sc I3 >650 (5/5) >650 (0/6) 
Goat-Sc I9 600±43 (5/5) >650 (0/6) 
Goat-Sc S2 449±62 (9/9) >650 (0/6) 
Goat-BSE1 497±31 (5/5) >650 (0/6) 
Goat-BSE2 484±34 (7/7) 582 (1/5) 
Cattle-BSE 501±35 (6/6) >650 (0/6) 
Healthy goat brain >650 (0/6) >650 (0/6) 
a n/n0: diseased, PrPres: positive/inoculated animals. 
b PrPC level of expression in the brain compared to PrPC in goat and sheep brains as 
assessed by Western blot analysis (Fig. 13A and C). 
 
H154-Tg563 mice inoculated with healthy goat brain showed any sign of 
neurological disease (Table 14). Neither PrPres nor histopathological alterations 
were observed in the brains of these animals. 
Attending to the PrPres WB glycoprofile, no differences were observed between 
Wt-Tg501 and H154-Tg563 infected mice (Fig. 21).  
 
Figure 21. PrPres of Goat-BSE2 and Goat-ScF2 after transmission in Wt-Tg501 and 
H154-Tg563 mice. Immunoblots of brain PrPres from Wt-Tg501 and H154-Tg563 mice 
infected with Goat-BSE2 and Goat-Sc F2 isolates detected with Sha31 mAb. Similar 
quantities of sample (10% brain homogenate) were loaded for adequate comparison. 
Molecular weights in kilodaltons are shown on the right-hand side of the blot. 
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Finally, PrPSc deposition and spongiform changes were only detected in the 
brains of H154-Tg563 mice infected with Goat-Sc F2 and Goat-BSE2. No major 
differences were observed in the histopathological outcomes of H154-Tg563 mice 
compared to Wt-Tg501 mice (data not shown).  
1.3.4 Prion transmission features in goat M142-PrPC transgenic mice 
I/M142 polymorphism has been associated with decreased susceptibility to BSE 
and scrapie in experimentally inoculated goats (Goldmann et al., 1996). 
Moreover, several field studies have linked this PrPC variant to low 
susceptibility to classical scrapie (Barillet et al., 2009; Goldmann et al., 2011; 
Gonzalez et al., 2010). Nevertheless, the role of M142-PrPC variant in the 
resistance/susceptibility of goats to atypical scrapie infection has not yet been 
assessed. Therefore, in order to clarify the effect of this goat PrPC polymorphism 
on prion infection, Tg mice expressing the M142-PrPC variant were IC inoculated 
with a panel of scrapie and BSE isolates and their transmission features were 
compared to those of goat Wt-Tg501 mice. 
M142-Tg541 mice expressing the M142-PrPC at around 1-fold the PrPC in the goat 
brain were fully susceptible to the primary transmission of most of the classical 
scrapie isolates tested here, albeit with significantly longer ST than those 
observed in Wt-Tg501 (Table 15). Only two of the isolates (Goat-Sc I3 and Goat-
Sc I9) were unable to transmit in this mouse model, probably due to an increase 
in ST that was already very long in Wt-Tg501 mice. These M142-Tg541 mice were 
scored as PrPres negative in their brains and had no neurological lesions or PrPSc 
deposits (Fig. 22).  
More interestingly, M142-Tg541 mice were resistant to the primary transmission 
of the atypical scrapie isolate Sheep-Sc M45 (Table 15). None of these mice 
showed any sign of neurological disease until the end of their lifespans and no 
PrPres was detected in their brains by WB analysis.  
In terms of BSE transmissions, M142-Tg541 mice were 100% susceptible to all the 
inoculated BSE isolates regardless of the PrP primary sequence of the isolate 
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(cattle, sheep, or goat), as previously observed in Wt-Tg501 mice (Table 15). 
Once again, ST were slightly longer than those obtained in Wt-Tg501 mice 
(except for the Sheep-BSE isolate); however, no statistically significant 
differences were detected in these cases (Table 15).  
Table 15. Transmission of a panel of scrapie and BSE isolates to Wt Tg501 and M142-
Tg541 mice 
Isolate 
Mean survival time in days ± SEM (n/n0)a 
P valuec 
Wt-Tg501 (I142/-) 
1Xb 
M142-Tg541 (M142/-) 
1X 
Goat-Sc F2 250±36 (4/4) 423±48 (7/7) 0.01073 
Goat-Sc F10 465±19(5/5) 542±26 (5/5) 0.01219 
Goat-Sc I3 >650 (5/5) >650 (0/5) - 
Goat-Sc I9 600±43 (5/5) >650 (0/5) - 
Goat-Sc S2 449±62 (9/9) 543±55(6/6) 0.04883 
Goat-Sc S3 298±22 (6/6) 439±65 (5/5) 0.008113 
Sheep-Sc Langlade >650 (3/3) 650±9 (3/4) 0.0489 
Sheep-Sc M45d 453±12 (5/5) >650 (0/6) - 
Goat-BSE1 497±31 (5/5) 521±46(5/5) 0.4034 
Goat-BSE2 484±34 (7/7) 537±65(6/6) 0.2298 
Sheep-BSE 485±62 (7/7) 423±36 (3/3) 0.1715 
Cattle-BSE 501±35 (6/6) 540±24 (4/4) 0.5959 
Healthy goat brain >650 (0/6) >650 (0/6) - 
a n/n0: diseased, PrPres: positive/inoculated animals. 
b PrPC level of expression in the brain compared to PrPC in goat and sheep brains as 
assessed by Western blot analyses (see Fig. 13A and B). 
c A non-parametric Mann-Whitney-U test was used to establish statistically significant 
differences in survival times between Wt-Tg501 and M142-Tg541 mouse lines inoculated 
during the different scrapie and BSE challenges. A difference of P<0.05 was considered 
to be significant. 
d Atypical scrapie isolate was inoculated in homozygous Wt-Tg501 (2X) and M142-
Tg541 mice (2X). 
 
Finally, when the M142-Tg541 mice inoculated with the healthy goat brain were 
euthanized at the end of their lifespan (650 dpi), they had no clinical signs of 
disease or PrPres in their brains, thereby ruling out the spontaneous 
development of disease. 
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Brain PrPres WB glycoprofile of infected M142-Tg541 mice were 
undistinguishable from those of infected Wt-Tg501 independently of the 
inoculated isolate (Fig. 22).  
 
Figure 22. PrPres of classical scrapie and BSE isolates after transmission in Wt-Tg501 
and M142-Tg541 mice. Immunoblots of brain PrPres from Wt-Tg501 and M142-Tg541 
mice infected with classical scrapie (A) and BSE (B) isolates detected with Sha31 mAb. 
Similar quantities of sample (10% brain homogenate) were loaded for adequate 
comparison. Molecular weights in kilodaltons are shown on the right-hand side of the 
blot. 
 
 
Histopathological studies confirmed the presence of PrPSc deposition and 
spongiform changes in the brains of all the M142-Tg541 mice infected with either 
BSE or classical scrapie isolates, except for those inoculated with Goat-Sc I3 (Fig. 
23A) or healthy goat brain.  PrPres deposition (Fig. 23A) and vacuolation profiles 
(Fig. 23B) in M142-Tg541 animals mostly overlapped with those previously 
determined in Wt-Tg501 mice. However, Goat-Sc F2 and Goat-Sc S2 produced 
different vacuolation profiles in M142-Tg541 animals from those in Wt-Tg501 
mice, even though the distribution of PrPSc deposits was very similar in both 
mouse lines (Fig. 23).   
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Figure 23. PrPSc distribution and lesion profile in brains of scrapie- and BSE-
inoculated M142-Tg541 mice. PET blots of representative coronal sections (A) at the 
level of thalamus of Wt-Tg501 and M142-Tg541 mice inoculated with Goat-Sc F2, Goat-
Sc F10, Goat-Sc I3, and Goat-BSE. 20x magnification level was used. Vacuolar lesion 
profile (B) in brains from both Wt-Tg501 and M142-Tg541 mice inoculated with Goat-Sc 
F2 (rhombuses, n = 4 animals), Goat-Sc F10 (circles, n = 4 animals), Goat-Sc I3 (crosses, 
n = 4 animals), and Goat-BSE (triangles, n = 5 animals). Lesion scoring was carried out 
as previously described for Wt-Tg501 mice (see section 1.2.2.3). Error bars indicate the 
standard error of the mean.   
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1.4 Susceptibility of transgenic mice expressing different sheep-PrPC 
polymorphic variants 
1.4.1 Prion transmission studies in R171-PrPC transgenic mice 
Due to its resistance to classical scrapie and BSE agents, R171-PrPC variant is 
widely used in breeding programs aimed at controlling and eradicating scrapie 
in sheep flocks. However, A136R154R171/ARR sheep succumb to cattle and sheep 
BSE infection after intracerebral challenges (Gonzalez et al., 2005) and natural 
cases of scrapie have been reported in these sheep from Germany and France 
(Groschup et al., 2007), and Japan (Ikeda et al., 1995). More recently, goats have 
been reported to harbor the Q/R171 polymorphism whose resistance to classical 
scrapie infection has been compared to that provided by the sheep A136R154R171 
genotype (Bouzalas et al., 2010). In the present study, we analyzed the 
susceptibility of R171-PrPC variant to prion infection and focused on the 
characterization of its assumed resistance to classical scrapie.  
R171-Tg552 mice expressing the R171-PrPC variant at 1-fold the PrPC in sheep 
brains were resistant to the primary inoculation of all the classical scrapie 
inoculated isolates (Table 16). All of these R171-Tg552 mice were euthanized at 
650 dpi showing neither clinical signs nor PrPSc in their brains by WB and PET-
blot analysis. On the other hand, none of the BSE-inoculated R171-Tg552 mice 
have yet succumbed to the prion disease and their ST now surpass those of 
their counterparts Wt-Tg501 mice (Table 16). 
Interestingly, R171-Tg552 mice were susceptible to atypical scrapie isolate (Table 
16). Although mice showed no sign of the neurological disease until they were 
euthanized, PrPres was detected in their brains by WB analysis (Fig. 19). PrPres 
WB profile in the brain of these animals showed no major differences to that 
previously observed for Wt-Tg501 mice (Fig. 19B).  
Finally, R171-Tg552 mice did not develop any neurological sign after inoculated 
with healthy goat brain (Table 16).  
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Table 16. Transmission of a panel of scrapie and BSE isolates to Wt-Tg501 and R171-
Tg552 mice 
Isolate 
Mean survival time in days ± SEM (n/n0)a 
Wt-Tg501 (Q171/-) 
1Xb 
R171-Tg552 (R171/-) 
1X 
Goat-Sc F2 250±36 (4/4) >650 (0/6) 
Goat-Sc F10 465±19(5/5) >650 (0/6) 
Goat-Sc I3 >650 (5/5) >650 (0/7) 
Goat-Sc I9 600±43 (5/5) >650 (0/5) 
Goat-Sc S2 449±62 (9/9) >650 (0/5) 
Goat-Sc S3 298±22 (6/6) >650 (0/6) 
Sheep-Sc 21  500±23 (4/4) >650 (0/5) 
Sheep-ScLanglade >650 (3/3) >650 (0/6) 
Sheep-Sc M45c 453±12 (5/5) >650 (5/5) 
Goat-BSE2 484±34 (7/7) >550 (ongoing) 
Sheep-BSE 485±62 (7/7) >550 (ongoing) 
Cattle-BSE 501±35 (6/6) >550 (ongoing) 
Healthy goat brain >650 (0/6) >650 (0/6) 
a n/n0: diseased, PrPres: positive/inoculated animals. 
b PrPC level of expression in the brain compared to PrPC in goat and sheep brains as 
assessed by Western blot analysis (Fig. 13A,C and D). 
c Atypical scrapie isolate Sheep-Sc M45 inoculated in homozygous Wt-Tg501 (2X) and 
R171-Tg552 mice (2X). 
1.4.2 Prion transmission studies in K176-PrPC transgenic mice 
K176 variant of the sheep PrPC was associated with a protective effect against the 
IC infection with classical scrapie and BSE (Vaccari et al., 2009b). This allele has 
only once been observed in a diseased sheep originating from a scrapie-affected 
herd (Vaccari et al., 2007); although the low frequency of this allele in healthy 
animals prevents from determining any significant protective effect (Bossers et 
al., 1996; Thorgeirsdottir et al., 1999; Vaccari et al., 2001). Thus, hemizygous 
K176-Tg570 mice expressing 2-fold the PrPC in a sheep brain were challenged 
with scrapie and BSE isolates and their transmission features were compared to 
those of homozygous Wt-Tg501 (likewise 2-fold the PrPC in a sheep brain). 
K176-Tg570 mice were resistant to the primary transmission of all the classical 
scrapie isolates inoculated (Table 17). These animals were euthanized at the end 
of their lifespan and no PrPres or histopathological alteration was detected in 
their brains by WB or PET-blot analysis.  
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Table 17. Transmission of a panel scrapie and BSE isolates to Wt-Tg501 and K176-Tg570 
mice 
Isolate 
Mean survival time in days ± SEM (n/n0)a 
Wt-Tg501 (N176/ N176) 
2Xb 
K176-Tg570 (K176/-) 
2X 
Goat-Sc F2 259±28 (4/4) >650 (0/5) 
Goat-Sc F10 449±19 (5/5) >650 (0/6) 
Goat-Sc I3 >650 (5/5) >650 (0/6) 
Goat-Sc I9 578±25 (5/5) >650 (0/6) 
Goat-Sc S2 228±15 (6/6) >650 (0/5) 
Goat-Sc S3 221±16 (6/6) >650 (0/7) 
Sheep-Sc 21  194±5 (6/6) >650 (0/6) 
Sheep-Sc Langlade >650 (3/3)  >630 (0/2)  
Sheep-Sc M45c 453±12 (5/5) 362±26 (7/7) 
Goat-BSE1  366±24 (5/5) 19K-BSE 
Sheep-BSE 405±37 (7/7) >650 (0/5) 
Ca-BSE  357±9 (6/6) >650 (0/5) 
Healthy goat brain >650 (0/6) >650 (0/6) 
a n/n0: diseased, PrPres: positive/inoculated animals. 
b PrPC level of expression in the brain compared to PrPC in goat and sheep brains as 
assessed by Western blot analysis (Fig. 13A and G). 
c Atypical scrapie isolate Sheep-Sc M45 inoculated in homozygous Wt-Tg501 (2X) and 
hemizgygous K176-Tg570 mice (2X). 
Intriguingly, K176-Tg570 mice were 100% susceptible to the inoculation with 
atypical scrapie Sheep-Sc M45 (Table 17) and had statistically significant 
(P<0.01041) shorter ST than Wt-Tg501 mice (Mann-Whitney-U test). No changes 
in the PrPres profile of atypical scrapie isolates were detected after passage in 
these K176-Tg570 mice (Fig. 19B). 
K176-Tg570 mice were resistant to BSE infection regardless of its PrPSc primary 
sequence (cattle, sheep, or goat) (Table 17). They were euthanized at the end of 
their lifespans without showing any apparent clinical signs of prion disease and 
no PrPres was detected in their brains by WB and PET-blot analysis  
Finally, none of the K176-Tg570 mice inoculated with healthy goat brain 
developed any neurological disease.  
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1.5 Protective effect of K222-PrPC on prion replication of the goat WT allele in 
heterozygous Q/K222 transgenic mice 
Homozygous K222-Tg516 mice were crossbred with homozygous Wt-Tg501 
mice to generate heterozygous (Q/K222) mice. These animals were 
intracerebrally inoculated with the same panel of TSE isolates previously used 
for Wt-Tg501 andK222-Tg516 mice challenges (Table 12) and their susceptibilities 
were compared to those of Wt-Tg501 and K222-Tg516 Tg mouse lines.  
Heterozygous Q/K222 animals were resistant to the primary transmission of 
Goat-Sc I3 and Goat-Sc S2 isolates (Table 18). These animals were sacrificed at 
650 dpi without showing any clinical signs of neurological disease; no 
detectable PrPres was found in their brains by either WB, IHC, or PET-blot 
analysis. However, Q/K222 mice succumbed to the infection with the rest of 
scrapie isolates inoculated and had reduced AR and/or much longer ST than 
those observed in Wt-Tg501 mice. The Q/K222 mice challenged with Goat-Sc F10 
and Sheep-Sc Langlade isolates were sacrificed at 650 dpi without exhibiting 
any apparent clinical signs but with PrPres present in their brains (Table 18).  
Table 18. Transmission of a panel of scrapie and BSE isolates to Wt-Tg501, K222-Tg516, 
and heterozygous Q/K222 mice 
Isolate 
Mean survival time in days ± SEM (n/n0)a 
Wt-Tg501 
(Q222/-) 
K222-Tg516 
(K222/-) 
Tg501 x Tg516 
(Q/K222)b 
Goat-Sc F2 250±36 (4/4) >650 (0/7) 630±26 (5/6) 
Goat-Sc F10 465±19(7/7) >650 (0/5) >650 (6/6) 
Goat-Sc I3 >650 (5/5) >650 (0/5) >650 (0/6) 
Goat-Sc I9 600±43 (5/5) >650 (0/5) >580 (ongoing) 
Goat-Sc S2 449±62 (9/9) >650(0/6) >650 (0/6) 
Goat-Sc S3 298±22 (6/6) >650 (0/6) >650 (2/6) 
Sheep-Sc 21  500±23 (4/4) >650 (0/6) 598±36 (7/7)  
Sheep-Sc Langlade >650 (3/3) >650 (0/6) >630 (5/5) 
Goat-BSE1  497±31 (5/5) 519±42(5/5) 533±44 (5/5) 
Goat-BSE2  484±34 (7/7) 478±31(4/4) 470±14 (5/5) 
Cattle-BSE  583±57 (6/6) >650 (0/6) 617±47 (5/5) 
a n/n0: diseased, PrPres: positive/inoculated animals. 
b Heterozygous Q/K222 mice were obtained by crossbreeding Wt-Tg501 and K222-Tg516 
mice.  
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When inoculated with Cattle-BSE, heterozygous Q/K222 animals had longer ST 
than Wt-Tg501 mice (Table 13). Nevertheless, goat-BSE isolates exhibited 
similar transmission features in all challenged Tg mouse models (W-Tg501, 
K222-Tg516, and Q/K222 mice) regardless of the expressed PrPC variant.  
Histopathological studies confirm the presence of PrPres and spongiform 
changes in the brains of heterozygous Q/K222 mice infected with Goat-Sc F2, 
Goat-Sc F10, Goat-Sc S3, Sheep-Sc 21, Sheep-ScLanglade, and goat and cattle-
BSE isolates. PrPres deposits and vacuolation profiles in these mice were similar 
but not identical to those from Wt-Tg501 mice infected with the same isolates 
(data not shown). However, we cannot rule out the possibility that these slight 
differences are in some way connected to the old age of Q/K222 mice that had 
longer survival times than Wt-Tg501.  
In order to determine which allele was responsible for the replication of the 
classical scrapie and cattle-BSE isolates in heterozygous Q/K222 mice, brain 
homogenate from Goat-Sc F2-infected Q/K222 mice was IC inoculated in both 
hemizygous goat Wt-Tg501 and hemizygous K222-Tg516 mice. 
Table 19. Transmission of Goat-Sc F2-passaged in Q/K222 heterozygous mice to Wt-
Tg501 and K222-Tg516 mice 
Isolate 
Mean survival time in days ± SEM (n/n0)a 
Wt-Tg501 (Q222/-) 
1Xb 
K222-Tg516 (K222/-) 
1X 
Goat-Sc F2/Tg511c  225±12 (5/5) >650 (0/5) 
Goat-Sc F2 250±36 (4/4) >650 (0/7) 
a n/n0: diseased, PrPres: positive/inoculated animals. 
b PrPC level of expression in the brain compared to PrPC in goat and sheep brains as assessed by 
Western blot analysis (Fig. 13A and E). 
c Pool of terminally ill Q/K222 heterozygous mice inoculated with Goat-Sc F2 
isolate. 
 
None of the hemizygous K222-Tg516 mice succumbed to the inoculation with 
Goat-Sc F2/Tg511 isolate (Table 19).  K222-Tg516 mice were sacrificed at the end 
of their lifespan and had neither clinical signs nor PrPres in their brains when 
assessed by WB analysis (data not shown). By contrast, all the hemizygous goat 
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Wt-Tg501 mice were infected with this isolate and had similar ST to the Wt-
Tg501 inoculated with the original Goat-Sc F2 (Table 19). 
2. Assessment of the resistance/susceptibility of polymorphic 
variants of the prion protein to prion infection in natural host 
(goats) 
In an attempt to validate our Tg mice as a model for studying the role of goat 
PrPC polymorphic variants in resistance/susceptibility to prion infection in the 
natural host (goats), we worked in collaboration with two different research 
groups in the framework of the StrepBSE in goat EU project (UE-FP6-2005-
FOOD4B-036353). Dr. Olivier Andréoletti headed the experimental scrapie 
transmissions to goats at the École Nationale Vétérinaire (ENV-INRA) in 
Toulouse (France), while Dr. Martin Groshup´s group performed the oral Goat-
BSE inoculations in goats at the Institute for Novel and Emerging Infectious 
Diseases, Friedrich-Loeffler-Institut (FLI), Insel Riems (Germany). 
2.1. Susceptibility of WT, I/M142, R/H154, R/Q211, and Q/K222 goats to oral and 
intracerebral infection with classical scrapie 
Goats harboring different prnp genotypes (WT: I142R154R211Q222/I142R154R211Q222 
or prnp variants M142, H154, Q211 or K222) in either homozygosis or heterozygosis 
were challenged with a natural scrapie isolate (see Materials and Methods, 
section 2.2.1 for more information about the inoculum) via intracerebral (IC) or 
oral routes in the ENV-INRA in Toulouse (France) following the procedures 
described in Materials and Methods, section 2.2.1. For oral challenges, goat kids 
received the inoculum (scrapie-infected brain) by natural suckling within 48 
hours of birth and a second dose at the age of 30 days. For IC challenges, 
inoculum (the same homogenized scrapie-infected brain) was injected into the 
temporal cortex of six-month-old goats. Both groups of animals were monitored 
for the development of neurological diseases and euthanized at the clinical 
stage of the disease. The presence of PrPSc was assessed in brains by WB and 
IHC analysis.  The effect of each polymorphism on the susceptibility of goats to 
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scrapie was assessed and compared to the outcomes obtained in Tg mice. This 
bioassay also permitted us to analyze the effect of the inoculation route in prion 
transmission. 
Results indicated that all the WT goats were susceptible to the classical scrapie 
infection, both via oral and IC inoculation routes (Table 20). Goats developed 
neurological signs of scrapie disease – mainly motor alterations – and PrPSc was 
detected in their brains by WB and IHC analysis (data not shown).  
Table 20. Scrapie incubation periods in goats inoculated via oral and intracerebral 
routes according to their genotypes at codon 142, 154, 211 and 222 of the prnp 
prnp genotype
 
 
Incubation period in days ± SEM (n/n0)
b
 
Oral inoculation
 
Intracerebral inoculation 
wt
 a
 1141±93 (9/9) 486±21 (5/5) 
wt; I/ M
142
 1490±126 (4/4) 788±99 (5/5) 
wt; R/ H
154
 >2500 (0/6) 624±148 (5/5) 
wt; R /Q
211
 >2500 (0/6) 1291±325 (5/5) 
wt; Q /Q
211
 NA 770±139 (10/10) 
wt; Q /K
222
 >2500 (0/5) 1900, 2174 (2/5) 
wt; K /K
222
 NA 2101 (1/5) 
a Goats were sequenced following the procedures described in Materials and Methods 
(see section 2.1.1). Wild type (wt) PrPC sequence (I142R154R211Q222/I142R154R211Q222) and 
the polymorphic variants observed are indicated. 
b n/n0: diseased, PrPres: positive/inoculated animals. 
NA: Not analyzed. 
As in the case of the Wt goats, all goats harboring the I/M142 prnp genotype 
developed a clinical TSE, although with some delays in the disease onset in 
comparison to WT goats (Table 20). These prolonged incubation periods were 
reported in both oral and IC challenges and agree with the delays in ST that we 
previously described for scrapie-infected M142-Tg541 mice (Table 15), which 
further reinforces the idea that M142-PrPC polymorphic variant is not associated 
with resistance to classical scrapie infection.  
On the other hand, none of the goats harboring the H154, Q211 or K222-PrPC 
variants succumbed to the oral scrapie inoculation after over 2500 days. None of 
these goats showed any sign of prion disease and were culled due to 
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intercurrent diseases (Table 20). PrPSc was not detected by WB or IHC analysis 
of the brains of any of these goats. Unlike the oral challenges, the heterozygous 
R/H154 and R/Q211 goats – as well as the Q/Q211 homozygous animals that were 
IC inoculated – developed a clinical TSE with much longer incubation periods 
than IC-inoculated WT goats (Table 20). Interestingly, only two heterozygous 
goats and one homozygous K222 goat developed prion disease after an IC 
challenge, all with four-to-five times longer incubation times than WT goats. 
These delays in incubation periods compared to IC inoculated WT goats agree 
with the prolonged ST and resistance registered for Q211-Tg580 and K222-Tg516 
mice IC-inoculated with different classical scrapie strains (Tables 12 and 13).  
2.2. Susceptibility of WT, R/Q211, and Q/K222 goats to oral infection with goat-
BSE 
Goats harboring WT (R211Q222/R211Q222), R/Q211, or Q/K222 prnp genotypes were 
orally inoculated with a BSE adapted to goat isolate (Foster et al., 1993; 
Goldmann et al., 1996) (see Table 6 in Materials and Methods for more 
information about the inoculum) and were monitored for the development of 
prion disease. Goats were euthanized at the clinical stage or at scheduled times 
during the incubation period to follow: 
- Disease onset, neurological lesions and PrPSc deposition at FLI, InselRiems (see 
Materials and Methods, sections 2.2.1-2.2.3). 
- Presence of PrPres and prion infectivity in brain and/or certain peripheral 
tissues at CISA-INIA, Madrid (see Materials and Methods, sections 2.2.4 and 
2.3).  
By combining all these results, the relative susceptibility of each goat prnp 
genotype to oral infection with Goat-BSE was assessed and compared to that 
obtained from goat-PrP Tg mice. In this way, we were able to determine the 
reliability of the results obtained in BSE transmission studies in goat PrP-Tg 
mice.  
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2.2.1 Onset of clinical signs and PrPSc accumulation 
None of the WT goats killed at either six or 12 mpi exhibited any signs 
associated with BSE disease (Table 26) in the brain and the peripheral tissues 
examined here, neither by histopathology and Immunohistochemistry (IHC) 
nor by Western-blot (WB) analysis. Clinical signs of the disease were first 
observed in a WT goat (ZG01) at 24 mpi (Table 21). This animal revealed clear 
neurological signs and a spongiform encephalopathy associated with distinct 
accumulation of PrPSc in the brain stem as demonstrated by Hematoxylin-Eosin 
(HE) and immunohistochemistry analysis. WB (Fig. 24) analysis confirmed the 
presence of BSE-derived PrPres in this goat’s brain. However, in the lymph node 
(LN) poplitealis, retractor bulbi muscle or psoas major muscle all methods 
applied failed to detect any amount of PrPSc (Table 21).  
In contrast to WT goats, WB, IHC, and HE analysis of one R/Q211 goat killed at 
24 mpi revealed the absence of any PrPSc deposits and neurodegenerative 
alterations in its brain (Table 21). However, three R/Q211 goats reached the 
clinical phase of BSE disease at 33 (ZG28), 34 (ZG05), and 36 (ZG20) mpi (Table 
21) associated with clear spongiform encephalopathy and accumulation of PrPSc 
as shown in IHC analysis. Additionally, all three R/Q211 goats (33–36 mpi) were 
scored as PrPres positive in their brains by WB analysis (Fig. 24) but not in their 
muscles or popliteal LN, again similar to the WT goats. Together, these results 
indicate that the Q211-PrPC variant has a non-substantial effect on the 
susceptibility of goats to oral infection with Goat-BSE since this effect only 
extends the incubation periods of the disease.  
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Table 21. Clinical sign evaluation and PrPSc detection in tissues of WT, R/Q211, and Q/K222 goats 
orally challenged with a Goat-BSE isolate and then sequentially culled 
prnp genotype Goat code Endpoint (mpi) Clinical signs Goat tissue WB PrP
res d IHC PrP
Sc e
 
WT
a
 
 
ZG26 6 - 
brain - - 
m
b
. psoas major - NA
 
m.retractorbulbi - NA 
popliteal LN
c
 - NA 
ZG32 6 - 
brain - - 
m. psoas major - NA 
m.retractorbulbi - NA 
popliteal LN - NA 
ZG35 6 - 
brain - - 
m. psoas major - NA 
m.retractorbulbi - NA 
popliteal LN - NA 
ZG19 12 - 
brain - - 
m. psoas major - NA 
m.retractorbulbi - NA 
popliteal LN - NA 
ZG24 12 - 
brain - - 
m. psoas major - NA 
m.retractorbulbi - NA 
popliteal LN - NA 
ZG30 12 - 
brain - - 
m. psoas major - NA 
m.retractorbulbi - NA 
popliteal LN - NA 
ZG01 24 + 
brain + + 
m. psoas major - - 
m.retractorbulbi - - 
popliteal LN - - 
R/Q211 
 
ZG13 24 - brain - - 
ZG28 33 + 
brain + + 
m. psoas major - - 
m.retractorbulbi - - 
popliteal LN - - 
ZG05 34 + 
brain + + 
m. psoas major - - 
m.retractorbulbi - - 
popliteal LN - - 
 
ZG20 36 + 
brain + + 
m. psoas major - - 
m.retractorbulbi - - 
popliteal LN - - 
Q/K222 
 
ZG10 24 - brain - - 
ZG25 44 - 
brain - - 
m. psoas major - - 
popliteal LN - - 
ZG11 45 
 brain - - 
      - m. psoas major - - 
 popliteal LN - - 
ZG03 86 - 
brain - - 
m. psoas major - - 
m.retractorbulbi - - 
popliteal LN - - 
See next page for footnotes. 
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a Goats were sequenced following the procedures described in Materials and Methods 
(see section 2.1.1). Wild type (wt) PrPC sequence (R211Q222/R211Q222); the polymorphic 
variants observed are indicated. 
b Muscle.  
c Limphonode. 
d Brain PrPres was detected by Western blot using Sha31 mAb (Fig. 24).  
e Brain PrPSc was detected by Immunohistochemistry (IHC) as described in Materials 
and Methods section 2.2.3.  
NA: Not analyzed 
 
None of the Q/K222 goats killed at 24, 44 and 45 mpi showed any evidence of 
prion disease (Table 21). Moreover, all of these goats were scored as PrPSc 
negative for all of their analized tissues by IHC and WB (Table 21) thereby 
suggesting that K222-PrPC variant provides goats with resistance to the oral 
infection with goat-BSE. These results contrast with the total susceptibility of 
the Tg mice expressing this polymorphic variant (K222-Tg516 mice) to IC 
infection with Goat-BSE prions (Table 12). K222-Tg516 mice had very similar ST 
to goat Wt-Tg501 mice, which suggests that the K222-PrPC variant does not affect 
susceptibility to Goat-BSE. Thus, non-genetic factors such as the inoculation 
route are the probable origin of the resistance of Q/K222 goats to oral infection 
with Goat-BSE. 
WB analysis of the brain PrPSc in both WT- and R/Q211-infected goats showed a 
typical BSE PrPSc banding pattern characterized by a 19K unglycosilated band 
and prominent diglycosylated species. The glycoprofiles were indistinguishable 
from those produced by the goat-BSE isolate originally used in the goat 
challenges (Fig. 24). 
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Figure 24. Brain PrPres from wild type (WT) and R/Q211 goats orally inoculated with a 
goat-BSE isolate. Immunoblots of brain PrPres detected with Sha31 mAb. Identical 
amounts of 10% brain homogenate were loaded in each lane. The original Goat-BSE 
isolate used for goat inoculations (Foster et al., 1993; Goldmann et al., 1996) was also 
included in the blot (Goat-BSE). Molecular weights in kilodaltons are shown on the 
right-hand side of the blot.  
 
2.1.2. Infectivity in different tissues from inoculated goats 
2.1.2.1. Titration of the goat-BSE isolate used for goat inoculations 
PrPSc is a specific and widely used TSE marker. Nevertheless, its sensitivity can 
be lower than the infectivity measured by mouse bioassay. In order to select the 
most sensitive mouse bioassay, the goat-BSE isolate originally used for the goat-
transmission inoculations (Foster et al., 1993; Goldmann et al., 1996) was 
titrated in both BoPrP-Tg110 and WT-Tg501 mice by end-point dilution. BoPrP-
Tg110 and WT-Tg501 mice were intracerebrally inoculated with 20µl of 10-fold 
serial dilutions of the goat-BSE isolate (10% brain homogenate); the infectious 
titer of the isolate was calculated by the Reed-Muench method (see Materials 
and Methods, section 2.3.2).  
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Table 22. Titration of the Goat-BSE isolate by end-point titration in both BoPrP-Tg110 
and goat Wt-Tg501 mice 
Inoculum 
dilution 
Equivalent grams of 
inoculated braina 
Mean survival time in days ± SEM (n/n0)b  
BoPrP-Tg110c Wt-Tg501 (1X)d 
 0,002 (2 x 10-3) 239±66 (6/6) 381±43 (6/6) 
10-1 0,0002 (2 x 10-4) 289±24 (6/6) 367±12 (6/6) 
10-2 0,00002 (2 x 10-5) 345±57 (6/6) 408±24 (6/6) 
10-3 0,000002 (2 x 10-6) 373±29 (6/6) 528±64 (3/7) 
10-4 0,0000002 (2 x 10-7) 351±14 (4/6) >600 (0/6) 
10-5 0,00000002 (2 x 10-8) 441, 450 (2/6) >600 (0/6) 
Infectious titer of the Goat-BSE isolatee 1.58 x 107 ID/g 3.79 x 105 ID/g 
a Grams of Goat-BSE-infected brain inoculated in each IC dose (20µl of brain 
homogenate per mouse). 
b n/n0: diseased, PrPres: positive/inoculated animals. 
c Transgenic mice expressing the bovine PrPC sequence (Castilla et al., 2003). 
d PrPC level of expression in the brain compared to PrPC in goat and sheep brain as 
assessed by Western blot analysis (Fig. 13A). 
e Infectious titer calculated by the Reed-Muench method and expressed as ID per grams 
(ID/g) of Goat-BSE-infected brain inoculated in each mouse model. 
 
BoPrP-Tg110 mice were selected for detecting prion infectivity in goat tissues 
because of their greater sensitiveness to the prion infectivity detection of the 
Goat-BSE isolate than Wt-Tg501 mice (Table 22). Then, a regression curve was 
drawn with the dilutions of the Goat-BSE isolate that produced 100% attack 
rates in BoPrP-Tg110 mice (Fig. 25). Finally, an equation fitting the data was 
obtained (y = 288,12e-0,049x) and used to obtain the infectious titers (y) in the goat 
tissues from their survival times values (x) (Table 22). 
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Figure 25. Titration of the Goat-BSE isolate (Foster et al., 1993; Goldmann et al., 1996) 
by end-point dilution in BoPrP-Tg110 mice. aMean survival times in days± standard 
error of the mean (n/n0: diseased, PrPrespositive/inoculated animals) are represented 
on the x-axis of the plot and the equivalent grams of the inoculated Goat-BSE-infected 
brain on the y-axis.  
 
 
2.1.2.2 Relative infectivity in tissues from goats inoculated with goat-BSE 
No prion infectivity was detected in any tissue from WT goats killed at 6 or 12 
mpi. When their brain and peripheral tissue homogenates were inoculated into 
BoPrP-Tg110 mice, none of the mice succumbed to prion disease. All were 
euthanized at 650 dpi and none had any clinical signs or PrPres in their brains by 
WB analysis. Prion infectivity was detected in the brain of a WT goat killed at 
24 mpi (ZG01 goat). After inoculation, BoPrP-Tg110 mice had 100% AR and 
short ST (261±20 dpi) (Table 23), which correspond to a highly infectious titer 
(6.35 x 106 ID/g). Interestingly, BoPrP-Tg110 mice also succumbed to the 
inoculation of PrPSc negative popliteal LN, psoas major muscle, and retractor 
bulbi muscle homogenates from this goat, and had longer ST and lower AR 
than those obtained with the brain homogenate (Table 23).  
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Table 23.  Infectious titer in tissues from Goat-BSE orally inoculated WT, R/Q211, and 
Q/K222 prnp goats as determined by mouse bioassay 
prnp 
genotype 
Goat codes of 
pooled tissues 
End 
point 
(mpi) Goat  tissue 
Mouse bioassay in BoPrP-Tg110 
mice 
ST±SEM 
(n/n0)b Infectious titer
c 
WTa 
ZG26-ZG32-
ZG35 
 
6 
brain 650 (0/6) <5x 102 d 
psoas major muscle 650 (0/6) <5x 102 
retractor bulbi muscle 650 (0/6) <5x 102 
popliteal lymph node  650 (0/6) <5x 102 
ZG19-ZG24-
ZG30 
 
12 
brain 650 (0/6) <5x 102 
psoas major muscle 650 (0/6) <5x 102 
popliteal lymph node 650 (0/6) <5x 102 
ZG01 
 
24 
brain 261±20 (6/6) 6.35 x 106 
psoas major muscle 
596, 598 
(2/6) 
<5x 102 
retractor bulbi muscle 469±29 (3/6) <5x 102 
popliteal lymph node 526 (1/6) <5x 102 
R/Q211 
ZG13 24 brain 650 (0/6) <5x 102 
ZG28-ZG05-
ZG20 
 
33-34-36 
brain 258±15 (6/6) 7.36 x 106 
psoas major muscle 334±24 (6/6) 1.78 x 105 
retractor bulbi muscle 307±84 (5/5) 6.67 x 105 
popliteal lymph node 406±50 (2/4) <5x 102 
Q/K222 
ZG10 24 brain 650 (0/6) <5x 102 
ZG25 
 
44 
brain 650 (0/6) <5x 102 
psoas major muscle 650 (0/6) <5x 102 
popliteal lymph node 650 (0/6) <5x 102 
ZG11 45 
brain 400±50 (6/6) 7.00 x 103 
psoas major muscle 522 (1/6) <5x 102 
popliteal lymph node 650 (0/6) <5x 102 
ZG03 86 
brain ongoing ND 
psoas major muscle ongoing ND 
retractor bulbi muscle ongoing ND 
 popliteal lymph node ongoing ND 
a Goats were sequenced following the procedures described in Materials and Methods (see 
section 2.1.1). Wt type (wt) PrPSc sequence: A136R154Q171/A136R154Q171. 
b Mean Survival Time in days ± Standard error of the mean (n/n0: diseased, 
PrPrespositive/inoculated animals). 
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c The infectious titer of each goat tissue was calculated as a function of the survival times 
obtained after their inoculation in BoPrP-Tg110 mice and expressed as ID per grams of the 
inoculated tissue (ID/g) (see supplemental data). 
d Limit of detection of the mouse bioassay calculated as ID/g of inoculated brain in each 20ul of 
inoculated homogenate using the Reed-Muench method. 
 
Prion infectivity was not detected in the brain of the R/Q211 goat killed at 24 
mpi (Table 23). However, all BoPrP-Tg110 mice succumbed to the inoculation of 
the pooled brain homogenates from ZG28, ZG05, and ZG20 R/Q211 goats killed 
at 33–36 mpi. These mice had similar ST (258±15 dpi) to those previously 
obtained from the inoculation of the ZG01 WT goat brain and therefore their 
infectious titers were comparable (7.36 x 106 ID/g and 6.35 x 106 ID/g, 
respectively). Like the WT goat, R/Q211 goats also had prion infectivity in their 
PrPSc negative peripheral tissues. Pooled homogenates from popliteal LN, psoas 
major muscle, and retractor bulbi muscle infected BoPrP-Tg110 mice with 
higher AR and lower ST than peripheral tissues from ZG01 WT goat (Table 23). 
Only the brain from a Q/K222 goat killed at 45 mpi (ZG11) had a low infectivity 
(Table 29), while the brain from a Q/K222 goat killed at 44 mpi (ZG25) harbored 
no prion infectivity. All the BoPrP-Tg110 mice succumbed to the brain 
inoculation from goat ZG11, albeit with considerably longer ST (400±50 dpi) 
than those obtained with brains from WT (261±20 dpi) and R/Q211 (258±15 dpi) 
goats. Traces of infectivity were also detected in PrPSc negative muscle psoas 
major from both Q/K222 goats with a low AR (1/6) and very long ST (550 and 
522 dpi) in BoPrP-Tg110 mice. Tissues from the Q/K222 goat culled at 76 mpi 
have recently been inoculated in BoPrP-Tg110 mice but with no results as yet 
(Table 23). 
In all cases, brain PrPres patterns from infected BoPrP-Tg110 mice were similar 
to those observed in the original goat-BSE isolate (Foster et al., 1993; Goldmann 
et al., 1996), as well as to those found in goat tissue homogenates, regardless of 
the goat prnp genotype (WT, R/Q211, or Q/K222) or the inoculated tissue (Fig. 
26).  
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Figure 26. Brain PrPres detected in BoPrP-Tg110 mice inoculated with different goat 
tissue homogenates. Immunoblots of PrPres in BoPrP-Tg110 mice inoculated with 
different tissue homogenates from ZG01 WT (R211Q222/RQ) goat, ZG28, ZG05 and 
ZG20 R/Q211 goats (pooled homogenates), and ZG11 Q/K222 goat. Similar quantities of 
PrPres were loaded to enable adequate comparison; immunoblots were detected with 
Sha31 mAb.  The original goat-BSE isolate used for goat inoculations (Foster et al., 
1993; Goldmann et al., 1996) was also included in the blot (Goat-BSE). Molecular 
weights in kilodaltons are shown on the right-hand side of the blot. M: muscle; LN: 
lymph node. 
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A fundamental event in the pathogenesis of prion diseases is the misfolding of 
host cellular prion protein (PrPC) into pathological prion protein (PrPSc). It is 
well known that certain amino acid changes in the PrPC sequence can affect the 
efficiency of PrPSc replication and prion transmission. Besides the PrP amino 
acid differences between host PrPC and donor PrPSc, prion strains also modulate 
prion conversion, possibly as a result of the variety of conformations that PrPSc 
can adopt. It is important therefore to study PrP sequence changes in 
combination with prion strains as a way of understanding the molecular 
mechanisms governing the susceptibility/resistance to prion infection.  
In this work we generated a panel of transgenic (Tg) mouse lines expressing 
either the goat wild type PrPC or this PrPC  with single amino acid exchanges 
corresponding to goat or sheep PrPC polymorphic variants (I/M142, R/H154, 
R/Q211, Q/K222, Q/R171, and N/K176) that were subsequently challenged with 
several prion strains. Their susceptibilities were assessed and compared to 
determine the individual effect of each PrPC variant in the 
resistance/susceptibility to prion infection. At the same time as these 
transmission studies in Tg mice were being carried out, experimental goat 
inoculations with either a scrapie field case or a goat-BSE isolate were 
performed thanks to a collaborative work in ENVT (Toulouse) and FLI (Insel 
Riems), respectively, and their results were compared with those obtained in 
the transmission studies in Tg mice. In this way, we were able to confirm in the 
natural host (goats) the reliability of our results for mouse models and to 
evaluate the effect of PrPC polymorphic variants on the susceptibility of goats to 
prion infection.   
Tg mouse lines expressing different polymorphic variants of the PrPC (M142, 
H154, R171, K176, Q211, and K222) were generated by directed mutagenesis of the 
pMo-GoPrP.Xho plasmid used for generating the goat Wt-Tg501 mouse line. Of 
these mouse lines, we selected at least one founder expressing a physiological 
brain PrPC level similar and/or comparable to that in goats. The only exception 
was H154-Tg563, for which no founder expressing more than 0.25-fold the PrPC 
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(0.25X) in the goat brain was obtained, despite the large number of 
microinjections performed (Table 8); this suggests that higher levels of H154-
PrPC could be toxic.  The hemizygous Q211-Tg580 (0.5X) mouse line was bred to 
homozygosis in order to obtain mice with a physiological brain PrPC level 
comparable to hemizygous Wt-Tg501 mice (1X). Finally, the hemizygous K176-
Tg570 (2X) mouse line had a similar brain PrPC level to that of the homozygous 
Wt-Tg501 mice (2X). Selected mouse lines were healthy and exhibited 
physiological behavior until the end of their lifespans; no histopathological 
lesion due to prion disease was observed in their brains, thereby ruling out the 
possibility of spontaneous disease development as a result of the expression of 
the mutated PrPC. Together, this collection of mouse lines is deemed to be 
suitable for studying the role of polymorphic variants in goat and sheep PrPC in 
the susceptibility to prion infection. 
1. Susceptibility of goat WT-PrP Tg501 mice to scrapie and BSE infection 
Wt-Tg501 mice were susceptible to all tested scrapie and BSE isolates regardless 
of the strain (classical or atypical scrapie, and classical or atypical BSE), 
geographical origin, PrPSc genotype, PrPres Western blot (WB) profile, or 
behavior upon passage in BoPrP-Tg110 mice of the prion isolates (Table 11). 
However, transmission features clearly varied in terms of these factors (see 
below).  
Brain PrPres glycoprofile of the classical scrapie-infected Wt-Tg501 mice 
analyzed using WB demonstrated that our Wt-Tg501 mice largely reproduce 
the WB signature of the inoculated isolate (Fig. 16A). Most of these isolates 
appeared to give a molecular glycoprofile with a 21K unglycosilated band that 
was fairly well maintained in the Wt-Tg501 mouse brain, except for Goat-Sc 
UKA2 where some infected mouse brains showed a 21K unglycosilated band, 
while others exhibited a double 19-21K unglycosilated band. These findings 
point to the coexistence of two different agents in this isolate. Finally, two 
isolates (Goat-Sc F14 and Goat-Sc UKB2) maintained their double 19-21K 
unglycosilated band after passage in the Wt-Tg501 mouse brain.  
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Other transmission features in Wt-Tg501 mice revealed additional differences in 
the panel of classical scrapie isolates. Highly variable ST (Table 11) and 
neuropathological alterations (Fig. 17) were obtained, which indicates the 
existence of at least three types of classical scrapie isolates: “Italian” isolates, 
“non-Italian fast” isolates, and “non-Italian slow” isolates. “Italian” isolates 
displayed the longest ST (550–650 dpi) (Table 11) and shared particular 
histopathological alterations (Fig. 17) that differed from the other isolates (non-
Italian). Among the “non-Italian” isolates, “fast” (<300 dpi after second 
passage) and “slow” (>300 dpi after second passage) isolates could be identified 
irrespective of their geographical origin (Table 11). Histolopathological analysis 
(Fig. 17) revealed a specific and distinct neuropathological pattern for isolates 
belonging to each of these two groups (fast or slow). Within “non-Italian fast” 
isolates two different subgroups could be differentiated on the basis of the 
molecular weight of the brain PrPres unglycosilated band (21K or 19-21K) (Table 
11). Taken together, the homogeneity of the transmission features within each 
group suggests that the different isolates included in each group belong to the 
same scrapie strain and so all our panel might include at least four classical 
scrapie strains.  
Transmission experiments in BoPrP-Tg110 mice –and notably, the analysis of 
the brain PrPres glycoprofile in BoPrP-Tg110 mice– revealed additional 
information that helps type classical scrapie isolates (Table 24). An analysis of 
this feature clearly distinguishes two groups of scrapie isolates: those that 
showed a 19K unglycosilated band and those that produced a 21K band (Fig. 
15A). Interestingly, all Italian isolates transmitted to BoPrP-Tg110 mice had a 
brain PrPres 21K unglycosilated band in this mouse model (Table 24), which 
provides further supporting evidence for the existence of an “Italian” classical 
scrapie strain that differs from the rest of scrapie isolates inoculated. The 
absence of transmission of two “Italian” isolates (Goat-Sc I4 and Goat-Sc I12) to 
BoPrP-Tg110 mice could be the result of a combination of a low infectious titter 
of these isolates and the high transmission barrier of these mice to all Italian 
isolates.
  
 
 
 
Table 24. Summary of the survival times, attack rates and brain PrPres WB profile of classical scrapie isolates obtained during the 
transmission studies in goat Wt-Tg501 and BoPrP-Tg110 mouse lines 
Isolate 
Transmission in Wt-Tg501 mice Transmission inBoPrP-Tg110 mice 
Group 
1
st
 passage 2
nd
 passage 1
st
 passage 2
nd
 passage 
Name 
PrPres 
profile
a
 
ST ± SEM 
(n/n0)
b 
PrP
res
 
profile 
ST ± SEM 
(n/n0)
c 
PrP
res
 
profile 
ST ± SEM 
(n/n0)
 
PrP
res
 
profile 
ST ± SEM 
(n/n0)
 
PrP
res
 
profile 
Goat-Sc I2 21K 526±13 (6/6) 21K >600 (ongoing) - 453 (1/6) 21K 167±9 (7/7) 21K 
I (Tg501VS21K / Tg110F21K) 
Goat-Sc I3 21K >650 (5/5) 21K >600 (ongoing) - 464 (1/7) 21K 163±16 (7/7) 21K 
Goat-Sc I4 21K 582±20 (6/6) 21K >350 (ongoing) 21K >650 (0/5) - NA NA 
Goat-Sc I9 21K 578±25 (5/5) 21K 547±25 (6/6) 21K 324±90 (6/6) 21K 174±8 (5/5) 21K 
Goat-Sc I12 21K 591±42 (4/4) 21K >350 (ongoing) 21K >650 (0/7) - NA - 
Goat-Sc F16 21K 551±89 (3/3) 21K 242±26 (5/5) 21K 348±58 (3/6) 21K 177±9 (6/6) 21K I (Tg501F21K / Tg110F21K) 
Goat-Sc F2 21K 259±28 (4/4) 21K 212±16(6/6) 21K 343±163 (4/5) 19K 198±13 (6/6) 19K 
NI (Tg501F21K / Tg110F19K) 
Goat-Sc F3 21K 287±14 (6/6) 21K 228±7 (6/6) 21K 290±48 (3/6) 19K 191±3 (6/6) 19K 
Goat-Sc F6 21K 468±15 (4/4) 21K 299±6 (6/6) 21K 523±166 (6/6) 19K 178±13 (5/5) 19K 
Goat-Sc N3 21K 451±9 (4/4) 21K 254±50 (6/6) 21K 324, 703 (2/6)* 19K 
203±7 (5/5) 19K 
493±72 (6/6) 19K 
Goat-Sc S2 21K 228±15 (6/6) 21K 233±4 (6/6) 21K 384±149 (6/6) 19K 237±39 (9/9) 19K 
Goat-Sc S3 21K 221±16 (6/6) 21K 233±64 (5/5) 21K 271±19 (6/6) 19K 254±52 (4/4) 19K 
Sheep-Sc 21 21K 194±5 (6/6) 21K 205±18 (6/6) 21K 244±13 (6/6) 19K 187±2 (4/4) 19K 
Sheep-Sc Langlade 21K >650 (3/3) 21K 222±5 (6/6) 21K 504±47 (6/6) 19K 229±37 (4/4) 19K 
Sheep-Sc 09 21K 277±31 (5/5) 21K NA NA 230±66 (4/6) 19K 168±6 (6/6) 19K 
Goat-ScF14 19-21K 526±46 (4/4) 19-21K 287±94 (4/4) 19-21K >650 (0/6) - NA NA 
NI (Tg501F19-21K / Tg110F19K) Goat-Sc UKA2 21K 245±36 (5/5) 19-21K 252±8 (6/6) 19-21K 255±69 (5/5) 19K 187±6 (6/6) 19K 
Goat-Sc UKB2 19-21K 381 (1/5) 19-21K 214±34 (7/7) 19-21K 205±12 (7/7) 19K 196±5 (6/6) 19K 
Goat-Sc F10 21K 449±19 (5/5) 21K 372±14 (6/6) 21K 556±68 (4/4) 19K 575±43 (5/5) 19K 
NI (Tg501S21K / Tg110S19K) 
Goat-ScF11 21K >650 (6/6) 21K >330 (ongoing) 21K >650 (0/6) - NA NA 
Goat-ScG2 21K >650 (1/4) 21K >400 (ongoing) 21K 610 (1/6) 19K 348±85 (6/6) 19K 
Goat-ScG3 21K 466±35 (4/4) 21K 375±25 (4/4) 21K >650 (0/6) - NA - 
Goat-Sc N1 21K 535±8 (5/5) 21K 339±19 (5/5) 21K 649±9 (3/3) 19K >450 (ongoing) - 
Goat-Sc N2 21K 555±4 (5/5) 21K >350 (ongoing) - >650 (0/13) - NA - 
Goat-Sc UKD2 21K 547±100(5/5) 21K >450 (ongoing) - >650 (0/7) - NA NA 
Goat-Sc Zyp13 21K 483±15 (4/4) 21K 301±10 (4/4) 21K 650 (2/2) 19K 371±51 (6/6) 19K 
Goat-Sc Zyp21 21K 475±31 (5/5) 21K 324±9 (4/4) 21K >650 (2/6) 19K 387±12 (3/3) 19K 
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a Brain PrPres was detected by Western blot using Sha31 (Fig. 14–16). The apparent 
molecular mass of the PrPres unglycosilated band is given in kilodaltons (K).  
b n/n0: diseased, PrPres: positive/inoculated animals.  
c Isolates were considered fast (in red) if survival times were <300 days post-
inoculation (dpi) at second passage, or slow (in blue) when survival times were >300 
dpi at second passage. 
* Among the Goat-Sc N3 infected BoPrP-Tg110 mice one exhibited very long survival 
times of 703 dpi. The brain from this animal was further passaged in BoPrP-Tg110 mice 
(in blue) separately from the other mouse (in red). 
I: Italian 
NI: Non-Italian 
F: fast 
S: slow 
VS: very slow 
NA: Not analyzed 
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Apart from the Italian isolates, Goat-scrapie F16 was the only isolate that 
exhibited a brain PrPres 21K unglycosilated band in the BoPrP-Tg110 mice. 
Nevertheless, unlike the “Italian” isolates, this isolate was transmitted to goat 
Wt-Tg501 mice as a fast isolate with a high transmission barrier (Table 24). 
These results suggest that Goat-Sc F16 could contain more than one strain that 
selectively replicates in terms of the PrPC species context (goat or bovine). As in 
the Conformational Selection model (Beringue et al., 2008b; Collinge and 
Clarke, 2007), the degree of overlap between the strains that the prion agent 
harbors and the conformational constraints imposed by the host PrPC (goat Wt-
Tg501 vs. BoPrP-Tg110 mice) determine which strain is replicated. 
The rest of the isolates (non-Italians) transmitted to the BoPrP-Tg110 mice can 
be separated into two groups according to the ST after second passage: “non-
Italian fast” isolates (<300 dpi after second passage) or “non-Italian slow” 
isolates (>300 dpi after second passage) (Table 24). A number of “non-Italian” 
isolates were not transmitted in these mice, probably as a consequence of the 
“slow” condition previously described in Wt-Tg501 mice for these isolates in 
combination with a low infectious titer. For this reason, these isolates were 
included in the group of “non-Italian slow” isolates (Table 24).  
The distribution of the two groups of “non-Italian isolates” (“fast” and “slow”) 
overlaps considerably with that proposed for the Wt-Tg501 mice. Interestingly, 
an unexpectedly long ST in one BoPrP-Tg110 mouse infected with Goat-Sc N3 
isolate (Table 24) indicates the possible co-existence of two different agents (a 
“non-Italian fast” plus a “non-Italian slow”) in this isolate. This assumption was 
confirmed by further passages of this mouse brain that were undertaken 
separately from the rest of the mice with shorter ST (Table 24). Nevertheless, the 
question remains as to whether the Goat-Sc N3 as Goat-Sc F16 isolates 
originally contained more than one scrapie agent or whether new agents 
emerged after a mutation process occurring upon crossing the transmission 
barrier of BoPrP-Tg110 mice. Indeed, transmission of goat or sheep scrapie 
isolates in bovinized mice involves a species barrier that may result in the 
generation of new strain phenotypes (Beringue et al., 2008b; Collinge and 
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Clarke, 2007). Therefore, the serial passages of scrapie isolates in BoPrP-Tg110 
mice might not reflect the original properties of the agent. The fact that different 
scrapie phenotypes can emerge from the same original isolate upon serial 
transmission in different mouse lines or animal species (Beck et al., 2012; 
Thackray et al., 2011; Thackray et al., 2008) highlights the need to use in 
combination a number of different animal models to characterize in detail the 
properties of scrapie strains.  
Transmission studies of atypical scrapie isolates in both Wt-Tg501 and BoPrP-
Tg110 models revealed a different scenario to classical scrapie isolates. All 
atypical scrapie isolates transmitted readily at first passage in Wt-Tg501 mice 
and had a 100% AR (Table 11), thereby confirming the potential for the natural 
transmission previously proposed for this atypical prion agent (Simmons et al., 
2007; Simmons et al., 2011). In contrast to classical scrapie transmissions, 
atypical isolates consistently produced long ST (≈500–600 dpi), (Table 11), 
despite the high level of expression (2X) of the homozygous Wt-Tg501 mice 
used in this experiment. These results suggest that atypical scrapie is a slow 
infectious agent in their natural PrPC species context, which is consistent with 
the old age of naturally affected goats and sheep (Benestad et al., 2008).  
In goat Wt-Tg501 mice, all the different atypical scrapie isolates exhibited 
indistinguishable PrPres WB glycoprofiles (Fig. 16B). Moreover, very similar 
transmission features were observed within atypical scrapie-infected BoPrP-
Tg110 mice. Two different atypical scrapie isolates were able to infect these 
mice and a molecular shift to a BSE-like PrPres glycoprofile was observed in all 
infected brains (Fig. 15B).  
Although histopathological analysis are not yet available, the homogeneity of 
the transmission results at first passage in both Wt-Tg501 and BoPrP-Tg110 
mice supports the view that atypical scrapie isolates constitute a single prion 
agent (Gotte et al., 2011; Griffiths et al., 2010; Le Dur et al., 2005; Pirisinu et al., 
2010; Pirisinu et al., 2013).   
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Wt-Tg501 mice were fully susceptible to the tested BSE isolates (Table 11) 
irrespective of their PrPSc primary sequence (goat, sheep, or cattle). Goat-BSE 
isolates displayed similar ST to Cattle-BSE isolate at primary passage; no 
significant reduction in ST was observed for Cattle-BSE at second passage in 
goat Wt-Tg501 mice, thereby confirming the low transmission barrier of goats 
to cattle-BSE previously reported in experimentally challenged goats (Foster et 
al., 1993). Moreover, PrPres WB profile (Fig. 16) and histopathological alterations 
(Fig. 18A and B) in both goat-BSE- and cattle-BSE-infected Wt-Tg501 mice 
brains were similar in many ways. 
By contrast, atypical Cattle-BSE L displayed an apparent transmission barrier in 
Wt-Tg501 mice that was similar to the one previously observed in ovinized 
TgOvPrP4 and Tg338 mice (Baron et al., 2007; Beringue et al., 2007; Nicot et al., 
2013). Both 100% AR and very long ST were registered at first passage in Cattle-
BSE L-infected Wt-Tg501 mice (Table 11). ST significantly decreased at second 
passage and was even shorter than those in cattle-BSE. Interestingly, atypical 
BSE L acquired a classical BSE-like PrPres WB profile in Wt-Tg501 mice (Fig. 
16C) consistent with the phenotype shift of this agent in ovine-PrP Tg338 mice 
(Beringue et al., 2007). However, histopathological outcomes in atypical BSE L-
infected mice clearly differed from those of classical BSE-infected animals at 
first passage (Fig. 18). Histopathological analysis of second passages are still 
ongoing aimed at determining whether atypical Cattle-BSE L acquires a 
classical BSE strain-like profile in further passages in goat Wt-Tg501 mice, as 
has been proposed by some authors (Beringue et al., 2007), or  whether it 
maintains its specific strain properties as stated by others (Baron et al., 2007; 
Nicot et al., 2013). 
It is important to note that some classical scrapie isolates showed an apparent 
transmission barrier when inoculated in goat Wt-Tg501 mice (Table 11). The 
origin of this barrier could be the presence of certain polymorphic variants in 
the PrPSc sequence of some isolates that could have affected transmission 
efficiency at first passage. However, low infectious titers appear to be a more 
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likely cause of the limited transmissions observed at first passage since some of 
these polymorphic variants were harbored by other isolates that produced no 
transmission barriers (in orange in Table 11). 
The effects of the PrP amino acid differences between hosts and donors in prion 
transmission and disease phenotype have been reported on numerous 
occasions for different combinations of prion strain-species (Barron et al., 2001; 
Manson et al., 1999). Intriguingly, although the histopathological analysis 
indicates the existence of distinct scrapie disease phenotypes (Fig. 17) among 
the scrapie-challenged Wt-Tg501 mice, the presence of polymorphisms in the 
amino acid sequence of the scrapie isolates did not seem to play any decisive 
role at this point. That is to say, Goat-Sc I3 and Goat-Sc I9, both classified as 
“Italian” isolates, were clearly different in their amino acid substitution at 
codon 143 (R/H143) but exhibited no major differences in their neurological 
lesions (Fig. 17A) or PrPSc distribution patterns (Fig. 16B). On the other hand, 
Goat-Sc F2 (“non-Italian fast” strain) and Goat-Sc F10 (“non-Italian slow” 
strain), both harboring the same PrPSc amino acid sequence, clearly differed in 
their vacuolation scores when infecting Wt-Tg501 mice (Fig. 17B). Taken 
together, these results support the view that prion transmission features in Wt-
Tg501 mice are mainly determined by the strain properties of the agent, while 
PrP amino acid sequence differences between hosts and donors only play a 
relatively minor role. In line with this view, atypical Cattle-BSE L showed a 
clear transmission barrier in goat Wt-Tg501, whereas classical Cattle-BSE, 
harboring the same PrPSc sequence as Cattle-BSE L, was transmitted in this goat 
context without any apparent transmission barrier. As previously proposed by 
our group (Torres et al., 2014), these results recognize the pivotal role of the 
strain properties of a prion agent in the efficiency of its transmission to different 
species.  
Taken together, all the scrapie and BSE transmission studies in Wt-Tg501 mice 
indicate that this mouse line is a highly valuable model i) for studying the 
susceptibility of goats and sheep to different scrapie and BSE strains and ii) for 
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identifying the scrapie strains affecting sheep and goat given that it reproduces 
their biological and biochemical properties. However, transmission studies in 
other animal models such as the BoPrP-Tg110 are also useful in understanding 
the variety of scrapie strains that are currently circulating in Europe and the 
mechanisms through which they are selected and/or adapted during 
transmission between species or even PrP genotypes. 
2. Analysis of the individual role of certain goat and sheep PrPC polymorphic 
variants in the susceptibility/resistance to prion infection by transmission 
studies in Tg mice. 
Amino acid differences between host PrPC and infectious PrPSc can directly 
determine the rate of conversion of PrPC into PrPSc and so reflect the 
transmissibility of prion agents and the susceptibility of hosts to prion infection 
(Bossers et al., 1997; Bossers et al., 2000). Interestingly, some polymorphic 
variants have no effect on this process, which thus suggests that not all variants 
influence prion conversion or prion replication in the same way.  
To address this question, we produced transgenic (Tg) mice expressing 
different PrPC polymorphic variants (I/M142, R/H154, R/Q211, Q/K222, Q/R171, or 
N/K176) naturally found in sheep and/or goat species that vary only by a single 
amino acid at the corresponding PrP residue. M142-Tg541, H154-Tg563, Q211-
Tg580, K222-Tg516, R171-Tg552, and K176-Tg570 mouse lines were IC inoculated 
with a variety of scrapie and BSE isolates previously used in the Wt-Tg501 mice 
challenges. The relative susceptibilities of these Tg mouse lines were compared 
with those obtained in Wt-Tg501 mice to determine the individual role of each 
polymorphic variant in the susceptibility/resistance to prion infection.  
K222-Tg516 mice expressing the K222-PrPC variant were fairly resistant to all the 
inoculated classical scrapie isolates (Table 12), regardless of their geographical 
origin, the polymorphic variants originally in their PrPSc sequences, their PrPres 
WB profile, or their behavior upon passage in both BoPrP-Tg110 (Table 10) and 
Wt-Tg501 mice (Table 11). No PrPres or histological alterations were observed in 
any of the brains of these challenged K222-Tg516 mice and only some 
vacuolation – similar to that of non-inoculated aged mice – was detected (Fig. 
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20). Since both Wt-Tg501 and K222-Tg516 mice express exactly the same PrPC 
sequence (except for the Q/K222 amino acid substitution) and have similar PrPC 
expression levels, we can assume that the lack of transmission efficiency for 
classical scrapie in K222-Tg516 mice is linked to the Q/K222 polymorphism. This 
conclusion is consistent with previous epidemiological studies carried out in 
numerous European goat scrapie outbreaks in which the K222-PrPC variant was 
only detected in healthy goats (Acin et al., 2013; Acutis et al., 2006; Barillet et al., 
2009; Kanata et al., 2014; Vaccari et al., 2006). Taken together, these results 
suggest that the K222 variant of goat PrPC is strongly resistant to a wide range of 
classical scrapie isolates. Intriguingly, atypical scrapie isolate Sheep-M45 
infected 100% K222-Tg516 mice with similar ST (Table 12), PrPres WB 
glycoprofile (Fig. 19), and histopathological alterations (Fig. 20) than those 
observed in Wt-Tg501 mice. These results suggest that, despite its high 
resistance to classical scrapie, the K222-PrPC variant confers no resistance to the 
replication of the atypical scrapie agent. 
BSE transmission experiments showed that K222-Tg516 mice were resistant to 
classical Cattle-BSE and atypical Cattle-BSE L but not to goat-BSE or sheep-BSE 
isolates (Table 12). The failure of the cattle-BSE isolate to be transmitted to K222-
PrPC mice can be explained by the dual influence of the PrPC sequence 
differences in prion cross-species transmission (Agrimi et al., 2003; Baylis et al., 
2004; Torres et al., 2014) and the effect of the Q/K222 amino acid substitution. In 
this sense, the effect of the PrPC primary sequence of the donor (bovine) is not 
strong enough to avoid cattle-BSE replication in goat Wt-Tg501 mice (Table 9). 
However, after the Q/K222 substitution in K222-Tg516 mice, the cattle-BSE agent 
is unable to replicate. This view is fully consistent with the fact that K222-Tg516 
mice were susceptible to BSE only after passage in sheep, goat, or Wt-Tg501 
mice (Table 12). Therefore, the transmission barrier toward the BSE agent is 
complex and is modulated not only by the K222 allele but also by other 
determinants such as the PrP amino acid differences between hosts and donors 
(goats vs. cattle).  
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 Taken together these transmission experiments demonstrate that the 
single amino acid exchange from a glutamine to a histidine at codon 222 
(Q/K222) provides resistance to infection with classical scrapie, classical cattle 
BSE, and atypical cattle BSE L but not to atypical scrapie, sheep BSE, or goat 
BSE. Most of these results, together with some transmission outcomes in the 
goat Wt-Tg501 mouse line, have been published recently (Aguilar-Calvo et al., 
2014). 
Q211-Tg580 mice expressing the Q211-PrPC variant were resistant to all the 
inoculated classical scrapie isolates (Table 13). Scrapie-challenged Q211-Tg580 
mice showed no neurological sign of prion disease or PrPSc in their brains after 
analysis by WB or PET-blot (Table 13), thereby suggesting that, like the K222 
variant, the Q211-PrPC variant confers high resistance to classical scrapie 
infection. This assumption is consistent with the decreased susceptibility to 
natural infection with classical scrapie associated with R/Q211 goats (Barillet et 
al., 2009; Bouzalas et al., 2010). However, unlike the K222-PrPC variant, natural 
scrapie infection in R/Q211 goats has been more often reported than in Q/K222 
goats (Acutis et al., 2006; Barillet et al., 2009; Fragkiadaki et al., 2011), which 
indicates that the K222-PrPC variant would provide a greater degree of resistance 
to classical scrapie than the Q211-PrPC variant. Accordingly, cell-free conversion 
studies have shown that the conversion capacity of the K222 allele with scrapie is 
completely abolished, while the Q211 allele only has a lower conversion capacity 
than the goat WT allele (Eiden et al., 2011). 
The atypical scrapie transmission studies revealed that Q211-Tg580 mice were 
susceptible to this prion agent, albeit with very long ST (>650 dpi) compared to 
homozygous Wt-Tg501 mice (Table 13). These prolonged ST could be associated 
with the decreased susceptibility to atypical scrapie provided by the Q211-PrPC 
variant; nevertheless, lower PrPC levels of expression in the brain of Q211-Tg580 
mice (1X) than homozygous Wt-Tg501 mice (2X) could also have caused these 
contrasting results. Finally, no Q211-Tg580 mice have yet succumbed to the 
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infection with any of the BSE isolates inoculated. Experiments are ongoing to 
conclude at this point. 
 All in all, these transmission experiments with Q211-Tg580 mice suggest 
that the arginine-to-glutamine amino acid substitution at codon 211 (R/Q211) 
leaves the mutated PrPC unable to replicate any classical scrapie agent but has 
any substantial effect in the susceptibility to the infection with atypical scrapie.  
Despite the low levels of PrPC expressed in their brains (0.25X), H154-Tg563 mice 
were susceptible to some scrapie and BSE isolates (Table 14). These positive 
transmissions suggest a low or null effect of the H154-PrPC variant in 
susceptibility/resistance to scrapie and BSE infection. In line with this view, 
homozygous H/H154 sheep and goats were reported to be susceptible to both 
scrapie (Luhken et al., 2004) and BSE infection (Foster et al., 2001a). A Tg mouse 
line expressing higher levels of brain H15-PrPC would be required to be able to 
draw conclusions regarding the role of this polymorphic variant in 
susceptibility to prion infection.  
M142-Tg541 mice were susceptible to most of the inoculated classical scrapie 
isolates despite displaying statistically significant longer ST than Wt-Tg501 
mice in all the cases. These delays in ST agree with the decreased susceptibility 
to scrapie associated with I/M142 polymorphism in several naturally infected 
goat herds (Acin et al., 2013; Barillet et al., 2009; Goldmann et al., 2011; 
Gonzalez et al., 2010), as well as in experimental transmission studies 
(Goldmann et al., 1996), but also support the contention that the effect of M142 
PrPC polymorphic variant is limited to prolonging survival times (ST). 
Curiously, the delays in ST observed in scrapie-infected M142-Tg541 mice were 
significantly higher in “non-Italian fast” isolates (Goat-Sc F2, Goat-Sc S3, and 
Sheep-Sc Langlade) than in “non-Italian slow” isolates (Goat-Sc F10 and Goat-
Sc S2), whilst “Italian isolates” (Goat-Sc I3 and Goat-Sc I9) were not 
transmissible in M142-Tg541 mice (Table 13). These results suggest a strain-
dependent effect for M142-PrPC in infection with classical scrapie agents. The 
failure of “Italian” isolates to replicate in M142-Tg541 mice could result from the 
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combination of the slow velocity of replication of these isolates (Table 15) and 
the effect of long ST provided by the M142-PrPC variant. Further passages are 
currently in progress aimed at tackling these questions and discarding a 
possible strain-dependent resistance of this polymorphic variant to “Italian” 
scrapies. 
Unlike the scrapie challenges, no effect of the I/M142 polymorphism could be 
observed in the BSE transmissions in M142-Tg541 mice (Table 15). These animals 
succumbed to all the BSE isolates inoculated and showed very similar ST than 
Wt-Tg501 mice, which contradicts the lower susceptibility to BSE attributed to 
the I/M142 polymorphism in previous experimental inoculations in goats 
(Goldmann et al., 1996). The influence of other genetic factors besides prnp 
genotype could have biased the results obtained in the goat bioassay in which 
the animals were of a genetic mixture (Goldmann et al., 1996). More 
interestingly, none of the M142-Tg541 mice showed any sign of neurological 
disease when challenged with atypical scrapie isolates (Table 15) and no PrPres 
could be detected in their brains by WB analysis. These results suggest that the 
I/M142 polymorphism might play a determinant role in susceptibility to 
atypical scrapie infection. To our knowledge, this is the first time that a goat 
PrPC variant has been associated with greater resistance to atypical scrapie, a 
finding that may have important implications in the control of this disease in 
goat herds. 
 These transmission experiments in M142-Tg541 mice demonstrate that the 
single isoleucine-to-methionine amino acid exchange at codon 142 (I/M142) 
affects the replication with classical and atypical scrapie agents in a strain-
dependent manner; but has any substantial effect on BSE replication.  
R171-Tg552 mice, expressing the R171-PrPC variant, were resistant to all the 
scrapie isolates inoculated. These animals showed no clinical signs of prion 
disease and neither PrPres was detected in their brains (Table 16). These results 
are consistent with the high resistance of Q/R171 polymorphism to prion 
infection obtained in numerous epidemiological and experimental studies in 
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sheep and goats (Bouzalas et al., 2010; Gonzalez et al., 2007; Gonzalez et al., 
2005; Greenlee et al., 2014) and the low number of naturally infected sheep or 
goats harboring this polymorphism (Groschup et al., 2007; Ikeda et al., 1995) 
and are the basis of the selection of the R171-PrPC variant in selective breeding 
programs against scrapie.  
By contrast, R171-Tg552 mice were susceptible to the infection with atypical 
scrapie (Table 16). The susceptibility of ARR sheep to atypical scrapie is well 
known; however we could not determine an increased susceptibility of the R171-
PrPC variant to atypical scrapie, as proposed by epidemiological studies 
(Benestad et al., 2008). BSE transmission studies in R171-Tg552 mice are still 
ongoing. Though ST of these mice surpass those of Wt-Tg501 mice, we cannot 
draw final conclusions regarding the effect of the R171-PrPC variant in the 
susceptibility to BSE infection. 
 Hence, transmission studies in R171-Tg552 mice demonstrate that the 
single amino acid exchange glutamine-to-arginine at codon 171 (Q/R171) confers 
resistance to infection with classical scrapie but not with atypical scrapie. 
Transmission studies in K176-Tg570 mice produced highly promising results. 
None of the K176-Tg570 mice succumbed to the primary transmission of any 
inoculated classical scrapie isolates (Table 17). No PrPres or neuropathological 
alterations were observed in these mice. The K176-PrPC variant has previously 
been linked to a high level of protection against scrapie in epidemiological 
studies (Maestrale et al., 2009; Vaccari et al., 2009b) in sheep experimentally 
challenged with one scrapie isolate (Vaccari et al., 2007) and in PMCA studies 
(Bucalossi et al., 2011). Moreover, only one scrapie field case of a sheep 
harboring this prnp genotype in heterozygosis has ever been documented 
(Maestrale et al., 2009), which is evidence of the good resistance of the K176-PrPC 
variant to classical scrapie. By contrast, K176-Tg570 mice succumbed to atypical 
scrapie transmission and had even shorter ST than Wt-Tg501 mice (Table 17). 
These transmission results suggest that the K176-PrPC variant could increase the 
capacity of the mutated PrPC to replicate atypical scrapie agents. 
DISCUSSION 
 
 
168 
 
The decisive role of the K176-PrPC variant against infection with classical BSE 
was successfully established during our transmission studies with Tg mice. 
K176-Tg570 mice did not succumb to the inoculation with Cattle-BSE (Table 17) 
and their brains were scored PrPres negative by WB analysis. Consistent with 
our results is the increased resistance of the K176-PrPC variant to the IC 
transmission of cattle-BSE that has previously been reported in sheep (Vaccari 
et al., 2007). Remarkably, our transmission studies in Tg mice permitted us to 
demonstrate the resistance of the K176-PrPC variant to BSE even after being 
adapted to sheep and goat PrPC sequences (Table 17), as was previously 
observed in goat Q211-Tg580 mice but not in K222-Tg516 mice. Therefore, 
contrary to Q/K222, the effect of the N/K176 amino acid exchange is strong 
enough to block the transmission of the BSE agent without adding the effect of 
the PrPC sequence differences in prion cross-species transmission (bovine vs. 
ovine).   
 Taken together, these transmission results strongly support the view that 
the single amino acid asparagine-to-lysine substitution at codon 176 (N/K176) 
triggers a high level of resistance to infection with classical scrapie and BSE. 
This affirmation is reinforced by the fact that K176-Tg570 mice overexpress the 
K176-PrPC variant (2-fold the PrPC expression in the sheep brain) and therefore a 
low PrPC expression in these mice cannot explain the resistance to these TSEs. 
These studies also indicate that the N/K176 polymorphism might increase 
susceptibility to atypical scrapie infection. Results from prion transmission 
experiments in both R171-Tg552 and K176-Tg570 mouse lines will be included in 
two articles in preparation (see Publications section). 
In summary, the use of this panel of transgenic mice, all with very similar 
genetic backgrounds and the same goat-wt PrPC but with a single amino acid 
substitutions, allowed us to identify certain amino acid substitutions as the sole 
cause of the differential susceptibility to prion infection, thereby excluding the 
possibility of any part played by other genetic factors. In addition, the 
intracerebral inoculation route provided the best scenario for prion replication 
since the inoculum was placed directly in the target tissue. Therefore, our 
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results offer solid arguments to support the hypothesis that certain variants of 
the PrPC strongly modulate the susceptibility of sheep and goats to classical 
scrapie, classical BSE, and/or atypical BSE L. These studies also indicate that 
the amino acid exchanges tested in this work have no major effect in the brain 
PrPres WB profile and in the histopathological outcomes.  
Interestingly the effect of the PrPC polymorphic variant in susceptibility to 
prion infection was extremely affected by the prion agent in these studies (Table 
25). This phenomenon was particularly remarkable in the case of scrapie 
infections. Therefore, the polymorphic variants associated with high resistance 
to classical scrapie (K222-, Q211-, K171- and K176-PrPC variants) were susceptible to 
atypical scrapie, whereas those that exhibited no or no major effect on 
susceptibility to classical scrapie infection (M142-PrPC variant) appeared as 
strong modulators of susceptibility to atypical scrapie (Table 25), which 
indicates that there might be an opposite effect of polymorphic variants in 
susceptibility to classical and atypical scrapie infection. This assumption was 
previously proposed for sheep naturally infected with atypical scrapie. Hence, 
ARR sheep are more frequently affected by atypical scrapie disease than ARQ 
or VRQ sheep (Benestad et al., 2008). Nevertheless, more information is still 
required to understand the role of prnp genotype in the susceptibility to this 
agent. 
Table 25. Summary of the results obtained during the transmission studies in the 
different goat and sheep PrP Tg mouse lines 
TSE M142-Tg541 H154-Tg563 K222-Tg516 Q211-Tg580 R171-Tg552 K176-Tg570 
Classical 
scrapie 
Prolonged 
STa 
No effect* 
High 
resistance 
High 
resistance 
High 
resistance 
High 
resistance 
Atypical 
scrapie 
High 
resistance 
NA No effect No effect No effect No effect 
Goat-BSE 
No effect No effect* 
No effect 
Ongoing Ongoing 
High 
resistance 
Sheep-BSE 
Cattle-BSE High 
resistance 
Atypical BSE L NA NA 
High 
resistance 
NA Ongoing Ongoing 
a Survival times. 
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* The low levels of PrPC expressed in the brain of H154-Tg563 mice prevents from 
concluding on the effect of this PrPC variant in the susceptibility to prion infection. 
NA: Not analyzed. 
 
The molecular mechanisms through which PrPC polymorphic variants affect 
susceptibility to prion infection are not known. It has been proposed that 
mutations in the PrPC sequence may influence the capacity of the prion protein 
to bind PrPSc (Eiden et al., 2011; Perrier et al., 2002). However, it has also been 
reported that scrapie-resistant variant R171-PrPC binds to PrPSc as efficiently as 
prion-susceptible variant V136-PrPC and sheep wt-PrPC (Rigter and Bossers, 
2005). In addition, in vitro experiments have shown that the PrPC of more than 
one species (hamster and mouse) binds equally efficiently to mouse PrPSc but 
preserves its conversion specificity (Horiuchi et al., 2000). Therefore, a further 
step in the conversion process could decrease or inhibit prion conversion. This 
information provides clues for designing therapeutic strategies based on 
blocking PrPSc through binding prion-resistant PrPC variants (see below).  
An effect of PrPC variants on the thermodynamic stability and PrPC-folding 
kinetics of the prion protein has been previously reported (Eghiaian et al., 2004; 
Fitzmaurice et al., 2008; Paludi et al., 2007; Rezaei et al., 2002). Indeed, the 
amino acid exchange from a glutamine to an arginine at codon 171 (Q/R171) has 
been reported to cause the destabilization of the prion protein conformation 
(Eghiaian et al., 2004) (Fig. 31) and to be associated with increased protease 
sensitivity and decreased formation of large amyloid fibrils (lower 
amyloidogenesis) (Rezaei et al., 2002). A/V136 sheep polymorphism also affects 
PrPC stability since it is close to the region that is supposedly involved in 
refolding PrPC to PrPSc (residues 129–134 and 163–167 of the sheep sequence) 
(Eghiaian et al., 2004; Rezaei et al., 2002), while the R/H154 amino acid exchange 
alters the α-helix 1 of the sheep PrPC (Megy et al., 2004). These findings suggest 
the need for a structural analysis of our PrPC variants as a means of addressing 
the molecular basis of their variable role in susceptibility/resistance to the 
infection with different prion strains. 
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3 Protective effect of the K222 polymorphic variant of goat PrPC on prion 
replication of the goat-wild type allele 
In order to study the hypothetical inhibitory influence of the K222-PrPC variant 
on goat wt PrPC, heterozygous Q/K222 mice were obtained and IC-challenged 
with a variety of scrapie and BSE isolates. 
Heterozygous Q/K222 mice were resistant to most of the classical scrapie 
isolates and, once they succumbed to the infection, had very long ST and lower 
AR than Wt-Tg501 mice (Table 18). These results support the contention that 
the K222-PrPC variant has a dominant negative effect over the wild type PrPC 
sequence. This phenomenon is consistent with the stone-fence model 
(Kobayashi et al., 2009) that predicts that, for a given TSE agent, the 
incorporation of a conversion-incompetent PrPC variant (K222) will interfere 
with wild type PrPSc replication, thereby resulting in less efficient prion 
propagation. This decreased propagation efficiency would lead to lower AR 
and/or prolonged ST – as shown in our study – and could explain the lack of 
epidemiological evidence linking scrapie with the K222 allele (Barillet et al., 2009; 
Fragkiadaki et al., 2011; Jeffrey et al., 2014; Papasavva-Stylianou et al., 2011). 
Interestingly, the previously determined transmission barrier of K222-Tg516 
mice to Cattle-BSE was abolished when the K222-PrPC variant was found in 
heterozygosis (Table 18), which indicates that for classical BSE Q/K222 amino 
acid substitution does not interfere with the conversion of wt Q222-PrPC into 
PrPSc.   
The question remains, though, whether the wt allele or the K222-PrPC variant is 
responsible for prion replication in scrapie and BSE-infected Q/K222 mice (Table 
25). The existence of a monoclonal antibody (mAb) able to selectively target the 
K222 epitope instead of Q222 would help solve this question. Unfortunately, this 
Ab does not exist and so further passages of scrapie and BSE adapted to 
heterozygous Q/K222 mice in both Wt-Tg501 and K222-Tg516 mice (Table 19) 
were necessary. The positive transmission observed in Wt-Tg501 mice together 
with the resistance of K222-Tg516 mice to this inoculation allow us to conclude 
that goat wt allele (Q222) is the only allele replicating the prion agent in Q/K222 
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heterozygous mice, at least for the Goat-Sc F2 isolate. However, the absolute 
inability of K222 allele to replicate scrapie can be ruled out if we bear in mind 
our transmission studies in goats in which one homozygous K/K222 goat was 
infected by the IC route with one classical scrapie case (Table 20). A reason for 
this discrepancy could be the shorter lifespan of mice than goats, which could 
hinder the development of the prion disease or the scrapie strain. Thus, further 
studies are still needed to provide an answer to this question.  
This dominant negative effect provided by the goat K222-PrPC variant against 
the scrapie replication has previously been described by cell-free conversion 
analysis (Eiden et al., 2011). Furthermore, an inhibitory effect on the prion 
replication of equivalent K222 variants in other species has also been described. 
Human E/K219 polymorphism (homologous to the Q/K222 polymorphic variant 
of the goat PrPC) has been linked to protecting humans against sporadic 
Creutzfeldt-Jakob-Disease in epidemiological studies in Japanese (Shibuya et 
al., 1998) and other Asiatic (Soldevila et al., 2003) populations. Moreover, KI Tg 
mice expressing the E/K219 polymorphism in heterozygosis were resistant to 
sCJD (Hizume et al., 2009). Similarly, the equivalent K218 variant of the mouse 
PrPC significantly reduced the fibril aggregation kinetics and generated non-
proteinase K-resistant PrP in fibrillization experiments with recombinant 
Q/K218 (Lee et al., 2007). The dominant-negative inhibition provided by this 
polymorphism has also been demonstrated in scrapie-infected neuroblastoma 
cells (Crozet et al., 2004; Kaneko et al., 1997), as well as by PMCA (Geoghegan 
et al., 2009). 
The molecular mechanism driving this inhibitory effect is poorly known. A 
plausible reason could be the insertion of an additional positive charge at codon 
222, 219, or 218 (of the goat, human, and mouse PrP sequences, respectively) 
provided by the lysine amino acid (K), which would interfere with the 
PrPC/PrPSc interaction and lead to abolished or low conversion rates of PrPSc 
(Eiden et al., 2011). In this sense, comparative studies of the NMR structures of 
human recombinant prion protein harboring either the wt genotype or the 
E/K219 polymorphism have linked the protective effect of this polymorphism to 
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perturbations in surface charge distribution and structural rearrangements 
(mainly localized at the β2-α2 loop region) (Biljan et al., 2012). More recently, 
molecular dynamic studies comparing human dimeric homozygous Wt PrP-Wt 
PrP forms to heterozygous Wt PrP-K219 PrP forms suggest that the dominant-
negative effect of this protective mutation of this polymorphism (E/K219) is due 
to the incompatible structures and dynamics of allelic variants during the 
conversion process (Jahandideh et al., 2014). 
Similarly, the resistance provided by the K222-PrPC variant in our Tg mice could 
depend on the conformational changes derived from the Q-to-K amino acid 
substitution at codon 222. Therefore, comparative studies on the conformational 
stability of Q222 and K222 prion proteins will help understand the molecular basis 
of the selective resistance of goat Q/K222 polymorphic variant to classical 
scrapie and cattle-BSE but not to atypical scrapie or goat or sheep-BSE. 
Understanding these phenomena would finally help us to design therapeutic 
strategies based on blocking prion replication. 
4. Effect of polymorphic variants of the PrPC on susceptibility to prion 
infection in the natural host (goats) 
Our results in Tg mice models offer solid arguments supporting the view that 
certain variants of the PrPC strongly modulate the susceptibility of sheep and 
goats to prion infection. However, our procedure neither mimics the natural 
route of scrapie infection nor the complex pathogenesis involving prion 
replication in peripheral tissues, thereby highlighting the necessity to confirm 
this outcome in a natural host. Thus, to study the reliability of the results 
obtained in Tg mice, we worked in collaboration with two other research 
groups, with whom we performed the IC and/or oral inoculations with a 
classical scrapie isolate and a goat-BSE isolate in different PrP genotype goats.  
Experimental transmissions of a scrapie field case by either the oral or the IC 
route to goats clearly reveal the effect of PrPC variants on the susceptibility of 
this species to classical scrapie. This goat bioassay, performed in the ENVT 
(Toulouse) within the framework of a collaboration with Dr. Andreoletti´s 
group, showed that goats harboring the M142-PrPC variant were fully 
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susceptible to both the oral and the IC inoculation of the scrapie isolate, albeit 
with much longer survival periods than WT PrP goats (Table 20). These results 
agree with the delays in ST registered in scrapie-infected M142-Tg541 mice 
(Table 15) and confirm that the M142-PrPC variant does not play a decisive role 
in the susceptibility of goats to classical scrapie infection. 
H154 and Q211 goats were resistant to oral inoculation in this scrapie field case 
(Table 20). However, 100% AR was observed in animals bearing these 
genotypes after an IC challenge, thereby indicating that H154 and Q211-PrPC 
variants have a strong protective effect against oral scrapie infection, which can 
be overcome by the IC route. Notably, IC-challenged Q211 goats had three-times 
longer incubation periods than WT animals (Table 20), while IC-challenged H154 
goats had smaller delays in incubation periods than even M142 goats (Table 20).  
Most interestingly, the high resistance to classical scrapie associated with K222-
PrPC variant in our transmission studies in Tg mice was reinforced in the goat 
bioassay. None of the K222 goats succumbed to the oral infection with the 
classical scrapie isolate and only a few succumbed to the IC infection, and all 
had very long survival times (four- to five-times the incubation periods in WT 
goats). Remarkably, of the goats that succumbed to the scrapie IC challenge, 
one was homozygous for the K222 genotype, which shows that the K222-PrPC 
variant is able to replicate at least one classical scrapie isolate and that the 
resistance provided by the K222-PrPC variant is extremely high but not absolute.  
In combination, these transmission experiments in goats confirmed most of the 
results obtained in the different Tg mouse lines and therefore were recently 
published (Lacroux et al., 2014a) along with the transmission studies in Tg mice 
(Aguilar-Calvo et al., 2014). 
A genotype-dependent transmission of goat-BSE was demonstrated by goat 
bioassay at the FLV (Insel Riems). In this study, Goat-BSE-orally infected WT 
goats developed the first clinical signs of TSE at 24 mpi after inoculation (Table 
21). Clinical signs were similar to previous BSE inoculations in sheep and goats 
(Foster et al., 2001a; van Keulen et al., 2008a). PrPSc deposits in the brain and 
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neurodegenerative lesions also agreed with those previously observed in BSE-
inoculated sheep and goats (Foster et al., 2001a; Gonzalez et al., 2005; Lezmi et 
al., 2011), and were mainly detected at the level of the obex. Additionally, prion 
infectivity was also present in muscles and LN tissues (detected by mouse 
bioassay), albeit with smaller titers than in the brain. These results are 
consistent with PrPSc spread from the central nervous system (CNS) to 
peripheral tissues as reported in BSE oral transmission in sheep and cattle 
(Buschmann and Groschup, 2005; van Keulen et al., 2008b).  
R/Q211 goats first developed BSE at 33 mpi (Table 21). Prion infectivity in 
R/Q211 goats was noticeably higher in the brain than in peripheral tissues, once 
again in agreement with the WT goat results (Table 23). Interestingly, for the 
R/Q211 goats the onset of the disease was delayed by 9–12 months, which 
suggests the existence of a genotype-dependent transmission of BSE to goats in 
which the Q211 PrPC polymorphic variant might have an effect on the incubation 
period but not on susceptibility. Therefore, R/Q211 polymorphism could be 
associated with low resistance to goat-BSE, in contrast to the high resistance to 
scrapie associated with this polymorphism in field studies (Bouzalas et al., 2010; 
Corbiere et al., 2013b) and our experimental transmissions in goats. This 
discrepancy in the results regarding the Q211 PrPC variant and TSEs 
transmission is likely also to be linked to the prion strain as a determinant 
factor in BSE and scrapie occurrence (Aguzzi et al., 2007), as revealed by our 
transmission studies in Tg mice (Table 13).  
In contrast to the susceptibility of WT and R/Q211 goats to goat-BSE, none of the 
Q/K222 goats showed any evidence of disease (Table 21) and were culled at 86 
mpi because of intercurrent diseases. No clinical signs or PrPres were observed 
in any of these Q/K222 goats and histopathological analysis revealed no PrPSc 
deposits or neurological lesions. However, low infectivity was detected in the 
brain of one of the two Q/K222 goats euthanized at 44-45mpi (Table 23). Traces 
of infectivity were also detected in psoas major muscles from both goats, 
thereby suggesting that the K222 prnp variant drastically decreases the 
susceptibility of goats to goat-BSE. In fact, transmission studies in Tg mice have 
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shown that K222-Tg516 mice expressing the goat K222-PrPC variant were 100% 
susceptible to the IC transmission of goat-BSE and had similar ST to goat wt-
PrP transgenic mice (Table 12). This result suggests that the K222-PrPC variant is 
as able to replicate the goat-adapted BSE as the goat WT-PrPC. Hence, the 
resistance to goat-BSE might not be an intrinsic molecular property of the K222-
PrPC variant and the low susceptibility of Q/K222 goats to oral infection with 
goat-BSE might also be influenced by factors other than the host prnp genotype. 
A plausible reason for the discrepancy between the results from goat-BSE 
transmissions to Q/K222 goats and K222-Tg516 mice could be the infection route. 
Intracerebral inoculation (performed for transmission studies in Tg mice) 
provides the best route for prion replication since the inoculum is directly 
placed in the target tissue. By contrast, in oral transmission (used for goat 
inoculation) prions must overcome a succession of obstacles if they are to reach 
the target tissues: i) the crossing of the mucosal barrier, ii) amplification in gut-
associated lymphoid tissues, iii) lymphatic/haematogenic dissemination, iv) 
neuroinvasion via the peripheral nervous system (PNS), and, finally, v) reach 
the CNS (van Keulen et al., 2008a). One or more of these steps might be affected 
in some way by the prnp genotype and thus modulate the BSE capacity to 
replicate and/or spread through the organism. 
In line with this view, some authors have proposed that the ability of 
peripherally injected prions to replicate in extra-neural tissues such as Peyer’s 
patches in the intestinal tract, spleen, tonsils, appendix, and lymph nodes may 
be critical in determining whether or not prions can persist in the host before 
spreading to the PNS and then to the CNS (Beringue et al., 2008b). 
Lymphotropism seems to play an important role in prion infection. While BSE-
PrPSc in cattle is mainly confined to the CNS and the vegetative nervous system 
(Buschmann and Groschup, 2005; Kaatz et al., 2012), the BSE agent becomes 
lymphotropic in sheep and goats and a more widespread PrPSc distribution 
including several lymphoid tissues (Bellworthy et al., 2005; Foster et al., 1996a; 
Foster et al., 2001b) has been observed in BSE-infected goats and sheep. In BSE 
oral infected sheep, a PrPSc replication in certain lymphoid tissues such as the 
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tonsils and ileal Peyer’s patches before the infection of some areas of the ENS 
has been reported (Andreoletti et al., 2000; Kujala et al., 2011). On this basis, we 
hypothesize that the resistance of Q/K222 goats to oral goat-BSE infection could 
be linked to the poorer capacity of goat-BSE to convert K222-PrPC in peripheral 
organs. Lower levels of expression of K222-PrPC, together with the regional 
variability of the K222-PrPC isoforms in these organs of primary transmission, 
cannot be ruled out.  
Discrepancies in prion transmission efficiency linked to the inoculation route 
have previously been described (see review in (Beringue et al., 2008c)). In our 
goat bioassay, H154, Q211, and K222 goats were completely resistant to scrapie 
inoculation via the oral route but susceptible via the intracerebral route (Table 
20). Interestingly, while 100% of the H154 and Q211 goats succumbed to the 
scrapie IC inoculation, only few K222 goats developed the disease with 4–5 times 
longer incubation periods than WT goats, which supports the view that the K222 
variant renders goats less susceptible to scrapie infection than the Q211 variant. 
This statement could be extended to BSE infection, as supported by our 
transmission experiments of goat-BSE to goats.  
Alternatively, different levels of the C1 fragment in K222-PrPC could exist. For 
sheep, the proteolytic processing of its PrPC seems to be prnp genotype-
dependent. Hence, more of the C1 fragment and less of the C2 fragment were 
reported in brains from sheep linked to resistance to scrapie (Campbell et al., 
2013). Indeed, the recombinant protein comprising the C1 fragment of the ovine 
ARR variant was reported to delay or even inhibit the fibrillization of full 
length PrP (Campbell et al., 2013). Similarly, the proteolytic processing of the 
K222-PrPC variant could produce greater amounts of C1 fragment than goat wt-
PrPC, thereby blocking or decreasing the aggregation of this polymorphic 
variant.  
Finally, it is important to note that heterozygous Q/K222 goats were 
considerably less susceptible to the transmission of goat-BSE than WT goats 
(Table 21), indicating that the K222 PrPC variant could also protect against goat-
BSE oral infection. Nevertheless, since homozygous K/K222 goats were not 
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challenged in this study, we cannot draw any conclusions regarding the level of 
resistance provided by this variant or its ability to replicate goat-BSE. 
The results obtained in Goat-BSE oral transmission to goats demonstrate 
genotype-dependent transmission in which the K222-PrPC variant plays a 
decisive role.  The protective effect provided by the K222-PrPC variant against 
goat-BSE (results included in a recently submitted article; see Publications 
section) complement well its protective effect against scrapie, previously 
reported in goats and Tg mice. This finding further confirms the ability of the 
K222-PrPC variant to control the horizontal transmission of both classical scrapie 
and goat-BSE diseases in goat herds through selective breeding programs. 
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1. Wt-Tg501 mouse line is a highly valuable model for studying the 
susceptibility of goats and sheep to different scrapie and BSE strains and for 
identifying the scrapie strains affecting sheep and goat. Transmission 
studies in other animal models such as the BoPrP-Tg110 are also useful in 
understanding the prion strain diversity. 
2. Transmission experiments in both Wt-Tg501 and BoPrP-Tg110 mice show 
the existence of at least four classical scrapie strains circulating in Europe 
and exhibiting a regional distribution. By contrast, atypical scrapie appears 
to be a homogeneous disease –unique strain- with the potential for natural 
transmission in both the goat- and bovine-PrP context. 
3. Goat Wt-Tg501 mice showed low or null transmission barrier to classical 
cattle-BSE but moderate to high transmission barrier towards atypical 
cattle-BSE L which highlights the effect of the strain in the bovine-goat 
species barrier.  
4. Transmission studies in Tg mice expressing goat and sheep PrPC 
polymorphic variants allowed us to conclude that the single glutamine-to-
lysine amino acid substitution at codon 222 (Q/K222) provides resistance to 
infection with classical scrapie, classical cattle BSE, and atypical cattle BSE L 
but not to atypical scrapie, sheep BSE, or goat BSE. Moreover, the K222-PrPC 
variant displays a dominant negative effect over the wild-type PrPC 
sequence which results in a lower efficacy of classical scrapie prion 
propagation.  
5. The arginine-to-glutamine amino acid substitution at codon 211 (R/Q211) 
leaves the mutated PrPC unable to replicate any classical scrapie agent but 
has any substantial effect in the susceptibility to the infection with atypical 
scrapie. 
6. The low levels of PrPC expression in H154-Tg563 mice don´t allow us to 
conclude about the effect of the arginine-to-histidine amino acid exchange 
at codon 154 (R/H154) of the goat PrPC in susceptibility/resistance to prion 
infection. However, the positive transmission of some scrapie and BSE 
isolates suggest a low or null effect. 
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7. The single isoleucine-to-methionine amino acid exchange at codon 142 
(I/M142) affects the replication with classical and atypical scrapie agents in a 
strain-dependent manner; but has any substantial effect on BSE replication.  
8. The single glutamine-to-arginine amino acid exchange at codon 171 
(Q/R171) confers resistance to infection with classical scrapie but not with 
atypical scrapie.  
9. The single asparagine-to-lysine amino acid substitution at codon 176 
(N/K176) triggers a high level of resistance to infection with classical scrapie 
and BSE; although it seems to increase the level of susceptibility to atypical 
scrapie. 
10. H154-, Q211- and K222-PrPC variants in the natural host (goat) protect against 
the oral infection with classical scrapie. This protective effect is overcome 
by the intracerebral route in all cases except for K222-PrPC variant which is 
able to largely protect heterozygous Q/K222 goats against the intracerebral 
infection. Thus, the route of inoculation is a determinant factor in the 
susceptibility of H154-, Q211- and K222-PrPC polymorphic variants to classical 
scrapie infection in goats. 
11. Goat-BSE agent produces a genotype dependent transmission to goats 
where Q211-PrPC variant has an effect limited to prolong incubation periods 
while K222 variant plays a determinant role in the susceptibility of goats to 
this agent. 
12. Similarities in both the natural host and transgenic mice results 
demonstrate the reliability of transgenic mouse models expressing PrPC 
polymorphic variants to predict the genotype-dependent susceptibility to 
prion infection. 
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1. La línea de ratón Wt-Tg501 es un modelo muy valioso para el estudio de la 
susceptibilidad de las cabras y ovejas a diferentes cepas de tembladera y 
EEB así como para la identificación de las cepas de tembladera que afectan 
a estos pequeños rumiantes. Los estudios de transmisión en otros modelos 
animales como la línea de ratón BoPrP-Tg110 son útiles para entender la 
diversidad de cepas de prión existentes. 
2. Los estudios de transmisión en los ratones Wt-Tg501 y BoPrP-Tg110 
muestran la existencia de al menos cuatro cepas de tembladera clásica 
circulando por Europa con una distribución regional. Por el contrario, la 
tembladera atípica parece ser una enfermedad homogénea (sólo una cepa) 
con potencial para la transmisión natural tanto en el contexto de PrP 
caprina como bovina. 
3. Los ratones de cabra Wt-Tg501 muestran una baja o nula barrera de 
transmisión a la EEB clásica de vaca pero moderada o alta barrera a la EEB 
atípica L de vaca, lo que resalta el efecto de la cepa en la barrera de especie 
bovina-cabra.  
4. Los estudios de transmisión en ratones transgénicos que expresan 
diferentes variantes polimórficas de la PrPC nos permitieron concluir que el 
único cambio aminoacídico glutamina-lisina en el codón 222 (Q/K222) 
produce resistencia a la infección con los agentes de tembladera clásica, EEB 
clásica de vaca y EEB-L atípica de vaca pero no a los agentes de tembladera 
atípica, EEB de oveja o EEB de cabra. Es más, la variante de la PrPC K222 
proporciona un efecto dominante negativo sobre la secuencia de PrPC wt 
que resulta en una reducción de la eficacia de propagación de la tembladera 
clásica.  
5. El cambio aminoacídico arginina-glutamina en el codón 211 (R/Q211) 
conlleva la inutilidad de la PrPC mutada de replicar cualquier agente de 
tembladera clásica aunque no tiene ningún efecto sustancial en la 
susceptibilidad a la infección con el agente de tembladera atípica.  
6. Los bajos niveles de expresión de la PrPC en los ratones H154-Tg563 no nos 
permiten concluir sobre el efecto del cambio aminoacídico arginina-
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histidina en el codón 154 (R/H154) en la susceptibilidad/resistencia a la 
infección con priones. Sin embargo, la transmisión positiva de algunos 
aislados de tembladera y EEB en estos ratones sugiere un bajo o nulo efecto 
del cambio aminoacídico R/H154. 
7. El cambio aminoacídico isoleucina-metionina en el codón 142 (I/M142) tiene 
un efecto en la replicación con agentes de tembladera clásica y atípica que 
depende de la cepa; pero no tiene ningún efecto sustancial en la replicación 
de la EEB.  
8. El cambio aminoacídico glutamina-arginina en el codón 171 (Q/R171) 
confiere resistencia a la infección con el agente de tembladera clásica pero 
no de tembladera atípica. 
9. El cambio aminoacídico asparragina-lisina en el codón 176 (N/K176) 
confiere alta resistencia a la infección con los agentes de tembladera clásica 
y EEB; aunque parece aumentar la susceptibilidad a la tembladera atípica. 
10. Las variantes polimórficas de la PrPC H154-, Q211- y K222- protegen al 
hospedador natural (cabras) frente a la infección oral por tembladera 
clásica. Este efecto protector es revocado por vía intracerebral en todos los 
casos excepto en el de la variante de la PrPC K222 que protege casi 
totalmente a las cabras heterozigotas Q/K222 frente a la infección 
intracerebral por tembladera clásica. Por lo tanto, la ruta de inoculación es 
un factor determinante en la susceptibilidad de las variantes polimórficas 
H154-, Q211- y K222- a la infección con este agente de prión. 
11. La transmisión del agente EEB de cabra a las cabras es dependiente de 
genotipo: la variante polimórfica Q211 tiene un efecto limitado a prolongar 
los tiempos de incubación mientras que la variante K222 juega un papel 
fundamental en la susceptibilidad de las cabras a la EEB de cabra.  
12. Las similitudes en los resultados tanto en el huésped natural como en los 
ratones transgénicos demuestran la idoneidad de los modelos de ratón 
transgénico que expresan diferentes variantes de la PrPC para predecir la 
susceptibilidad a la infección con priones en función del genotipo de la PrP.  
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